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Urea was first isolated in urine in 1773.[1] And almost half a century later, the German 
scientist Friedrich Wöhler from Göttingen realized the synthesis of urea by heating an 
aqueous solution of ammonium cyanate which is regarded as the first organic compound 
obtained from inorganic mixtures.[2] Since then, organic chemistry has been viewed as an 
essential part of chemistry. Now, urea is widely used in agricultural industry improving the 
yields of crops, which helped to relieve the starvation all around the world significantly. 
Over the last century, different types of reactions have been developed. So, with all these 
chemical methods in hand, scientists synthesized different kinds of polymers, life-saving 
drugs, pesticides, dyes and finished the total synthesis of many natural compounds. Due 
to resource and energy consumption, waste generation, byproducts and the use of 
dangerous chemicals, chemistry continues to be regarded as one contributing factor to 
pollution. A new concept, sustainable development, was proposed by Brundtland that 
meets the present needs without compromising the ability of future generations to meet 
their own needs.[3] It’s urgent to remove or at least to minimize the disadvantages. 
Thereafter, the development of more environment-friendly, resource-,[4] atom-[5] and step-
economic[6] reactions are highly desirable. Many interests in chemical academia have been 
paid to Domino reactions[7] which can construct several C–C and C–Het bonds in a single 
step and some reactions also have been modified to work in green solvents, such as 
biomass-derived glycerol.[8] With the insightful understanding of chemical processes and 
the development of new ligands, stoichiometric reactions can work in catalytic version with 
high efficiency and the temperature of some reactions can be decreased dramatically. In 
addition, CO2 can also be used to synthesize value-added products, polymers and widely 
used chemical materials.[9] Throughout the development of chemistry, chemists are guided 





1.1 C–H Functionalization  
Organic chemistry mainly studies the cleavage and formation of bonds in a practical and 
selective fashion, and the formation of carbon-carbon (C–C)[11] and C–Heteroatom (C–
Het)[12] bonds is the most important part, since it can serve as a valuable tool for scientists 
to design and synthesize different kinds of functional materials and bioactive molecules. 
Original works in coupling reactions were realized by Glaser[13] in the late of 19th century 
and Ullmann[14] in the early of 20th century using stoichiometric or catalytic amounts of 
copper. Now highly efficient transition-metal catalyzed organic reactions have made a huge 
impact on organic transformations for C–C and C–Het bond formations. In the recent 
decades, significant progress have been further witnessed in this area by the invention of 
a variety of named cross-coupling reactions, such as the Kumada-Corriu-coupling,[15] 
Mizoroki-Heck-coupling,[16] Negishi-coupling,[17] Stille-coupling,[18] Hiyama-coupling,[19] 
Suzuki-Miyaura-coupling,[20] and Sonogashira-coupling[21] reactions. Thus, transition 
metal-catalyzed cross-coupling reactions performed as a powerful tool in organic synthesis, 
with applications ranging from the construction of natural product and useful materials to 
the modifications of biologically active chemicals,[11, 12] and their significance was further 
reflected by Heck, Negishi and Suzuki being collectively awarded with the Nobel Prize in 
chemistry in 2010.[23] 
Based on transition-metal catalysis, this newly acquired ability to forge carbon–carbon 
bonds between or within functionalized and often sensitive substrates provided new 
opportunities, particularly in total synthesis but also in medicinal chemistry as well as in 
chemical biology and nanotechnology. Prominent among these processes are the 
palladium-catalyzed C–C bond-forming reactions. The historical, mechanistic, theoretical, 
and practical aspects of these processes have been amply discussed. Indeed, these 
protocols have revolutionized organic syntheses, albeit a few problems still exist. First, the 
use of pre-functionalized starting materials is needed, such as the organic (pseudo)halides. 
And even for the widely used organic nucleophiles, multiple synthetic steps, difficulty in 




Therefore, the selective C–H functionalization can serve as an elegant tool to diminish 
these problems,[24] combining the broad practicability of cross-couplings with the nature of 
green chemistry—atom economy and environmentally friendly methods (Scheme 1.1). 
Moreover, two-fold C–H dehydrogenative activation also contribute to the formation of    
C–C bonds while external oxidants are required in the dehydrative step.[25]  
 
Scheme 1.1. Comparison of traditional cross-coupling vs. C–H activation. 
The last thirty years have seen many examples of C–H activation at different metal centers, 
usually with good regio- and chemoselectivity and under mild conditions. The selective 
transformation of ubiquitous but inert C–H bonds to other functional groups has far-
reaching practical implications, ranging from more efficient strategies for fine chemical 
synthesis to the replacement of current petrochemical feedstocks by less expensive and 
more readily available alkanes.[26] All the potential practical applications have inspired 
chemists to study how these organometallic reactions occur, and what their inherent 
advantages and limitations for practical alkane conversion and late-stage functionalization 
are. As the transition metal-facilitated cleavage of the C–H bonds is the common key step 
in the above-mentioned C–H functionalization strategies, it has been heavily examined. 
Excluding outer-sphere mechanisms, such as carbene/nitrene insertions[27] or radical 
reactions[28], the bond dissociation proceeds generally via five different pathways, 
depending on the nature of the metal, the ligands and oxidation states.[29] These methods 
(Scheme 1.2) are oxidative addition, electrophilic substitution, -bond metathesis, 1,2-




are prone to cleave the inert C–H bonds by oxidative addition, while this mode of action is 
unfavorable for early transition metals.[29b] Most late transition metals in higher oxidation 
states often act as a Lewis acid to cleave C–H bond by an electrophilic substitution mode. 
The -bond metathesis is observed for early transition metals which cannot undergo 
oxidative addition. Metals containing an unsaturated M=X bond tend to undergo C–H 
activation via 1,2-addition. This fashion can be found in early transition metals. 
 
Scheme 1.2. Mechanistic pathways for the C–H activation. 
Besides the mechanistic scenarios, many examples proceed via the base-assisted C–H 
metalation events (Scheme 1.3). Further research on this base-assisted C–H activation 
led to the proposal of several transition states. The base-assisted deprotonation takes 




carboxylate or a secondary phosphine oxide.[29a, 30] This C–H cleavage mode was 
classified as Concerted Metalation-Deprotonation (CMD)[30b] and ambiphillic metal-ligand 
activation (AMLA).[31] An additional mechanism is the base assisted intramolecular 
electrophilic substitution (BIES), which is common for base assisted electrophilic transition 
metals.[32] 
 
Scheme 1.3. Transition states for the C–H cleavage in base-assisted C–H metalation. 
Although many modes have been proposed for the C–H cleavage, another big challenge 
about C–H activation is the regioselectivity due to the almost equal bond dissociation 
energies and acidities among several C‒H bonds.[33] This issue can be tackled through 
steric hindrance, electronic bias, or the incorporation of directing groups.[34] The lone pair 
of the directing groups can coordinate to the transition metal, thus bringing the catalyst in 
close proximity to the desired C–H bond (Scheme 1.4).[35] Remarkably, different 
templates[36] and strategies[37] have been developed for the para- and meta- C–H activation. 
Even free amine and hydroxyl groups could be used as directing groups to control the 
selectivity.[38] 
 





Scheme 1.5. Common directing groups for proximity induced C–H activation. 
 
1.2 Iron-Catalyzed C–H Activation 
Iron is the most abundant transition metal on the earth. The great abundance (6.3% 
abundance of iron in the Earth’s crust) and widespread distribution allow for the low cost 
as well as low biological toxicity in sharp contrast to the majority of other precious metals 
(e.g., 0.00000007% abundance of rhodium in the Earth’s crust).[39] So the use of iron as a 
substituent to precious metals is desirable in terms of both economy and sustainability. 
Organoiron chemistry was arguably initiated by the synthesis of pentacarbonyliron in 1891, 
independently by Mond[40] and Berthelot.[41] Another important breakthrough of iron-
chemistry was reported by the use of simple iron salt as precatalysts in reactions with 
Grignard reagent, including homocouplings, by Kharasch in 1941.[42] A subsequent 
milestone was the preparation of ferrocene accomplished by Pauson and Keary in 1951, 
which was formulated as dicyclopentadienyl iron.[43] Then a sandwich structure of 
ferrocene was proposed by Woodward and Wilkinson.[44] Transformative application of 
ferrocene made a great contribution to organic chemistry, especially for asymmetric 
synthesis.[45] A milestone in organoiron catalysis was the application of iron salts as 
catalysts in cross-couplings between Grignard reagents and vinyl bromides by Kochi in 
1971,[46] which, remarkably, preceded before studies with palladium catalysts. Despite the 
loss of interest in iron-catalyzed cross-couplings due to the development of palladium 
catalysis, it has recently witnessed a renaissance. In fact, iron complexes are often too 




hence it is difficult to design catalytic cycles of significance. Thus, the design of appropriate 
ligands for iron chemistry is in high demand. 
Chemists have received many inspirations from enzymes to accelerate the design and 
exploitation of ligands compatible with iron, including heme proteins.[49] In heme proteins, 
the iron is coordinated with four atoms that located in a macrocyclic porphyrin ring system. 
Thus, many types of porphyrins have been prepared to conduct different transformations 
catalyzed by iron (Scheme 1.6), which mostly limited to the carbene migration reactions 
and oxygenation reactions.[50] Thus ligands with new scaffold are in high need for efficient 
C–H activation.  
 
Scheme 1.6. Common structure of Fe-porphrin. 
It should be highlighted that the first stoichiometric iron-mediated C–H activation was 
described as early as in 1968 by Hata.[51] Ultraviolet-light irradiation of Fe(dppe)2(C2H4) 3 
resulted the loss of ethylene and shift of a hydrogen atom from a phenyl group of the ligand 
to the iron atom forming the new iron complex HFe(C6H4PPhCH2CH2PPh3)(dppe) 4 
(Scheme 1.7).  
 




Among others, Fe(PMe3)4, first synthesized by Schmidabauer[52] in 1975, has shown 
significant efficiency in directing group-assisted C–H cleavage, which indicating the 
feasibility of stoichiometric C–H activation with low-valent iron complex (Scheme 1.8).[53] 
Importantly, Fe(PMe3)4 tended to exist as an iron(II) species due to C–H activation of the 
phosphine ligand.[54] Fe(PMe3)4 showed great potential for the application of catalytic C–H 
activations.  
 
Scheme 1.8. Stoichiometric ortho-C–H metalation of imines with Fe(PMe3)4. 
Indeed, the first contribution of a catalytic C–H activation using an iron complex was made 
by Jones in 1987.[55] Here, the combination between the catalyst derived from Fe(PMe3)4 
and isocyanide ligands allowed for the formation of aldimines 10 from unactivated benzene 
under UV irradiation. Control experiment conducted in C6D6 proved that the solvent rather 
than the PMe3 ligand was the source of the aldimine’s hydrogen. The authors suggested 
that light was indispensable for the coordination of an isocyanide ligand to generate a 
reactive intermediate 9 capable to insert into an inert C–H bond (Scheme 1.9). Four 
decades after its original discovery, Fe(PMe3)4 was finally confirmed to be viable in iron-
catalyzed C–H activation free of additional ligands, as elegantly described by Kakiuchi and 





Scheme 1.9. Aldimine synthesis by iron-catalyzed C–H activation. 
In 2008, in the area of iron-catalyzed C–H activation was disclosed by Nakamura and 
coworkers via an iron-catalyzed oxidative C–H activation was disclosed.[57] This discovery 
was originated from an intended iron-catalyzed cross-coupling reaction.[58] Besides the 
desired product 12a, a small amount of the ortho-arylated phenylpyridine 13a was formed. 
Later, oxygen and 2,2’-bipyridine were identified as being pivotal to the C–H arylation 
(Scheme 1.10). 
 
Scheme 1.10. Iron-catalyzed C–H arylation as a byproduct of a cross-coupling reation. 
Extensive optimization of this iron-catalyzed arylation proved that 1,2-dichloro-2-
methylpropane (DCIB) was the very essential oxidant and phenanthroline served as the 
best ligand.[57] Surprisingly, the zinc salt was essential for the reaction also. It was 
postulated that the zinc additive was responsible for the in situ generation of arylzinc 
species, while Mg-free Ph2Zn and PhZnBr were unable to deliver the product, with or 
without TMEDA (Scheme 1.11). 
 
Scheme 1.11. First example of iron-catalyzed C–H arylation. 
Enormous efforts have been made on iron-catalyzed C(sp2)–H arylation, including the 




the use of environmentally benign oxygen as the oxidant,[61] the C(sp2)–H arylation of 
alkenes,[62] the direct use of Grignard reagents without zinc additives,[63] and the 
exploitation of metallic magnesium avoiding the use of dangerous and sensitive 
organometallic reagents.[64]  
Despite the significant contributions, a well-established mechanism was not shown in their 
original reports, then Nakamura and coworkers suggested a catalytic cycle on the basis of 
KIE studies and stoichiometric reactions (Scheme 1.12).[63] The catalytic cycle starts 
through the formation of an aryliron intermediate 14 by transmetalation from the aryl 
Grignard reagent to the iron center. Then, a reversible chelation of the iron center by the 
pyridine takes place followed by an irreversible C–H metalation with synergistic elimination 
of an arene via σ-bond metathesis. Next, the cyclometalated species 16 undergoes a 
reductive elimination with the assistance of DCIB to produce the desired arylated product 
13, isobutene and dichloroiron species. Finally, a transmetalation between dichloroiron 
species 17 and the Grignard reagent takes place to regenerate the active catalyst 14. 
 




Later the introduction of bidentate directing groups allowed for the challenging iron-
catalyzed C(sp3) –H activation expanding the scope beyond oxidative arylations with 
organometallic reagents (Scheme 1.13a).[65] After optimization they discovered that 8-
aminoquinoline directing group was optimal which was initially introduced by Daugulis for 
palladium-catalyzed C–H activations.[66] The KIE study and priority for terminal methyl 
group over internal methylene groups suggested an inner-sphere C–H activation process 
rather than a radical pathway. A biologically compatible triazole directing group was 
developed by Ackermann group which were effective for iron-catalyzed C(sp3)–H and 
C(sp2)–H arylations (Scheme 1.13b).[67]  
 
Scheme 1.13. Bidentate directing group enabled Iron-catalyzed C(sp3)–H arylation. 
After those pioneering studies, under the assistance of bidentate directing groups further 
important progress were realized by the research groups of Nakamura, Ackermann and 
Cook, among others. Thus, C–H alkylations with alkyl halides, alkenes, alkyl tosylates or 
Grignard reagents became available.[68] Alkynyl bromides were used for the preparation of 
the alkynylated product under iron-catalysis.[69] N-chloroamines proved to be a good 
aminating reagents.[70] Organoboron reagents proved viable for C–H alkenylations and 




heteroarenes in the presence of iron catalyst.[72] C(sp3)–H and C(sp2)–H methylations were 
also achieved.[73] 
Yoshikai reported an iron-catalyzed C–H activation in which a rare branched product 24 
was formed enabled by a modification of the N-heterocyclic carbene scaffold 25 (Scheme 
1.14). Alkynes were also suitable coupling partner after a slight modification of the reaction 
conditions.[74] 
 
Scheme 1.14. Iron-catalyzed hydroarylation of styrenes. 
The very first highly enantioselective iron-catalyzed C–H activation was realized by 
Ackermann and coworkers (Scheme 1.15a).[75] Shortly afterwards an asymmetric arylation 
of ferrocene was reported by Butenschoen,[76] giving the planar-chiral product in moderate 
enantiomeric excess (Scheme 1.15b).  
 




1.3 Manganese-catalyzed C–H Activations 
In the last few decades, significant attention has been paid to the development of 
sustainable and economic strategies for molecular synthesis. Despite significant advances, 
expensive transition metals, are predominantly needed to gain high efficiency, such as 
palladium, rhodium, ruthenium, and iridium complexes.[24b, 24c, 24g] Recent progress in this 
fast developing arena suggested the use of earth-abundant 3d transition metal complexes 
as catalysts in C–H activation.[24a, 24d] 
Manganese is the third most abundant transition metal just after iron, titanium and the 
twelfth most abundant element on earth.[39] In addition, it represents an essential trace 
element in the human body, with manganese cores served as an assistance factor.[77] 
Therefore, it is promising to utilize it as a catalyst due to its low price, availability and low 
toxicity.[78] The function of manganese in many enzymes inspired chemists to design 
ligands (Scheme 1.16), which can realize similar transformations accomplishing the C–H 
functionalization by outer–sphere mechanisms for a variety of transformations.[79] 
 
Scheme 1.16. Typical manganese complexes 28-31 for C–H functionalizations. 
This chapter will focus on the manganese-catalyzed reactions under chelation assistance. 
There are two parts in this chapter: i) manganese(I)-catalyzed C–H functionalization, ii) 




1.3.1 Manganese(I)-catalyzed C─H Functionalization 
The discovery of metal catalyzed C–H bond cleavage is often inspired by the stoichiometric 
investigations with metal complexes. The first manganese-catalyzed C–H activation traces 
back to the synthesis of the manganese complex 34 from [MnMe(CO)5] 32 through a C–H 
scission event, reported by Stone and Bruce in 1970 (Scheme 1.17).[80] The engagement 
of manganese(I) in the C–H activation was subsequently confirmed as various well-defined 
manganacycles were reported by different groups respectively, such as Woodgate[81] and 
Liebeskind[82] among others. 
 
Scheme 1.17. Stoichiometric manganese-mediated C–H activation. 
In 2007, the first catalytic manganese(I)-catalyzed C–H activation was achieved by 
Kuninobu and Takai.[83] They initiated the exploration by the stoichiometric C–H bond 
activation and insertion into aldehyde 36 with the manganese complex [MnBr(CO)5]. After 
the reaction mixture was heated for 10 hours the desired alcohol 37 was obtained in 52% 
yield (Scheme 1.18a). Despite the fact that the stoichiometric C–H bond scission and 
insertion of aldehyde proceeded smoothly with [MnBr(CO)5], only trace amount of alcohol 
37 was produced with catalytic amounts of the manganese complex 32. After optimization, 
triethylsilane 38 was found to be essential for regenerating the catalyst (Scheme 1.18b). A 
probable catalytic cycle was put forward based on mechanistic studies (Scheme 1.19). The 
catalytic cycle was initiated by the formation of a five-membered manganacycle 40 followed 
by the insertion into polar C=O bond to form the seven-membered manganese complex 
41. Finally, the silylethers 39 are formed via release of H2 and regeneration of the 





Scheme 1.18. Manganese(I)-catalyzed C–H addition to aldehydes 36. 
 





In 2015, Wang developed a manganese-catalyzed Grignard-type nucleophilic addition of 
C(sp2)–H bonds to aldehydes to access secondary alcohols (Scheme 1.20a),[84] which 
circumvents the limitation of previous rhodium and palladium catalytic systems. During the 
mechanistic studies, the authors found that [MnMe(CO)5] was an effective catalyst. Nitriles 
were also viable coupling partners to give ketones under this reaction. Later, Ackermann 
and Wang extended this kind nucleophilic transformation, as attack to C=Het double bond 
led to functionalized amines (Scheme 1.20b).[85] 
 
Scheme 1.20. Manganese-catalyzed nucleophilic addition. 
The extension of these C–H addition strategies from polar C=Het multiple bonds to 
nonpolar C=C double bonds was accomplished by Wang and co-workers.[86] The addition 
reaction showed a broad substrate scope, good functional group tolerance, and complete 
mono-selectivity. Ketimines 47 are also good substrates to form five-membered 
manganacycle 48. Ackermann’s group found an intramolecular nucleophile attack can 
occur to furnish useful β-amino acids 52 after the insertion of acrylate 49 to the complex 
48 (Scheme 1.21).[87] Using the same strategy, methylenecyclopropanes 53 (MCPs) 
containing electron-withdrawing groups were employed in the manganese-catalyzed C–H 
activation. The intramolecular nucleophile addition followed by zinc-mediated 





Scheme 1.21. Mechanism for the synthesis of β-amino acids. 
 
Scheme 1.22. C–H/C–C activation with MCP catalyzed by Manganese(I). 
Alkenes with leaving groups are also good coupling partners in the manganese-catalyzed 
C–H activations. Thus, alkenes with different leaving groups were designed by Ackermann 
for the unprecedented allylations on different functional molecules,[89] remarkably this 





Scheme 1.23. Products derived by manganese(I)-catalyzed C–H allylation. 
Alkynes are very important synthons widely used in the synthesis of high-value products, 
showed high reactivity towards manganese-catalyzed C–H activation. The first use of 
catalytic amounts of Brønsted acids in manganese-catalyzed C–H activation enabling 
chemoselective hydroarylations was achieved by Ackermann, which is fully tolerant of β-O 
leaving groups (Scheme 1.24).[91] At the same time, indoles were successfully allenated by 
alkynes bearing a leaving group in the presence of [MnBr(CO)5]. Optically active 
multisubstituted allenes were prepared with high enantiomeric excess through a highly 
efficient chirality transfer.[92] A general and scalable strategy was developed to 
regioselectively synthesize N-heterocycles by using alkyne coupling partners with ketimine 
and a simple manganese-based catalyst. This procedure overcomes the previous 
limitations of C–H activation with unsymmetrical alkyne coupling partners and was also 
demonstrated to be effective with unpolarized aliphatic alkynes, with the desired products 
obtained with complete regioselectivity.[93] The manganese-catalyzed C–H alkenylation 
with terminal alkynes was realized by Wang, highlighting not only a practical catalytic 
system comprised of easily available [MnBr(CO)5] and Cy2NH but also high levels control 




Scheme 1.24. Mn(I) catalyzed hydroarylation of alkynes. 
Domino reactions via C–H allenylation, Diels–Alder (DA) reaction, and retro Diels–Alder 
reaction pathway were realized by manganese catalysis in Ackermann and Li group 
respectively (Scheme 1.25).[95] To shed light into this cascade process, a stable DA adduct 
68 was isolated after the coupling of substrates 66 and 67 at a lower temperature, which 
proved to be an intermediate en route to the final product 70 via a retro-Diels-Alder event 





scheme 1.25. Manganese(I) catalyzed domino reactions. 
With the great success of allenes in the construction of complex compounds, it represents 
an appealing partner in manganese-catalyzed C–H functionalization. In 2017, allylation of 
indole was achieved by Wang’s group using 1,1-dimethylallene (Scheme 1.26a).[96] A 
manganese(I)-catalyzed region- and stereoselective 1,2-diheteroarylation of allenes was 
discovered by Wang and Rueping respectively,[97] which features the combination of C–H 
hydroarylation along with a Smiles rearrangement (Scheme 1.26 b). In the same year, 
polycyclization enabled by manganese(I)/silver(I) relay catalysis through one-pot 
manganese-catalyzed C–H allylation and silver-catalyzed Pavarov reaction was 





Scheme 1.26. Manganese(I) catalyzed transformations with allenes 72 and 74. 
 




Bromoallenes were efficiently employed in direct C–H propargylations with high selectivity 
under the synergy of manganese(I) and a Lewis acid. The axial chirality in the bromoallene 
(S)-79 could be successfully transferred to the central chirality at the propargylic position, 
a motif difficult to obtain by traditional methods (Scheme 1.27).[99] Manganese-catalyzed 
C–H annulation of ketimines 47 with allenes providing an approach to stereoselective 
synthesis of 1-aminoindanes 81 was also described.[100] 
With the rapidly growing interest in the application of photochemistry in organic synthesis, 
a photoredox Minisci reaction with unactivated iodoalkanes catalyzed by Mn2(CO)10 was 
developed, which was successfully employed in the late-stage functionalization of complex 
drugs.[101] Manganese-mediated photochemical generation of aryl radicals was likewise 
exploited for the direct C–H arylations of (het)arenes (Scheme 1.28).[102]  
 
Scheme 1.28. Visible-light and manganese-catalyzed reactions. 
Manganese(I) catalysis displayed great power in meaningful cyanation and 
aminocarboxylation.[103] Lastly, challenging C–H/C–F functionalization could be 
accomplished by manganese(I). It is noteworthy that C–F bonds are generally relatively 
inert due to the high bond energy and the reluctance of organofluorine compounds to 
coordinate to metal centers.[104] Despite these challenges, C–H/C–F activation has been 
successfully employed in the manganese-catalyzed perfluoroallylation and 
monofluoroalkenylation.[105] 
1.3.2 Low-valent Manganese(II)-catalyzed C─H Functionalization 
Despite a plethora of transformations enabled by manganese(I)-catalyzed C─H 
functionalization, these methods are restricted to the addition of double bonds. The 




bromides 86 (Scheme 1.29a). The unprecedented manganese(II)-catalyzed C─H cleavage 
occurred without the use of expensive phosphine ligands in the absence of zinc, providing 
versatile access to alkylated benzamides through assistance of the removable TAM 
(triazolyl-methyl) group (Scheme 1.29a).[106] Versatile manganese-catalyzed C─H 
arylations on synthetically meaningful pyridines were accomplished with sustainable MnCl2 
as the catalyst as disclosed one year later.[107] The oxidative C─H functionalization proved 
viable with a user-friendly and safe continuous flow setup.  
 
Scheme 1.29. Low-valent manganese(II)-catalyzed C─H functionalization. 
Later, Nakamura reported a manganese-catalyzed C─H methylation, using MeMgBr, a 
catalytic amount of MnCl2·2LiCl, and an organic dihalide as the oxidant (Scheme 1.29b).[108] 
1.4 Rhodium-catalyzed C─H Activation 
As the formation of C─C bond is the most important objective within synthetic chemistry, 
different types of coupling reactions have been developed to achieve the formation of C─C 
bonds. Most of these transformations proceed in the presence of palladium. Many new 
reactions catalyzed by rhodium complexes show great potential.[109] In addition, rhodium 




that does not require organometallic reagents. Cycloadditions, hydroacylation reactions, 
and allylic functionalization are representative examples for rhodium-catalyzed C–C bonds 
formations.[110] Rhodium-derived complexes also provide a powerful tool for the 
asymmetric hydrogenation of prochiral unsaturated compounds to give optically pure 
alcohols, amines and other hydrocarbons.[111]  
The utility of C–H activation in lieu of substrate prefunctionalization has featured a 
tantalizing alternative to classical cross-coupling reactions but the challenges ahead are 
the selectivity and reactivity associated with otherwise inert C–H bonds. Literature reports 
on selectivity based on steric effects, acidity, and electronic and directing group effects are 
now numerous. The designs of directing groups and ligands allow the rhodium to conduct 
the cleavage of inert C–H bond efficiently with good selectivity. For this part, rhodium-
catalyzed C–H activation will be divided into two parts: (i) rhodium-catalyzed inner-sphere 
C–H activation (ii) rhodaelectro-catalyzed C–H activation. 
1.4.1 Rh-catalyzed Inner-sphere C–H Activation 
Due to the difficulty to control the selectivity, simple benzene and linear hydrocarbons were 
ideal model substrates to explore the process of C–H cleavage in the early stages of C–H 
activation. In 1984, Bergman and Jones found that photolysis of Cp*Rh(PMe3)H2 96 in a 
hydrocarbon solvent led to the loss of H2 and the C–H activation of solvent.[112] 
Unfortunately, the 16-electron Cp*Rh(PMe3) 97 viewed to be accountable for hydrocarbon 
oxidative addition was not detectable (Scheme 1.30).  
 
Scheme 1.30. Early study of C–H activation by Bergman. 
Inspired by the early rhodium-mediated C–H activation, the inert methane successfully 




conditions with the use of oxygen as the oxidant (Scheme 1.31a).[113] However, the yield of 
this process was not mentioned. Besides the alkane carboxylation, photochemical 
transformations of alkanes to aldehyde 38a catalyzed by RhCl(PMe3)3 (99) have also been 
observed (Scheme 1.31b).[114] Mechanistic studies by Goldman provided evidence that the 
CO-dissociated species is not responsible for the C–H activation step. Goldman proposed 
that the principal photo-process in this reaction involves direct C–H oxidation addition to 
the four-coordinate rhodium(I) center to deliver a six-coordinate intermediate, which then 
undergoes CO insertion in the following step.[115]  
 
Scheme 1.31. Rh(I) catalyzed transformations of hydrocarbons. 
Alkynes tend to experience dimerization or polymerization in the presence rhodium 
complexes especially at high temperatures.[116] In the early stage of rhodium catalyzed 
C(sp2)–H activation, alkenes are the ideal substrates for the position-selective C–H 
activation. In one of the earliest reports of rhodium-catalyzed C–C bond formation by C–H 
activation, Lim and Kang showed that pyridine functioned as a directing group to achieve 
C–H alkylation, albeit without tolerance of any other functional groups.[117]  
 
Scheme 1.32. Rhodium-catalyzed C–H alkylation. 
Subsequently, the imine functionality enjoyed widespread use and development in the 
realm of C–H bond functionalization by Rhodium (I). Specifically, RhCl(PPh3)3 (100 
Wilkinson’s catalyst) was determined to be the optimal catalyst for this transformation.[118] 




case. It was further discovered by Jun and co-workers that imines 103 were capable to 
undergo alkylation to generate the corresponding imines 104 (Scheme 1.33).[119] 
 
Scheme 1.33. Imine directed alkylation. 
The widely accepted mechanism for chelation-assisted C–H bond alkylation catalyzed by 
rhodium(I) demonstrated in Scheme 1.34. Initial coordination of rhodium by the chelating 
heteroatom of imine 105 followed by facile C–H bond activation gives metallacyclic 
intermediate 107. Dissociation of a phosphine ligand, followed by olefin binding and 
hydride insertion, gives 108. Reductive elimination of 109 produces the product 110 and 
closes the catalytic cycle.[120] The reductive elimination step has been demonstrated to be 





Scheme 1.34. Mechanism for rhodium(I) catalyzed alkylation. 
While the hydroarylation of olefins has seen broad success using rhodium(I)-catalyzed 
chelation-assisted methods, the tendency of alkynes, in particular terminal alkynes, to 
undergo rhodium-catalyzed alkyne dimerization or trimerization has made their use 
problematic.[116] Internal alkynes, much like internal olefins, are often unreactive in C–H 
bond functionalization reactions. Under assistance of the reliable mechanism, several 
groups have successfully developed heteroatom-chelated vinylation methods. Lim and 
Kang reported the first example of chelation-assisted hydroarylation of an internal alkyne 
113 realizing the ortho-alkenylation of 2-phenylpyridines by using Wilkinson’s catalyst 
(Scheme 1.35a).[121] The scope of alkyne was limited primarily to internal and symmetrical 
alkynes. Terminal alkynes generated mainly polymeric materials,[116] and unsymmetrical 
alkynes, such as 2-hepyne, led to regioisomeric mixtures.[122] Internal alkynes were 
smoothly used for the alkenylation with the assistance of imine using RhCl(PPh3)3 as the 




prolonged reaction times ultimately produced isoquinoline products 116 in nearly 
quantitative amounts (Scheme 1.35c).[123] When triisopropylsilylacetylene is used as the 
coupling partner, the substrate scope of the alkenylation in the presence of a RhCl(PPh3)3 
catalyst was expanded to imidazole and benzimidazole directing groups (Scheme 1.36).[122]  
 





Scheme 1.36. Alkenylation by using triisopropylsilylacetylene. 
Carboxylate groups can also function as effective directing groups in oxidative coupling of 
benzoic acids and alkynes using a rhodium(III)-copper(II) co-catalytic system, where the 
copper(II) serves to oxidize the rhodium catalyst in order to reinitiate the catalytic cycle 
(Scheme 1.37). A series of isocoumarin derivatives 119 was thereby synthesized from 
benzoic acids and internal alkynes using [Cp*RhCl2]2 as the catalyst.[124] Both electron-
deficient and electron-rich benzoic acids were suitable substrates, and alkyl or aryl 
substituted alkynes were used.  
 
Scheme 1.37. Oxidative coupling of benzoic acids with alkynes. 
A plausible mechanism for the reaction of benzoic acid 118 with alkyne 113 is shown in 
Scheme 1.38. Coordination of the carboxylate oxygen to Cp*Rh(III) (OAc)2 120 is followed 
by ortho rhodation to form a rhodacycle intermediate 121. Afterwards alkyne insertion and 
reductive elimination occurs to produce isocoumarin 119. The resulting rhodium(I) species 





Scheme 1.38. Plausible mechanism for rhodium-catalyzed isocoumarin synthesis. 
Encouraged by the significant breakthrough of the carboxylate-assisted C–H activation 
reported by Miura, the reactions of 1-naphthols (124) (Scheme 1.39) and analogues 
including 4-hydroxycoumarin, quinolinone and 9-phenylxanthen-9-ol were discovered to 
undergo peri C–H bond cleavage to produce fused pyran derivatives.[125]  
 
Scheme 1.39. The coupling of 1-naphthols with alkynes. 
In contrast to the couplings described above (Scheme 1.39), treatment of equimolar 




of [Cp*RhCl2]2 (1 mol%) selectively furnished 5-(2-hydroxyphenyl)-1,2,3,4-tetraphenyl-
naphthalene 127 in 81% yield (Scheme 1.40).[125] 
 
Scheme 1.40. The coupling of 2-phenylphenol with diphenylacetylene. 
In 2008, Fagnou found that alkynes oxidatively coupled with acetanilides 128 by using 
rhodium(III) catalyst and Cu(OAc)2 as the oxidant through ortho C–H bond cleavage to 
furnish N-acetylindoles 129 (Scheme 1.41a).[126] Meanwhile, Miura found that benzanilides 
130, which possess two types of cleavable ortho C–H bonds on aniline and benzoic acid 
moieties, undergo the oxidative coupling with alkynes involving the selective cleavage of 
the latter to produce isoquinolinone derivatives 131.[127] 
 
Scheme 1.41. The coupling of N-acylanilines with alkynes. 
Under similar conditions, N-unsubstituted benzamides 132 undergo a cascade coupling 
accompanied by two C–H and two N–H bond cleavages to construct a tetracyclic 





Scheme 1.42. The coupling of N-unsubstituted benzamides with diarylacetylenes. 
In 2011, Glorius reported a rhodium-catalyzed oxidative olefination by chelation-assisted 
C–H activation of N-methoxy benzamides 134. In this mild process, the N–O bond serves 
as an internal oxidant. In addition, a small modification of the substituent of the 
directing/oxidizing group results in the selective generation of valuable 
tetrahydroisoquinolinone products 135 (Scheme 1.43a).[128] After changing the Cp ligand 
from Cp* to much bulkier Cpt, synthesis of dihydroisoquinolones 137 from aliphatic alkenes 
and O-pivaloyl benzhydroxamic acids 136 mediated by a rhodium precatalyst was 
achieved with excellent regioselectivity (Scheme 1.43b).[129] 
 




Inspired by this oxidizing group, an unprecedented rhodium-catalyzed C–H activation of 
benzamides and methylenecyclopropanes 138 for the selective synthesis of spiro 
dihydroisoquinolinones 139 was reported by Cui (Scheme 1.44a).[130] Interestingly, when 
the furan-derived amide 140 coupled with methylenecyclopropanes under higher 
temperature, a furan-fused azepinone 141 was formed in high yield (Scheme 1.44b).  
 
Scheme 1.44. Synthesis of spiro dihydroisoquinolinones 139 and furan-fused azepinone 141. 
Another diastereoselective coupling of arylhydroxamates 136 and cyclopropenes 142 was 
successfully developed by rhodium catalysis (Scheme 1.45). Through ligand development, 
the diastereoselectivity of this reaction was improved using a heptamethylindenyl (Ind*) 
ligand. In addition, the nature of the O-substituted ester of benzhydroxamic acid proved 
important for achieving high diastereoselectivity.[131] 
 




In 2014, Wang group reported the use of cyclopropene as a three-carbon unit in 
rhodium(III)-catalyzed C–H bond activation.[132] An efficient rhodium(III)-catalyzed 
synthesis of 2H-chromene 145 from N-phenoxyacetamides 144 and cyclopropenes 
through C–H activation has been achieved (Scheme 1.46). The reaction proceeded at 
room temperature without using external oxidants. 
 
Scheme 1.46. Synthesis of 2H-chromene 145 from N-phenoxyacetamides 144 and 
cyclopropenes 142.  
A combination of C–H activation with ring opening of cyclopropanols by rhodium(III)-
catalysis, offering an efficient route to access β-aryl ketones was reported by Li.[133] The 
reaction proceeded under mild conditions with ample scope, high regioselectivity, and 
excellent functional group tolerance. Both oxime ethers and N-pyrimidylindoles proved to 
be viable substrates. In 2018, Li reported rhodium(III)-catalyzed C–H activation of nitrones 
146 and azomethine imines 147, followed by a dipolar cycloaddition with 
alkylidenecyclopropanes 138 (ACPs) (Scheme 1.47). Taking advantage of the ring strain 
in ACPs, the reaction with aryl nitrones delivered bridged [3.2.1] bicyclic isoxazolidines 148, 
and reaction with azomethine imines afforded bridged tricyclic pyrazolones 149 under the 
same conditions.[134]  
 





The arylnitrones 150 were coupled with internal alkynes 113 to form indolines 151 in the 
presence of rhodium(III) catalyst free of external oxidants (Scheme 1.48). A dual role of the 
rhodium catalyst is proposed, initially enabling the C–H cleavage and O-atom transfer 
process. The cyclization worked well under mild conditions furnishing the desired products 
151 with moderate to high diastereoselectivity.[135]  
 
Scheme 1.48. Cyclization of arylnitrones to indolines. 
In 2012, Chang and coworkers reported the first rhodium(III)-catalyzed C–H amidation 
reaction using sulfonyl azides as the amino source, releasing N2 as the sole byproduct 
without the use of external oxidants (Scheme 1.49a).[136] A more challenging rhodium(III)-
catalyzed chelation-assisted activation of unreactive C(sp3)–H bonds has been disclosed 
in You’s lab (Scheme 1.49b), thus providing a practical and step-economic route to 2-
(pyridine-2-yl)ethanamine derivatives via an intermolecular amidation. In contrast to 
Chang’s system, external oxidant PhI(OAc)2 was responsible for the generation of nitrene, 
which undergoes subsequent migratory insertion.[137] Dioxazolone, N-methoxyamide and 
amidobenziodoxolones were also successfully developed as suitable nitrogenation 






Scheme 1.49. Rhodium(III)-catalyzed C–H amidation. 
Despite the plethora of C2 functionalization of indole, the selective C7 transformation of 
indole is scarce. Through elaborate modification of the directing groups, C7 olefination, 
arylation, methylation and alkylation were available in Shi’s and Ma’s lab (Scheme 1.50).[139] 
 




Further important functional groups have been directly introduced to useful molecules 
under the assistance of rhodium catalyst, such as Br, I, CN and N3.[140] Many structurally 
complex molecules become available via strategic chelation-assisted and rhodium-
catalyzed C–H functionalizations (Scheme 1.51).[141] 
 
Scheme 1.51. Complex structures obtained by rhodium(III) catalyzed C–H activation. 
1.4.2 Rhodaelectro-catalyzed C–H Activation 
In the last a few years, the use of electricity as a redox reagent to drive chemical reactions 
has emerged as an increasingly-viable platform.[142] Significant achievements have been 
realized by the merger of metallaelectrocatalysis and C–H activation, thus eliminating the 
use of toxic and expensive oxidants.[143] The exploitation of efficient and more 
environmentally-friendly synthetic methods is still highly desirable. Many opportunities lie 
ahead to explore rhodaelectro-catalyzed C–H activation. Thus, when replacing the 
chemical oxidants with electricity, new reaction pathway and new reaction manifold will be 
found. 
In 2018, Ackermann and coworkers reported the first rhodaelectro-catalyzed C–H 
activation (Scheme 1.52).[144] Hence, cross-dehydrogenative C–H/C–H alkenylations were 




the proof of concept for the 4d-metal electrocatalyzed C–H activation. The optimal reaction 
conditions featured a user-friendly undivided cell setup, KOAc as the additive and full water 
tolerance. 
 
Scheme 1.52. First rhodaelectro-catalyzed C–H activation. 
In contrast to the alkenylation with α,β-unsaturated carbonyl compounds under 
rhodaelectro-catalysis, Ackermann recently reported an intriguing alkenylation reaction 
using unactivated alkenes 23 with weakly coordinating benzamides 92 (Scheme 1.53).[145] 
The rhodaelectro-catalyzed C–H alkenylation was shown to proceed with ample substrate 
scope, including heterocycles and valuable electrophilic functional groups, such as chloride, 
bromo and nitrile. Likewise, a variety of alkenes proved to be amenable, especially 
oxidation-sensitive hydroxyl substituents. A gram-scale reaction without the decrease of 
yield highlighted the synthetic utility of the rhodaelectro-catalyzed C–H activation. 
 
Scheme 1.53. Rhodaelectro-catalyzed C–H alkenylation. 
Electrooxidative C–B/C–H [2+2+2] cyclization was realized with a variety of boronic acids 
via versatile rhodium catalysis (Scheme 1.54).[146] The C–B/C–H annulation was efficiently 
established with ample scope and remarkable levels of functional group tolerance, such as 




chemoselectivity of the conversion of sensitive iodo-substituted boronic acids could be 
significantly improved as compared to transformations with the typical chemical oxidants, 
such as AgOAc and Cu(OAc)2. 
 
Scheme 1.54. Electrooxidative C–B/C–H [2+2+2] cyclization. 
Ackermann also found a robust flow-rhodaelectro-catalyzed alkynes cyclization utilizing 
aryl imidates 107 as the substrates (Scheme 1.55).[147] It is worth noting that C–H/N–H 
alkyne annulations were amenable to an electroflow setup. This strategy represents a user-
friendly tool for the efficient upscaling of a reaction with significantly improved control of 
heat and mass transfer. This challenging flow-rhodaelectro-catalyzed alkyne annulations 
gave access to isoquinolines 174 as well as azo-tetracycles by an intramolecular reaction. 
 
Scheme 1.55. Flow-rhodaelectro-catalyzed alkyne cyclization. 
The Xu group then disclosed a phosphorylation using a N–coordinating directing groups 
(Scheme 1.56).[148] The broadly applicable concept of rhodaelectro-catalysis was further 
utilized for the effective C–H phosphorylation using diphenylphosphines 26. To 
demonstrate the scalability, a decagram scale reaction was successfully performed, 











The methyl group is widely found among various bioactive compounds, and the 
introduction of a single methyl substituent can significantly impact the biological activities 
and physical properties of pharmacologically relevant drug molecules by favoring the 
bioactive conformation or changing drug metabolism and pharmacokinetic (DMPK) 
properties.[149] Ackermann[73b] and Nakamura[73a] introduced a widely applicable iron-
catalyzed methylation protocol for C(sp2)-H bonds. Benzylamines represent the key 
molecular motif of various natural products and bioactive molecules.[150] With our continued 
interests in iron chemistry, the development of methylation of benzylamines catalyzed by 
iron continues to be in high demand (Scheme 2.1). 
 
Scheme 2.1. Iron-catalyzed C–H methylation. 
Alkylation is a very important strategy to form C(sp3)–C(sp3) and C(sp2)–C(sp3) bonds. 
Noble metals played an important role in the C–H alkyations.[151] Recently inexpensive 3d 
metal catalysts have gained considerable momentum for alkylations as a more 
environmentally-benign and economically-attractive alternative.[24a, 24d] under the 
assistance of triazole directing groups, the first example of manganese(II)-catalyzed 
alkylation was reported by Ackermann’s group.[106] Pyridinylamides including picolinamide, 
nicotinamide, and isonicotinamide are key structural units of numerous biologically active 
molecules, with notable applications to the life science.[152]. Thus, it is of high importance 
to introduce alkyl groups into pyridinylamides in the presence of manganese(II) in order to 
achieve derivatization of pyridinylamides or gain mechanistic insight into manganese(II)-





Scheme 2.2. Envisioned manganese(II)-catalyzed C–H alkylation. 
Cross-dehydrogenative couplings present the most atom-economic transformation in C–H 
activation. However, to achieve these transformations sacrificial oxidants are needed, 
which greatly reduces the atom economy of C–H activation. Furthermore, most 
transformations rely on expensive silver salts as oxidants, which drive the cost of the 
overall reactions.[24, 25] The assembly of atomically precise aza-PAHs in an efficient and 
economic manner has received considerable attention. However, the synthesis of PAHs 
and aza-PAHs generally relies on stepwise elaborations, largely involving Diels–Alder 
cycloadditions, dehydrogenative cyclization, and transition-metal-catalyzed cross-
couplings that require prefunctionalized substrates.[153] Transition-metal-catalyzed 
oxidative C–H activation/annulation has been proven to be a powerful tool for PAH 
syntheses.[154] The electrooxidative alkyne annulation was recently likewise merged with a 
multiple C–H domino strategy catalyzed by rhodium(III).[146] With our ongoing interest in 
material syntheses by metalla-electrocatalysis, it is promising to develop a one-step 
approach to the assembly of aza-PAHs via rhodaelectro-catalyzed cascade C–H 





Scheme 2.3. Synthesis of aza-nanographene via rhodaelectro-catalyzed Domino C−H 
annulations. 
Among a variety of pharmaceuticals, biologically active molecules and natural products, 
1,3-dienes[155] and cyclopropanes[156] represent a vital structure unit for their bioactivities. 
Ene-yne metathesis, Wittig-type olefinations, Mizoroki-Heck reactions and cross-coupling 
are among the traditional ways to synthesize 1,3-dienes,[157] while these procedures 
require the prefunctionalization of the substrates. Thus far, very few examples 
demonstrated the cyclopropylations by cleavage of C–H bonds[158] as cyclopropanes, the 
smallest rings, are prone to undergo ring-opening through metal-insertion or 
fragmentation.[159] The exploitation of efficient and more environmentally-friendly synthetic 
methods is still highly desirable. With our continued interest in rhodaelectro-catalyzed C–
H activation,[144-147] we wondered whether the C–H dienylation and cyclopropylation could 
be realized through rhodaelectro-catalysis (Scheme 2.4). 
 
Scheme 2.4. Dienylation and cyclopropylation enabled by rhodaelectro-catalysis. 
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3 Results and Discussion 
3.1 Triazole-Enabled C–H Activation of Benzylamines by Iron-
Catalysis 
Since the methyl group plays a very important role for the biological activities and physical 
properties of pharmacologically relevant drug molecules, many methylation reagents have 
been developed for direct C–H methylations, such as MeMgBr 187, AlMe3 188, MeI 189, 
Me3B3O3 190, MeOTs 191 and MeBF3K 192 (Scheme 3.1).[160] Bidentate directing groups 
were confirmed to be effective in iron-catalyzed C–H methylation.[73] In the previous reports, 
most of the methylation occurred on electron-deficient aromatic compounds.  
 
Scheme 3.1. Common methylation reagents. 
Benzylamines are widely distributed among bioactive molecules (Scheme 3.2).[150] In this 
context, we became interested in the development of an economical method for the 
methylation of electron-rich benzylamines. As shown in former studies, MeMgBr served as 
a suitable methylation reagent under the assistance of triazole directing group.[73b] We, 
hence, started to explore the feasibility of iron-mediated methylation of protected 
benzylamines 178a using MeMgBr as user-friendly and safe methylation reagent. 




Scheme 3.2. Biological compounds 193-195 containing benzylamines. 
3.1.1 Optimization Studies  
At the outset of our studies, Dr. Cera designed the tri-substituted triazole TST, which 
enabled the envisioned iron-catalyzed C–H methylation of benzylamide 178a. Dr. Cera 
conducted the following optimization (Table 3.1). Preliminary results revealed that nitrogen 
or NHC ligands fell short in enabling the desired C–H methylation (Table 3.1, Entries 1-3). 
The bidentate dppe ligand gave only unsatisfactory result (Entry 4), which could be 
rationalized with the need for a more rigid coordination environment at iron. In good 
agreement with this hypothesis, dppz and dppen led to the formation of the desired 
compound 179a in synthetically useful yields (Entries 5 and 6), particularly, when using 
2,3-dichlorobutane as the oxidizing agent. 
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Table 3.1. Optimization of iron-catalyzed C–H methylations of benzylamine 178a.[a] 
 
Entry Ligand Oxidant Yield [%] 
1 -- DCB -- 
2 Dtbpy DCB -- 
3 IPr.HCl DCB -- 
4 dppe DCB 21 
5 dppz DCB 45 
6 dppen DCIB 53 
7 dppen DCB 86 
[a] Reaction conditions: 178a (0.20 mmol), FeCl3 (15 mol %), ligand (15 mol %), MeMgBr (1.40 mmol), 
ZnCl2•TMEDA (0.60 mmol), oxidant (0.60 mmol), THF (0.5 M), 65 °C, 16 h, isolated yields. dppe = 1,2-
bis(diphenylphosphino)ethane; dppbz = 1,2-bis(diphenylphosphino)benzene; dppen = 1,2-
bis(diphenylphosphino)ethene. DCB = 2,3-dichlorobutane. DCIB = 1,2-dichloro-2-methylpropane. 
3.1.2 Scope of Triazole-Assisted C–H Methylation 
With the optimized reaction conditions in hand, we explored the influence exerted by the 
TST substitution pattern on the catalytic efficacy. Thus, various directing groups were 
tolerated in the C–H methylation 178 (Table 3.2), with the sterically congested gem-
disubstituted benzylamine 178b being efficiently converted. The iron-catalyzed C–H 
activation proved amenable to differently N-substituted triazoles, including alkyl- and aryl-
decorated derivatives 178c and 178d. The amide 178e without free NH-group failed to 
undergo C–H methylation, probably due to an anionic bidentate coordination mode at iron. 
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It is particularly noteworthy that the frequently used, picolinic acid-derived[161] benzylamine 
178f was less effective under otherwise identical reaction conditions. 
Table 3.2. Influence of the TST substitution pattern. 
 


























[a] Reaction conditions: 178 (0.20 mmol), FeCl3 (15 mol %), dppen (15 mol %), MeMgBr (1.40 mmol), 
ZnCl2•TMEDA (0.60 mmol), DCB (0.60 mmol), THF (0.5 M), 65 °C, 16 h, isolated yields. 
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After the optimal TST group was confirmed, we probed the versatility of the iron-catalyzed 
C–H activation with differently substituted benzylamines 178 (Table 3.3). To our delight, 
ortho-functionalized substrates furnished the products 178g-178l in good to excellent 
yields. The naphthalene derivative 178m underwent an unusual peri-C–H methylation, 
thereby furnishing the product 179m with excellent levels of positional selectivity. Para- 
and meta-substituted substrates were directly converted to the twofold methylated 
products 179n-179u. Given the practical importance of nitrogen-containing heterocycles, 
it is noteworthy that pyridine 179v could be obtained in synthetically useful yields as well. 
Likewise, bicyclic substrate delivered the desired product 179w featuring the sertraline 
motif – an important pharmacophore in medicinal chemistry.[162] 
Table 3.3. TST-assisted iron-catalyzed C–H methylation. 
 


































































































[a] Reaction conditions: 178 (0.20 mmol), FeCl3 (15 mol %), dppen (15 mol %), MeMgBr (1.4 mmol), 
ZnCl2•TMEDA (0.60 mmol), DCB (0.60 mmol), THF (0.5 M), 65 °C, 16 h, isolated yields. 
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The iron-catalyzed C–H activation strategy was not limited to direct methylation reactions. 
Indeed, the versatility of our approach was reflected by a high-yielding C–H ethylation of 
benzylamine 178h, with the best results being achieved by employing DCIB as the oxidant 
(Scheme 3.3). 
  
Scheme 3.3. TST-assisted iron-catalyzed C–H ethylation. 
Then we did some optimization for the iron-catalyzed C–H arylation (Table 3.4). We found 
that DCIB was more effective than 2,3-DCB giving the desired product 197a in 87% yield 
(entry 3). 
Table 3.4. Optimization of iron-catalyzed C‒H arylation.[a] 
 
entry Oxidant X Yield [%] 
1 2,3-DCB Br 17 
2 2,3-DCB Cl -- 
3 DCIB Br 87 
[a] Reaction conditions: 178h (0.20 mmol), FeCl3 (15 mol %), ZnCl2·TMEDA (0.6 mmol), ligand (15 mol %), 
PhMgX (1.4 mmol), Oxidant (0.6 mmol), isolated yield. 
Next, we tested the versatility of the iron-catalyzed C–H arylation (Table 3.5). Both electron-
deficient and electron-rich Grignard reagents furnished the products in excellent yields 
(197a-197c). Bicyclic amine 178w was also a reactive substrate in the C–H arylation. 
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Table 3.5. TST-assisted iron-catalyzed C–H arylation.[a] 
 



































[a] Reaction conditions: 1a (0.20 mmol), FeCl3 (15 mol %), ZnCl2·TMEDA (0.60 mmol), dppen (15 
mol %), Ar’MgBr (1.4 mmol), DCIB (0.6 mmol), isolated yield.  
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The synthetic utility of the iron-catalyzed C–H activation strategy was among others 
mirrored by the racemization-free modification of the enantiomerically-enriched 
benzylamine (S)-178a (Scheme 3.4). 
 
Scheme 3.4. Racemization-free C–H methylation of benzylamine (S)-178a. 
3.1.3 KIE studies of Iron-catalyzed Methylation 
As to the catalyst mode of action, we conducted kinetic studies through independent 
experiments and the conversions were determined by 19F NMR. To this end, we unraveled 
a kinetic isotope effect (KIE) of kH/kD ≈ 1.7, being suggestive that the C–H cleavage is 
before or in the rate-determining step (Scheme 3.5). The outstanding efficacy of the iron-
catalyzed C–H activation was further reflected by a 48% conversion of substrate 178k 
within only 25 minutes. 




Scheme 3.5. KIE studies by independent experiments. 
3.1.4 Deprotection of 179  
Finally, the TST group could be removed in a traceless fashion, furnishing the free primary 
benzylamines 198m and 198s, while the reusable TST acid 199a was recovered in high 
yield (Scheme 3.6).[163] 
 
Scheme 3.6. Removal of TST group in a traceless fashion. 
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3.2 Manganese-catalyzed Pyridinyl C–H Alkylation 
In the past few years, direct C–H alkylations of unreactive arenes with alkyl halides have 
been achieved in a site-selective manner by chelation assistance.[164] However, those 
works were mostly realized by expensive and toxic rare 4d and 5d transition metals.[151] 
Particularly, secondary C–H alkylations continue to be scarce, since in many cases β–H 
elimination is more favorable in presence of those metals. Recently much attention has 
shifted to less expensive earth-abundant 3d transition metals for C–H activations such as 
nickel,[165] iron[68, 73] and manganese.[106]  
3.3.1 Optimization of Pyridinyl Alkylation 
Pyridinylamides represent a key unit in a variety of bioactive molecules. Therefore, it is 
urgent to develop some efficient approaches to perform alkylation of pyridinylamide. We 
initiated the study of pyridinyl C–H alkylation by using cyclohexyl halide 180 as the 
alkylation reagents in the presence of MnCl2 (Table 3.6). Various bases including alkyl and 
phenyl Grignard reagents were tested, which showed that ethylmagnesium bromide was 
superior to others (entries 1-4). The chlorocyclohexane even featured higher reactivity for 
this pyridinyl C–H alkylation reaction, while iodocyclohexane gave a modest yield (entries 
5-6). It was found that no alkylated product was formed in the absence of the manganese 
catalyst or TMEDA additive (entries 7-8). Finally, the best result was obtained using      
10 mol % of MnCl2 combined with 1.0 equivalent of TMEDA (entries 9-12). 
Table 3.6. Optimization of pyridinyl C–H alkylation with a secondary alkyl halide.[a] 
 
Entry [Mn] [mol %] TMEDA 
[equiv] 
X RMgBr Yield [%] 
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1 MnCl2 (20) 2.0 Br i-PrMgBr (2.8 M in THF) 65 
2 MnCl2 (20) 2.0 Br EtMgBr (2.8 M in THF) 69 
3 MnCl2 (20) 2.0 Br t-BuCH2MgBr (1.5 M in THF) 56 
4 MnCl2 (20) 2.0 Br PhMgBr (2.3 M in THF) 45 
5 MnCl2 (20) 2.0 Cl EtMgBr (2.8 M in THF) 78 
6 MnCl2 (20) 2.0 I EtMgBr (2.8 M in THF) 48 
7 -- 2.0 Cl EtMgBr (2.8 M in THF) 0 
8 MnCl2 (20) -- Cl EtMgBr (2.8 M in THF) 0 
9 MnCl2 (10) 2.0 Cl EtMgBr (2.8 M in THF) 76 
10 MnCl2 (5) 2.0 Cl EtMgBr (2.8 M in THF) 54 
11 MnCl2 (10) 1.0 Cl EtMgBr (2.8 M in THF) 79 
12 MnCl2 (10) 0.5 Cl EtMgBr (2.8 M in THF) 64 
[a] Reaction conditions: 88a (0.20 mmol), 180 (3.0 equiv), MnCl2 catalyst, TMEDA, RMgBr (3.5 equiv), 
THF (0.6 mL) under N2 at 60 oC for 14 h, isolated yield. 
Dr. Huang finished the optimization of the primary alkylation by the reaction of N-(1-
phenylethyl)picolinamide 88a and n-butyl bromide 86a catalyzed by cost-efficient MnCl2 
(Table 3.7). The assessment of different Grignard reagent showed that bulkier Grignard 
reagents are more efficient to form the butylated product. When t-BuCH2MgBr was used, 
only butylation was observed without formation of any alkylated product generated by 
Grignard reagent (entries 1-7). Dr. Huang also studied other manganese catalysts, such 
as Mn(OAc)2, Mn2(CO)10 and MnBr(CO)5, without any alkylated product (entries 8-10). 
Control experiment without the manganese catalyst did not give the desired product, which 
confirmed that manganese is key for the catalytic reaction (entry 14). Decreased amounts 
of TMEDA gave less product as well (entry 15). 
 
 
Table 3.7. Optimization of pyridinyl C–H primary alkylation. 




Entry [TM] (mol %) TMEDA 
[equiv] 
RMgBr Yield [%] 
200aa/201 
1 MnCl2 (20) 2.0 PhMgBr (2.3 M in THF) 45/35 
2 MnCl2 (20) 2.0 MeMgBr (3.0 M in THF) 55/29 
3 MnCl2 (20) 2.0 EtMgBr (3.4 M in THF) 46/37 
4 MnCl2 (20) 2.0 i-PrMgBr (2.4 M in THF) 58/20 
5 MnCl2 (20) 2.0 i-PrMgBr (3.0 M in 2-MeTHF) 59/22 
6 MnCl2 (20) 2.0 i-PrMgCl (2.0 M in THF) 40/31 
7 MnCl2 (20) 2.0 t-BuCH2MgBr (1.5 M in THF) 69/0 
8 Mn(OAc)2 (20) 2.0 t-BuCH2MgBr (1.5 M in THF) 0/0 
9 Mn2(CO)10 (10) 2.0 t-BuCH2MgBr (1.5 M in THF) 0/0 
10 MnBr(CO)5 (20) 2.0 t-BuCH2MgBr (1.5 M in THF) 0/0 
11 Fe(acac)3 (10) 2.0 t-BuCH2MgBr (1.5 M in THF) 0/0 
12 FeCl3 (10) 2.0 t-BuCH2MgBr (1.5 M in THF) 0/0 
13 MnCl2 (10) 2.0 t-BuCH2MgBr (1.5 M in THF) 42/0 
14 -- 2.0 t-BuCH2MgBr (1.5 M in THF) 0/0 
15 MnCl2 (20) 1.0 t-BuCH2MgBr (1.5 M in THF) 50/0 
[a] Reaction conditions: 88a (0.20 mmol), n-BuBr (3.0 equiv), [Mn] catalyst, TMEDA, RMgBr (3.5 equiv), 
THF (0.2 mL) under N2 at 60 oC for 14 h, isolated yield. 
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3.2.2 Scope of Manganese Catalyzed Alkylation 
After the optimization of the pyridinyl C–H alkylation, the scope and limitation of the 
secondary alkylation was evaluated (Table 3.8). A variety of 3-cyclohexylated 
picolinamides 181aa-181ja was synthesized with high catalytic efficiency. Quinoline was 
also viable to be cyclohexylated (181ka). Significantly, the importance of the reaction was 
underlined by furnishing the compound 181fa on gram scale with a comparable catalytic 
efficiency. 
Table 3.8. Scope of manganese-catalyzed alkylation with chlorocyclohexane. 
 










































































[a] Reaction conditions: 88 (0.20 mmol), 180a (3.0 equiv), MnCl2 catalyst, TMEDA, EtMgBr (3.5 equiv), 
THF (0.6 mL) under N2 at 60 oC for 14 h, isolated yield. 
Then, various secondary alkyl chlorides were tested (Table 3.9). The versatility of the 
optimized methodology was further documented through the cyclopentylation and 
isopropylation of picolinamides (181ib, 181ie). The cyclic secondary alkylchlorides with 
different ring size afforded the corresponding pyridinylamides 181if-181ik. 
Table 3.9. Scope of manganese-catalyzed secondary alkylation with alkyl chlorides 180. 
 



































































[a] Reaction conditions: 88i (0.20 mmol), 180 (3.0 equiv), MnCl2 (10 mol %), TMEDA, EtMgBr (3.5 
equiv), THF (0.6 mL) under N2 at 60 oC for 14 h, isolated yield. 
Next, we turned our attention to the manganese-catalyzed n-butylation with differently 
substituted picolinamides 88 (Table 3.10). Variation of substituents on the amides 88 
were tolerated in this reaction to achieve products 200aa-200ga.  
Table 3.10. Scope of manganese catalyzed butylation. 
 







































[a] Reaction conditions: 88 (0.20 mmol), n-BuBr (3.0 equiv), MnCl2 (10 mol %), TMEDA (2.0 equiv), t-
BuCH2MgBr (3.5 equiv), THF (0.2 mL) under N2 at 60 oC for 14 h, isolated yield. 
Different primary alkylbromides 86 were probed thereafter (Table 3.11). Interestingly, 
terminal alkene and alkyl chlorides were tolerated by this primary alkylation catalyst (200ee 
and 200ef). 
Table 3.11. Scope of manganese catalyzed primary alkylation of pyridine. 
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[a] Reaction conditions: 88e (0.20 mmol), 86 (3.0 equiv), MnCl2 (10 mol %), TMEDA (2.0 equiv),       
t-BuCH2MgBr (3.5 equiv), THF (0.2 mL) under N2 at 60 oC for 14 h, isolated yield. 
The synthetic utility of our manganese-catalyzed C–H alkylation strategy was reflected by 
the derivatization of the optically enriched N-(1-phenylethyl)picolinamide 88a without 
racemization of the stereogenic center (Scheme 3.8). 




Scheme 3.8. Racemization-free C–H cyclohexylation of pyridine (S)-88a. 
3.2.3 Mechanistic Studies of Manganese Catalyzed Alkylation 
As to the elucidation of the reaction mechanism (Scheme 3.9), we subjected 
bromomethylcyclopropane 86g to the optimized conditions and obtained the ring-opening 
product 200ef, which indicated a radical pathway in the activation of the C–Br bond. 
However, the application of 6-bromohex-1-ene 86h only yielded the linear compound 
200eh. Then we performed independent reactions observing a kinetic isotopic effect (KIE) 
of kH/kD ≈ 2.6, thus indicating the C–H cleavage as the rate-determining step. 
 
Scheme 3.9. Mechanistic studies of manganese-catalyzed C–H alkylation. 




3.3 Rhodaelectro-Catalyzed Domino Alkyne Annulations to 
access Aza-Polycyclic Aromatic Hydrocarbons 
To meet the rising demand for the development of sustainable and green synthetic 
methodology, electrosynthesis has emerged as a powerful strategy in which stoichiometric 
amounts of oxidizing and reducing reagents as well as electron transfer events can be 
replaced by electric current. Therefore, the generation of waste can be diminished and 
broader functional groups tolerance can be accomplished. The first rhodaelecto-catalyzed 
annulation to form polycyclic aromatic hydrocarbons was reported by Ackermann.[146] 
Different transformations have been realized by rhodaelectro-catalysis, such as 
olefination,[145] alkylation[144] and annulation.[146, 147] Numerous examples of the formation 
of diverse heterocyclic compounds through the cleavage of C–H/N–H or C–H/O–H bonds 
followed by annulation reactions with alkynes catalyzed by Rhodium(III) have been 
reported.[127-134] Thus far, only a few examples achieved the double C–H activation and 
related C–C or C–X (X=N, O) bond formation.[127, 166] A multiple C–H activation and 
annulation strategy in the presence of rhodaelectro-catalysis to synthesize aza-polycyclic 
aromatic hydrocarbons is envisioned to be highly desirable.  
3.3.1 Optimization of Rhodaelectro-Catalyzed Domino Annulations 
On the basis of previous studies,[127, 146, 166] Dr. Kong from the Ackermann team designed 
a new directing group to investigate the C–H activation and alkyne annulation cascade via 
rhodaelectro-catalysis. The optimization was finished by Dr. Kong. Hence, I performed key 
control experiments. When cationic rhodium(III) catalyst [Cp*Rh(CH3CN)3](SbF6)2 was 
employed as catalyst, the product was obtained in 90% yield (Table 3.12, entry 1). Higher 
loading of the catalyst did not show a decrease of the efficiency (entry 3). When the 
reaction was attempted without electricity, only trace amounts of the desired product 183aa 
was formed (entry 4). No product was observed in the absence of the rhodium catalyst 
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(entry 5). A nitrogen atmosphere failed to improve the yield of this reaction (entry 6). The 
replacement of electricity by Cu(OAc)2 furnished the product in much lower yield (entry 7). 
The use of other electrode materials led to a sharp decrease of the yield. 
Table 3.12. Control experiments for the rhodaelectro-catalyzed cascade reactions.[a] 
 
Entry Variation of standard condotion Yield [%] 
1 no 90 
2 [Cp*RhCl2]2 (2.5 mol %) 75 
3 [Cp*Rh(CH3CN)3](SbF6)2 (2.5 mol %) 89 
4 without electricity trace 
5 Without rhodium catalyst 0 
6 under N2 60 
7 Cu(OAc)2 (4 equiv) instead of electricity 25 
8 platinum plate as anode electrode 67 
9 nickel foam as cathode electrode 65 
[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 182a (0.20 mmol), 113a (0.70 
mmol), [Cp*Rh(CH3CN)3](SbF6)2 (5.0 mol %), KOAc (2.0 equiv), AdCO2H (0.1 equiv), MeOH (4 mL), 35 oC 
under air, isolated yield. 
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3.3.2 Scope of Rhodaelectro-catalyzed C–H Activation and Annulation 
Cascade 
With the optimal reaction conditions in hand, the scope of the electrocatalysis was 
examined with different imidamides 182 (Table 3.13). A broad range of aryl imidamides 182 
bearing electron-donating (182b) and electron-withdrawing groups (182c) proved 
applicable to the electrocatalysis. 
Table 3.13. Rhodaelectro-catalyzed C–H activation with imidamide 182.  
 









































[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 182 (0.20 mmol), 113a (0.70 
mmol), [Cp*Rh(CH3CN)3](SbF6)2 (5.0 mol %), KOAc (2.0 equiv), AdCO2H (0.1 equiv), MeOH (4.0 mL), 35 
oC under air, isolated yield. 
Subsequently, a variety of alkynes 113 was evaluated in the rhodaelectro-catalyzed 
cascade C–H activations (Table 3.14). Alkynes 113 with electron-donating substituents on 
the arene motif delivered the desired products 183ab, 183ac, and 183ad. The trimethylsilyl 
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group was well tolerated under the electrolysis conditions, serving as a handle for further 
transformations, such as Hiyama cross-couplings.[167] The cascade annulative reaction 
proceeded equally well with meta-substituted alkyne 113f, affording the desired product 
183af in high yield and selectivity. Remarkably, challenging unsymmetrical alkyne 113g 
delivered the corresponding product with only two regioisomers and good selectivity. 
Table 3.14. Rhodaelectro-catalyzed C–H activation with alkyne 113. 
 


























































[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 182a (0.20 mmol), 113 (0.70 
mmol), [Cp*Rh(CH3CN)3](SbF6)2 (5.0 mol %), KOAc (0.40 mmol, 2.0 equiv), AdCO2H (0.1 equiv), solvent 
(4.0 mL), 35 oC under air, isolated yield. 
3.3.3 Mechanistic Studies 
The high efficacy of the rhodaelectro-catalyzed cascade C–H activation for aza-PAHs 
synthesis motivated us to delineate its mode of action (Scheme 3.10). Both rhodacycles 
202 and 203 showed catalytic reactivity for the electrocatalysis (Scheme 3.10a). This 
suggested that the three C–H activation steps took place in an order of 1→2→3 (Scheme 
3.10b), which was further substantiated by the structure of PAH 183ja when unsymmetrical 
substrate 182j was employed. As N-methoxylamide was widely used in rhodium- and 
ruthenium- catalyzed C–H annulation,[168] a similar pathway might proceed for our new N-
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methoxylamide directing group, as N–O bond cleavage was observed on rhodacycle 203 
and the products 183. 
 
Scheme 3.10. mechanistic studies of Rhodaelectro-catalyzed C–H activation with alkyne 113. 
3.3.4 Derivatization of Product 183aa 
The obtained aza-PAHs 183 could be easily transformed to valuable functional molecular 
analogs. Treating aza-PAH 183aa with iodomethane thus afforded a cationic nitrogen-
doped nanographene 204 in 93 % yield (Scheme 3.11).  




Scheme 3.11. Methylation of 183aa. 
 
3.4 Rhodaelectro-Catalyzed Switchable Indole Dienylation/ 
Cyclopropylation 
Conjugated dienes and cyclopropanes are key structural motifs in many natural products 
and drugs.[155, 156] These two structures can easily be transferred to other complex 
molecules. Rhodium(III) showed strong power in electricity-enabled C–H activations. 
3.4.1 Optimization Studies for the Switchable Dienylation and 
Cyclopropylation 
Numerous examples of C–H functionalization of indoles catalysed by rhodium(III) have 
been reported with the assistance of pyrimidine.[141d] Therefore, we chose 2-
indolepyrimidine 71a as the model substrate and a constant current of 3.0 mA was applied 
in an undivided cell setup. The optimization for the rhodaelectro-catalyzed dienylation was 
commenced by testing the effect of different carboxylate salts (Table 3.15). Initially, the 
commercially available NaOAc was used to give the dienylated product 184a in good yield 
with good Z/E ratio. The sterically encumbered NaOPiv failed to improve the 
regioselectivity of this transformation. Aromatic carboxylate salts failed to increase the yield 
and selectivity of the reaction (entries 3-4). Fortunately, the desired product 184a was 
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obtained in 85% yield and 4.5/1 Z/E ratio by NaO2CAd (entry 5). Then, weaker bases were 
also tested but not give better results (entries 6-7). 
Table 3.15. Screening of the bases.[a] 
 
Entry Base Yield [%] Z/E 
1 NaOAc 72 3.9/1 
2 NaOPiv 78 3.5/1 
3 NaO2CMes 60 4.0/1 
4 NaO2CPh 82 3.6/1 
5 NaO2CAd 85 4.5/1 
6 NaO2CCF3 72 3.5/1 
7 NaO3SCF3 trace -- 
[a] Undivided cell, graphite felt anode (GF), platinum plate cathode, 71a (0.10 mmol) 138a (0.16 mmol), 
[Cp*RhCl2]2 (2.5 mol %), base (20 mol %), CypCO2H (10 mol %), solvent (4.0 mL), 85 oC, CCE @ 3.0 mA, 
under air, yield of isolated product, Z/E ratio determined by 1H NMR, CypCO2H = cyclopentanecarboxylic 
acid.  
Next, we turned to the evaluation of the effect exerted by the acids (Table 3.16). The use 
of acetic acid showed lower efficiency than CypCO2H (entries 1-2). Other carboxylic acids 
with bulkier group also gave similar efficiency (entries 3-4). We also tried stronger 
carboxylic acids, but reaction efficiency was not improved (entries 5-6).  
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Table 3.16. Screening of different acids.[a] 
 
Entry Acid Yield [%] Z/E 
1 CypCO2H 85 4.5/1 
2 AcOH 76 3.6/1 
3 PivOH 82 3.3/1 
4 AdCO2H 82 4.0/1 
5 PhCO2H 79 3.7/1 
6 MesCO2H 78 3.8/1 
[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71a (0.10 mmol) 138a (0.16 mmol), 
[Cp*RhCl2]2 (2.5 mol %), NaO2CAd (20 mol %), acid (10 mol %), solvent (4.0 mL), 85 oC, CCE @ 3.0 mA, 
under air, 4.0 h, yield of isolated product, Z/E ratio determined by 1H NMR. 
Then, we resorted to the optimization of different solvents (Table 3.17). The variation of the 
ratio between 1,4-dioxane and water were conducted, yet not improve the efficiency of the 
reaction (entries 1-3). Another mixture of solvents t-AmOH/H2O (3/1) (entry 4), often used 
for the electrochemistry,[144] furnished the dienylated product 184aa in lower yield and Z/E 
ratio. The electrocatalysis was applicable to water-free system while with lower efficiency 
(entries 5-6). 
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Table 3.17. Optimization of solvents. 
 
Entry Solvent Yield (%) Z/E 
1 1,4-dioxane/H2O (1/1) 85 4.5/1 
2 H2O trace -- 
3 1,4-dioxane/H2O (2/1) 72 3.4/1 
4 t-AmOH/H2O (3/1) 82 2.5/1 
5 DMF trace -- 
6 EtOH 74 3.7/1 
[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71a (0.10 mmol) 184a (0.16 
mmol), [Cp*RhCl2]2 (2.5 mol %), base (20 mol %), acid (10 mol %), solvent (4.0 mL), 85 oC, CCE @ 3.0 
mA, under air, yield of isolated product, Z/E ratio determined by 1H NMR. 
Subsequently, control experiments were conducted (Table 3.18). The absence of the 
catalyst [Cp*RhCl2]2 resulted in no conversion of the starting material (Table 3.20, entry 2). 
Reactions in the absence of NaO2CAd or CpCO2H gave worse results. A low yield was 
obtained without electricity (entry 5). Other transition metal catalysts were tested, yet failed 
to assemble the desired product (entries 6-7).  
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Table 3.18. Control experiments.[a] 
 
Entry [TM] Base Acid Yield [%] Z/E 
1 [Cp*RhCl2]2 NaO2CAd CypCO2H 85 4.5/1 
2 -- NaO2CAd CypCO2H -- -- 
3 [Cp*RhCl2]2 -- CypCO2H 32 3.2/1 
4 [Cp*RhCl2]2 NaO2CAd -- 72 3.6/1 
5[b] [Cp*RhCl2]2 NaO2CAd CypCO2H 24 2.4/1 
6 [RuCl2(p-cymene)]2 NaO2CAd CypCO2H -- -- 
7 Pd(OAc)2 NaO2CAd CypCO2H -- -- 
[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71a (0.10 mmol) 138a (0.16 
mmol), [M] (2.5 mol %), NaO2CAd (20 mol %), CypCO2H (10 mol %), 1,4-Dioxane/H2O (1/1) (4.0 mL), 85 
oC, CCE @ 3.0 mA, under air, yield of isolated product, Z/E ratio determined by 1H NMR. [b] Without 
electricity, 12 h. 
Small variation of the current did not give better results (Table 3.19, entries 2-3). An 
increased amount of NaO2CAd displayed better selectivity (entry 4). The C–H dienylation 
proceeded well at larger scale and higher temperature with the desired product obtained 
in higher yield and selectivity. 
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Table 3.19. Further optimization of rhodaelectro-C–H-dienylation.[a] 
 
Entry Current (mA) t [H] Yield [%] Z/E 
1 3.0 4.0 85 4.5/1 
2 2.0 6.0 87 3.8/1 
3 4.0 3.0 72 3.2/1 
4[b] 3.0 4.0 82 6.0/1 
5[b, c] 5.0 3.0 87 6.5/1 
6[b, c, d] 5.0 3.0 89 7.0/1 
[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71a (0.10 mmol) 138a (0.16 
mmol), [Cp*RhCl2]2 (2.5 mol %), NaO2CAd (20 mol %), CypCO2H (10 mol %), 1,4-dioxane/H2O (1/1) 
4.0 mL, 85 oC, CCE @ 3.0 mA, under air, yield of isolated product, Z/E ratio determined by 1H NMR. 
[b] NaO2CAd (40 mol %). [c] reaction performed on 0.2 mmol scale. [d] at 95 ºC. 
With the optimized reaction conditions for the novel C–H dienylation reaction in hand, a 
benzyl substituted cyclopropane 185a was employed (Scheme 3.12), in which a unique 
direct C–H cyclopropanylated indole 186aa was formed in high yield without the detection 
of (Z)-conformation.  
 
Scheme 3.12. Cyclopropanylation of indole. 
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3.4.2 Scope of the Switchable Dienylation and Cyclopropanylation 
With the optimized reaction conditions for electrochemical C–H dienylations in hand, the 
versatility was explored with substituted indoles 71 (Table 3.20). Although 3- or 7-methyl 
indoles delivered the desired products in moderate yields, 3-methyl indole showed much 
a better selectivity (184ba, 184oa). Fluorine and methoxy-substituted indoles 71c and 71f 
were transformed efficiently, while 6-substituted indoles (184ka, 184ma) was converted 
less efficiently. Various functional group was tolerated, such as chloride, bromide and cyan. 
Interestingly, indoles 71n with ester functionality at the 6-position delivered 184na in high 
yield and good selectivity. This dienylation protocol was applicable to pyrrole 71p. 
Table 3.20. Electrochemical C–H dienylation of different indoles 71 with 185a.[a] 
 





























































































































[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71 (0.20 mmol) 138a (0.32 mmol, 
1.6 equiv), [Cp*RhCl2]2 (2.5 mol %), NaO2CAd (40 mol %), CypCO2H (10 mol %), 1,4-dioxane/H2O (1:1) 
8.0 mL, 95 ºC, CCE @ 5.0 mA, 3-5 h, under air, yield of isolated product, Z/E ratio determined by 1H NMR. 
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Next, the robustness of the rhodaelectro-catalyzed dienylation was evaluated with a variety 
of functionalized cyclopropanes 138 (Table 3.21). We found that methy- and phenyl- 
groups were tolerated by the electrocatalysis (184ab, 184ac). Substrates containing the 
bromo group delivered the products 184ae and 184am in good yields but with a lower Z/E 
ratio. Electron-deficient substrates 138i and 138j showed a good reactivity in this method 
in contrast to previous studies[144-147] and electron-rich compounds performed well in this 
transformation.  
Table 3.21. Electrochemical C–H Dienylation with cyclopropane 138.[a] 
 


































































































































[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71a (0.20 mmol) 184 (0.32 mmol), 
[Cp*RhCl2]2 (2.5 mol %), NaO2CAd (40 mol %), CypCO2H (10 mol %), 1,4-dioxane/H2O (1:1) 8.0 mL, 95 
ºC, CCE @ 5.0 mA, under air, yield of isolated product, Z/E ratio determined by 1H NMR. 
After the evaluation of the scope for the C–H dienylation, we turned to probing the versatility 
of the unprecedented electrochemical cyclopropylation with functionalized indoles 71 
(Table 3.22). We found that a reactive hydroxyl group is tolerated despite the steric 
hinderance 186qa. The halogen-containing indoles (186ga, 186ha and 186ra), even highly 
reactive iodo, were viable substrates. Indoles containing electron-withdrawing 71d, 71n or 
electron-donating groups 71c, 71i were transfered efficiently. For 7-methyl indole, the 
cyclopropylation showed higher efficiency compared to the dienylation (186oa). To our 
delight, 2-phenyl pyridine could also be employed under the reaction condition though with 
moderate yield (186sa). Interestingly, a tryptamine derived substrate could form the 
challenging ring-opening product 186ta’. 
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Table 3.22. Electrochemical C–H cyclopropylation of indole 71 with 185a. 
 










































































































[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71 (0.20 mmol) 185a (0.32 
mmol, 1.6 equiv), [Cp*RhCl2]2 (2.5 mol %), NaO2CAd (40 mol %), CypCO2H (10 mol %), 1,4-
dioxane/H2O (1:1) 8.0 mL, 95 ºC, CCE @ 5.0 mA, under air, yield of isolated product. 
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Subsequently a series of cyclopropanes 185 were examined for the C–H cyclopropylation 
reaction (Table 3.23). A substrate bearing the iodo-substituent gave the desired product 
186ac in moderate yield along with a small amount of the deiodinated product 
(186aa/186ac 1:3). The reaction conditions were compatible with linear or branched-alkyl 
derived cyclopropanes (186ad-186af). The challenging cyclopropane bearing a terminal 
alkene was also found to be a viable substrate, affording product 186ag in 79% yield. The 
transformation was also tolerant for other changes to the backbone of the cyclic alkanes 
and generated the expected products in moderate yields (186ah, 186ai). Indeed, the 
structurally complex natural product Citronellol-derived starting material could be 
selectively converted to the desired product 186aj. 
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Table 3.23. Electrochemical C–H cyclopropylation with methylenecyclopropanes 185.[a] 
 




























































[a] Undivided cell, graphite felt anode (GF), platinum plate cathode (Pt), 71a (0.20 mmol) 185 (0.32 mmol， 
1.6 equiv), [Cp*RhCl2]2 (2.5 mol %), NaO2CAd (40 mol %), CypCO2H (10 mol %), solvent (8.0 mL), 95 ºC,  
CCE @ 5.0 mA, under air, yield of isolated product. 
3.4.3 Derivatization of the Diene 184aa 
Based on the scope evaluation of both C–H dienylation and C–H cyclopropylation, some 
transformations of product diene 184aa were conducted (Scheme 3.13). Thus, a Diels-
Alder reaction of dienylated product 184aa with alkyne 207 was tried for the construction 
of the 1,4-cyclohexadiene skeleton (Scheme 3.13a). Hydroquinone[169] was confirmed to 
be a suitable catalyst to produce alkene 208 in good yield. With alkene 208 in hand, we 
extended the conjugation of the thus-formed product 208 through dehydrogenation of the 
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diene moiety. Thus, the desired product 209 was obtained in good yield using catalytic 
amounts of DDQ as the redox mediator at room temperature with CH2Cl2 and MeOH as 
the solvent (Scheme 3.13b). 
 
Scheme 3.13. Derivatization of 1,3-diene 184aa. 
3.4.4 Mechanistic Investigation of Cyclopropylation and Dienylation 
Based on a previously reported mechanism,[170] we propose a reasonable catalytic cycle 
for the C–H cyclopropylation (Figure 3.1) and C–H dienylation (Figure 3.2), respectively. 
The catalytic cycle is initiated by the formation of a catalytically competent mononuclear 
Cp*Rh(III) species 210. As shown in Figure 3.1, coordination by the nitrogen of the 
pyrimidine indole 71a to Cp*Rh(III) and the following C–H activation at the 2-position 
affords rhodacycle 211. Then, insertion of alkene 185a occurs to furnish intermediate 212, 
which undergoes β-H elimination to generate the cyclopropylated product 186aa along with 
a rhodium(I) complex.[125a] Finally the Cp*Rh(III) species 210 can be regenerated by 
reoxidation of rhodium(I) at the anode, generating molecular hydrogen as the byproduct 
produced at the cathode. 
 




Figure 3.1. Proposed mechanism for rhodaelectro-C–H-cyclopropylation. 
In terms of dienylation, the formed intermediate 213 after the insertion of alkene 138a to 
rhodacycle 211 can undergo β-C elimination to form intermediate 214 as there are no    
β-hydrogens in intermediate 213 (Figure 3.2). The resulted intermediate 214 undergoes β-
H elimination and delivers the dienylated indole 184aa. 
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4 Summary and Outlook 
The avoidance of time- and energy-consuming prefunctionalization which generate 
stoichiometric amounts of waste has made direct functionalization of C–H bonds emerging 
as an environmentally benign alternative. While major progress was realized with noble 
transition metal catalysts, the employment of cost-effective and earth-abundant 3d metals 
has gained significant momentum during the last decade. As stoichiometric amounts of 
oxidants are often needed for the C–H activation, electricity has been identified as an 
inexpensive, economical, and environmental benign alternative for chemical redox 
equivalents. Thus, my projects have focused on both the earth-abundant 3d metals and 
resource-economic electrochemical C–H bond transformations. 
In the first project, we achieved an expedient C–H functionalization of electron-rich benzyl 
and aryl amines by sustainable iron-catalysis with the assistance of a new fully substituted 
triazole TST directing group enabling C–H methylations, alkylations and arylations. This 
transformation featured racemization-free conditions and a newly developed reusable 
versatile TST group. Due to the magic contributions of methyl group to biological 
molecules,[149] this method may help to accelerate the discovery of new drugs. 
 
Scheme 4.1. Iron-catalyzed C–H functionalization by TST-assistance. 
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With the significant progresses in C–H activation, much attention has been paid to the use 
of weakly-coordinated directing groups and late-stage functionalization of biomolecules. In 
the second project, we developed a direct ortho-alkylation of pyridines by weak assistance 
of amides. A variety of alkylated pyridines were obtained via low-valent manganese-
catalyzed alkylations. Mechanistic studies showed that SET-type C–X bond cleavage 
occurred during the C–H functionalization. 
 
Scheme 4.2. Alkylation of pyridines catalyzed by manganese(II). 
In the third project, a modular assembly of aza-PAHs enabled by rhodaelectro-catalyzed 
cascade C–H functionalization was developed. A multifunctional and transformable O-
methylamidoxime was designed to guarantee the reactivity and selectivity. The isolation of 
two C–H-activated rhodacycles offered the proof for sequence of the cascade C–H 
activation. The electrosynthesis demonstrated broad substrate scope and excellent 
functional group tolerance, including iodo and azido groups. The practicality of this reaction 
was reflected by its mild conditions, most user-friendly setup, and easy scale-up.  




Scheme 4.3. Rhodaelectro-catalyzed Domino C−H annulations for the assembly of aza-
nanographenes. 
In the last project, we have developed a bifurcated C–H cyclopropylation and dienylation 
of indoles by rhodaelectro-catalysis under aqueous conditions, avoiding the use of 
stoichiometric amounts of chemical oxidants. The reactive catalyst can be regenerated by 
anodic oxidation, producing hydrogen as the sole byproduct. Thereby, a wealth of indoles 
can be directly dienylated and cyclopropylated with good chemo-, position- and 
regioselectivities. Notably, electron-deficient compounds also performed well in this 
reaction. This method can serve as a new strategy for developing drugs containing 
cyclopropane motifs. 
 
Scheme 4.4. Rhodaelectro-catalyzed bifurcated indole C−H activation with MCPS. 
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5 Experimental Section 
5.1 General Remarks 
All reactions involving reagents or products sensitive to moisture or air were performed 
under an atmosphere of nitrogen using standard Schlenk techniques and pre-dried 
glassware. If not mentioned otherwise, yields refer to isolated compounds, estimated to 
be >95% pure as determined by 1H NMR. In case NMR yields are reported, they were 
determined by using an internal standard. 
Vacuum 
The used Schlenk line was connected to a Vacuubrand® rotary vane pump. The following 
pressure was measured at the outlet of the used Schlenk line: 0.1 mbar. The values are 
not corrected. 
Melting points 
Melting points were measured by using a Stuart Melting Point Apparatus SMP3 from 
BarloworldScientific. The given values are not corrected. 
Chromatography 
Thin layer chromatography (TLC) was performed on Merck, silica gel 60 F254 aluminum 
TLC plates. Visualization of the substances was achieved by exposure to UV light at 254 
nm or by treatment of the plates with a chemical staining agent. Purification by column 
chromatography refers to flash column chromatography using Merck silica gel, grade 60 
(40–63 μm, 230-400 mesh ASTM) and pre-distilled solvents. 
Gas Chromatography 
Sample analysis and reaction monitoring was performed via coupled gas chromatography 
mass spectrometry on a 7890B GC System from Agilent Technologies coupled with either 
a 5977A or a 5977B mass detector from Agilent Technologies. 
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Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR spectra were recorded on Varian VX 300, Bruker Avance 300, Bruker Avance 400 
and 500 or Varian Inova 500 and 600 spectrometers in the solvent indicated. Chemical 
shifts are reported as δ values in ppm. 1H- and 13C-NMR spectra were referenced using 
the residual solvent signal. The coupling constants J are reported in Hertz (Hz). 
NMR 1H NMR 13C NMR 
CDCl3 7.26 77.16 
Abbreviations for the characterization of the signals are: s (singlet), d (doublet), t (triplet), 
q (quartet), dd (doublet of doublets), m (multiplet) and sbr (broad singlet) or analogous 
representations. For all spectra, a baseline and phase correction were performed. Mnova 
10 from Mestrelab Research was used for the processing and analysis of the spectra.  
Mass Spectrometry 
Electrospray ionization (ESI) and high-resolution mass spectra (HR-MS) spectra were 
recorded on either a time-of-flight mass spectrometer micrOTOF (ESI-TOF-MS) or a 
quadrupole time-of-flight maXis (ESI-QTOF-MS) spectrometer, both from Bruker Daltonic. 
Infrared Spectroscopy 
Infrared (IR) spectra were recorded on a Bruker Alpha-P ATR spectrometer. Liquid 
samples were measured as a film and solid samples were measured neat. The spectra 
were recorded in the range from 4000 to 400 cm⁻1. The analysis was performed using 
Opus 6 from Bruker. Reported are the most significant peaks and their respective wave 
numbers (cm-1). 
Electrochemistry 
Pt electrodes (10 mm × 15 mm × 0.25 mm, 99.9%; obtained from ChemPur®Karlsruhe, 
Germany) and RVC electrodes (10 mm×15 mm×6 mm, SIGRACELL®GFA 6 EA, obtained 
from SGL Carbon, Wiesbaden, Germany) were connecteC using stainless steel adapters. 
Electrolysis was conducteC using an AXIOMET AX-3003P potentiostat in constant current 
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mode. Divided cells separated by a P4-glassfrit were obtained from Glasgerätebau Ochs 
Laborfachhandel e. K. (Bovenden, Germany). 
Solvents 
Solvents used for column chromatography were purified by distillation under reduced 
pressure prior to use. Solvents purified by a solvent purification system (SPS-800) from M. 
Braun: dichloromethane, toluene, diethyl ether, tetrahydrofuran, and dimethylformamide. 
Solvents dried and distilled over sodium with benzophenone as an indicator: toluene, 
xylenes, mesitylene, 1,4-dioxane, di-n-butyl ether, and dimethoxyethane. Solvents dried 
and distilled over CaH2: 1,2-dichloroethane, dimethylacetamide, dimethylformamide, 
dimethylsulfoxide. Solvents dried over molecular sieves and degassed by freeze-pump-
thaw cycles: acetonitrile (3 Å). Water was degassed by sparging with N2 and simultaneous 
sonification for 2 h. 
Reagents 
Chemicals obtained from commercial suppliers (with a purity >95%) were used without 
further purification. The following compounds have been previously reported and were 
synthesized according to previously described literature protocols: 
TST amide 178,[67] N-(1-phenylethyl)picolinamide 178f,[171] heterocycles azine 88,[172] 
imidamides 182,[147] alkynes 113,[173] [Cp*Rh(CH3CN)3](SbF6)2,[174] N-Pyrimidyl indoles 
71,[175] methylenecyclopropanes 138 and 185.[176] 
The following chemicals were kindly supplied by the following coworkers: 
Karsten Rauch: [Cp*RhCl2]2. 
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5.2 General Procedures 
5.2.1 General Procedure A: Iron-catalyzed C–H Methylation 
To a schlenk tube charged with amide 178 (0.20 mmol), TMEDA∙ZnCl2 (152 mg, 0.60 mmol, 
3.0 equiv) and 1.0 mL THF was added MeMgBr (457 μL, 1.4 mmol, 3.0 M in ether, 7.0 
equiv) in one portion at room temperature. Five minutes later, dppen (11.9 mg, 0.03 mmol, 
15 mmol %) and FeCl3 (4.9 mg, 0.03 mmol, 15 mmol %) were added successively. Stirring 
at room temperature for another five minutes, 2,3-dichloridebutane was added and the 
reaction was moved to 65 oC oil bath stirring overnight. Then quenched with sat. aqueous 
NH4Cl, diluted with 10 mL water. The aqueous layer was extracted with EtOAc. The 
combined organic extracts were washed with brine and dried over Na2SO4. The filtrate was 
concentrated under reduced pressure and the crude product was purified by column 
chromatography on silica gel. 
5.2.2 General Procedure B: Iron-catalyzed C–H Arylation 
To a schlenk tube charged with amide 178 (0.20 mmol), TMEDA∙ZnCl2 (152 mg, 0.60 mmol, 
3.0 equiv) and 1.0 mL THF was added ArMgBr (457 μL, 1.0 mmol, 2.0 M in ether, 5.0 equiv) 
in one portion at room temperature. Five minutes later, dppen (11.9 mg, 0.03 mmol, 15 
mmol %) and FeCl3 (4.9 mg, 0.03 mmol, 15 mmol %) were added successively. Stirring at 
room temperature for another five minutes, 2,3-dichloridebutane was added and the 
reaction was moved to 65 oC oil bathe stirring overnight. Then quenched with sat. aqueous 
NH4Cl, diluted with 10 mL water. The aqueous layer was extracted with EtOAc. The 
combined organic extracts were washed with brine and dried over Na2SO4. The filtrate was 
concentrated under reduced pressure and the crude product was purified by column 
chromatography on silica gel. 
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5.2.3 General Procedure C: Manganese-catalyzed Secondary Alkylation 
To a Schlenk tube charged with amide 88 (0.20 mmol), TMEDA (30 µL, 0.20 mmol) MnCl2 
(2.7 mg, 0.02 mmol) and THF (0.60 mL), EtMgBr (0.25 mL, 0.70 mmol, 2.8 M in THF) was 
added dropwise at ambient temperature under N2 atmosphere. After stirring for 5 min, 
alkylchloride 2 (0.60 mmol) was added and the reaction mixture stirred at 60 oC for 14 h. 
Then, saturated aqueous NH4Cl (5.0 mL) and H2O (10 mL) were subsequently added to 
the reaction mixture. The aqueous layer was extracted with EtOAc (3 x 15 mL). The 
combined organic extracts were washed with brine and dried over Na2SO4. The filtrate was 
concentrated under reduced pressure and the crude product was purified by column 
chromatography on silica gel. 
5.2.4 General Procedure D: Manganese-catalyzed Primary Alkylation 
To a Schlenk tube charged with amide 88 (0.20 mmol), TMEDA (60 µL, 0.40 mmol) MnCl2 
(5.4 mg, 0.04 mmol) and THF (0.20 mL), t-BuCH2MgBr (0.47 mL, 0.7 mmol, 1.5 M in THF) 
was added dropwise at ambient temperature under N2 atmosphere. After stirring for 5 min, 
alkylchlorides 180 (0.60 mmol) was added and the reaction mixture stirred at 60 oC for 14 
h. Then, saturated aqueous NH4Cl (5.0 mL) and H2O (10 mL) were subsequently added to 
the reaction mixture. The aqueous layer was extracted with EtOAc (3 x 15 mL). The 
combined organic extracts were washed with brine and dried over Na2SO4. The filtrate was 
concentrated under reduced pressure and the crude product was purified by column 
chromatography on silica gel. 
5.2.5 General Procedure E: Rhodaelectro-catalyzed Domino alkyne 
annulation 
The electrocatalysis was carried out in an undivided cell with a graphite felt anode (10 mm 
× 15 mm × 6 mm) and a Pt cathode (10 mm × 15 mm × 0.25 mm). The cell was charged 
with imidamide 182 (0.20 mmol), alkyne 113 (0.70 mmol), KOAc (74.4 mg, 0.40 mmol), 1-
Adamantanecarboxylic acid (AdCO2H, 3.6 mg, 10 mol %), [Cp*Rh(CH3CN)3](SbF6)2 
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(8.4 mg, 5.0 mol %) and MeOH (4.0 mL). Electrocatalysis was performed at 35 °C with a 
constant current of 2.0 mA maintained for 12 h. The graphite felt anode was washed with 
CH2Cl2 (8 × 5 mL) in an ultrasonic bath. Evaporation of the solvents and subsequent 
column chromatography on silica gel afforded the corresponding product 183. 
5.2.6 General Procedure F: Rhodaelectro-Catalyzed Dienylation 
The electrolysis was carried out in an undivided cell with a GF (10 mm x 15 mm x 6 mm) 
and a Pt cathode (10 mm x 15 mm x 0.25 mm). [Cp*RhCl2]2 (3.0 mg, 0.005 mmol, 2.5 
mol %), NaO2CAd (16.0 mg, 0.80 mmol, 40 mol %), cyclopentanecarboxylic acid (2.3 mg, 
0.02 mmol, 10 mol %), cyclopropane 138 (0.32 mmol, 1.6 equiv) and indole 71 (0.20 mmol) 
were dissolved in 1,4-dioxane (4.0 mL) and then H2O (4.0 mL) was added sequentially. At 
95 °C, electrolysis was conducted with a constant current of 5.0 mA for 3 to 10 hours. Then 
the mixture was transferred to a flask and the electrodes were rinsed with EtOAc (3 x 5.0 
mL). The combined solvent was extracted with EtOAc (3 x 10 mL) for three times, 
combined the organic layer, removed the solvent under reduced pressure and subsequent 
column chromatography on silica gel (n-hexane/EtOAc) yielded the desired product 184. 
5.2.7 General Procedure G: Rhodaelectro-Catalyzed Cyclopropylation 
The electrolysis was carried out in an undivided cell with a GF (10 mm x 15 mm x 6 mm) 
and a platinum cathode (10 mm x 15 mm x 0.25 mm). [Cp*RhCl2]2 (3.0 mg, 0.005 mmol, 
2.5 mol %), NaO2CAd (16.0 mg, 0.80 mmol, 40 mol %), cyclopentanecarboxylic acid (2.3 
mg, 0.20 mmol, 10 mol %), cyclopropane 185 (0.32 mmol, 1.6 equiv) and indole 71 (0.20 
mmol) were dissolved in 1,4-dioxane (4.0 mL) and then water (4.0 mL) was added 
sequentially. At 95 °C, electrolysis was conducted with a constant current of 4.0 mA for 3 
to 10 hours. Then the mixture was transferred to a flask and the electrodes were rinsed 
with EtOAc (3 x 5.0 mL). The combined solvent was extracted with EtOAc (3 x 10 mL) for 
three times, combined the organic layer, removed the solvent under reduced pressure and 
subsequent column chromatography on silica gel (n-hexane/EtOAc) yielded the desired 
product 186. 




5.3 Iron Catalyzed C–H Activation 




Prepared following the general procedure A by using 178a (64.0 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179a (58.9 mg, 86%) 
as a white solid. M.p. = 72–73 °C. 1H NMR (300 MHz, CDCl3) δ = 7.76 (d, J = 7.7 Hz, 1H), 
7.37–7.30 (m, 3H), 7.15–7.12 (m, 2H), 7.06–6.97 (m, 3H), 5.70 (q, J = 7.3 Hz, 1H), 5.49 (s, 
2H), 2.54 (s, 6H), 2.46 (s, 3H), 1.61 (d, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 
160.2 (Cq), 139.0 (Cq), 138.7 (Cq), 135.9 (Cq), 135.3 (Cq), 134.0 (Cq), 129.4 (CH), 129.0 
(CH), 128.4 (CH), 127.0 (CH), 126.7 (CH), 51.8 (CH2), 45.2 (CH), 21.1 (CH3), 19.8 (CH3), 
8.8 (CH3). IR (ATR): 3359, 2963, 1650, 1505, 1073, 746, 402 cm–1. MS (ESI) m/z (relative 
intensity) 371 (100) [M+Na]+, 349 (30) [M+H]+, 217 (10), 133 (5). HR-MS (ESI) m/z calcd 
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Prepared following the general procedure A by using 178b (66.4 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179b (65.3 mg, 89%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 7.61 (brs, 1H), 7.38–7.31 (m, 3H), 
7.17–7.14 (m, 2H), 6.99–6.97 (m, 3H), 5.49 (s, 2H), 2.52 (s, 6H), 2.43 (s, 3H), 1.97 (s, 6H). 
13C NMR (75 MHz, CDCl3) δ = 159.3 (Cq), 143.0 (Cq), 139.2 (Cq), 136.0 (Cq), 135.4 (Cq), 
134.1 (Cq), 131.8 (CH), 129.1 (CH), 128.5 (CH), 127.2 (CH), 126.2 (CH), 58.7 (Cq), 51.8 
(CH2), 30.5 (CH3), 25.6 (CH3), 8.8 (CH3). IR (ATR): 3342, 2983, 1657, 1503, 1257, 604, 
573 cm–1. MS (ESI) m/z (relative intensity) 385 (100) [M+Na]+, 363 (80) [M+H]+, 257 (50), 





Prepared following the general procedure A by using 178c (67.2 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179c (65.3 mg, 89%) 
as a yellow solid. M.p. = 104–106 °C.1H NMR (300 MHz, CDCl3) δ = 7.81 (d, J = 7.7 Hz, 
1H), 7.36–7.31 (m, 2H), 7.07–6.98 (m, 5H), 5.73 (q, J = 7.3 Hz, 1H), 3.88 (s, 3H), 2.56 (s, 
6H), 2.55 (s, 3H), 1.64 (d, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 160.45 (Cq), 
160.24 (Cq), 139.00 (Cq), 138.20 (Cq), 136.57 (Cq), 135.31 (Cq), 129.4 (CH), 128.4 (Cq), 
126.7 (CH), 126.5 (CH), 114.6 (CH), 55.6 (CH3), 45.3 (CH), 21.1 (CH3), 19.8 (CH3), 9.7 
(CH3). IR (ATR): 3417, 2974, 1664, 1509, 1254, 766, 589 cm–1. MS (ESI) m/z (relative 
intensity) 387 (65) [M+Na]+, 365 (100) [M+H]+, 233 (70), 188 (2), 133 (65). HR-MS (ESI) 
m/z calcd for C21H25N4O2 [M+H]+ 365.1978 found 365.1972. 
 






Prepared following the general procedure A by using 178d (62.9 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179d (48.1 mg, 70%) 
as a yellow liquid. 1H NMR (300 MHz, CDCl3) δ = 7.74 (d, J = 7.3 Hz, 1H), 7.05–6.96 (m, 
3H), 5.70 (p, J = 7.3 Hz, 1H), 4.23 (t, J = 7.2 Hz, 2H), 2.56 (s, 3H), 2.54 (s, 6H), 1.91–1.78 
(m, 2H), 1.60 (d, J = 7.3 Hz, 3H), 1.34–1.26 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ = 160.3 (Cq), 139.0 (Cq), 138.1 (Cq), 135.3 (Cq), 129.4 (CH), 126.7 (CH), 
47.8 (CH2), 45.2 (CH), 31.2 (CH2), 29.7 (CH2), 26.1 (CH2), 22.4 (CH2), 21.0 (CH3), 19.7 
(CH3), 13.9 (CH3), 8.7 (CH3). IR (ATR): 3425, 2927, 1666, 1503, 1209, 772, 562 cm–1. MS 
(ESI) m/z (relative intensity) 365 (100) [M+Na]+, 343 (60) [M+H]+, 211 (30), 133 (20). HR-




Prepared following the general procedure A by using 178f (62.9 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 3:1) yielded 179f (26.7 mg, 51%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 8.57 (d, J = 6.4 Hz, 1H), 8.48 (ddd, J 
= 4.8, 1.7, 0.9 Hz, 1H), 8.08 (td, J = 7.7, 0.9 Hz, 1H), 7.75 (td, J = 7.7, 1.7 Hz, 1H), 7.33 
(ddd, J = 7.6, 4.8, 1.3 Hz, 1H), 6.99–6.90 (m, 3H), 5.72–5.62 (m, 1H), 2.48 (s, 6H), 1.57 (d, 
J = 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 163.2 (Cq), 150.0 (Cq), 148.1 (CH), 139.5 
(Cq), 137.3 (CH), 135.54 (Cq), 129.5 (CH), 126.9 (CH), 126.0 (CH), 122.2 (CH), 45.6 (CH), 
21.0 (CH3), 19.7 (CH3). IR (ATR): 3402, 2997, 1679, 1497, 991, 740, 560 cm–1. MS (ESI) 
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m/z (relative intensity) 277 (100) [M+Na]+, 255 (40) [M+H]+, 123 (30). HR-MS (ESI) m/z 





Prepared following the general procedure A by using 178g (70.2 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179g (64.3 mg, 88%) 
as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ = 8.67 (d, J = 9.6 Hz, 1H), 7.34–7.27 
(m, 3H), 7.14–7.08 (m, 3H), 6.80–6.77 (m, 2H), 5.74 (q, J = 7.0 Hz, 1H), 5.48 (s, 2H), 3.96 
(s, 3H), 2.48 (s, 3H), 2.47 (s, 3H), 1.55 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
= 160.2 (Cq), 158.1 (Cq), 139.2 (Cq), 136.3 (Cq), 135.9 (Cq), 134.2 (Cq), 129.1 (Cq), 129.0 
(CH), 128.4 (CH), 127.6 (CH), 127.1 (CH), 123.2 (CH), 109.3 (CH), 55.5 (CH3), 51.7 (CH2), 
43.1 (CH), 20.2 (CH3), 20.0 (CH3), 8.7 (CH3). IR (ATR): 3415, 2847, 1664, 1587, 1244, 
7330, 581 cm–1. MS (ESI) m/z (relative intensity) 387 (100) [M+Na]+, 365 (40) [M+H]+, 217 





Prepared following the general procedure A by using 178h (67.7 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179h (60.8 mg, 86%) 
as a white solid. M.p. = 92–94 °C. 1H NMR (400 MHz, CDCl3) δ = 7.97 (d, J = 9.0 Hz, 1H), 
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7.34–7.27 (m, 3H), 7.14–7.06 (m, 3H), 6.93–6.87 (m, 2H), 5.68–5.60 (m, 1H), 5.48 (s, 2H), 
2.51 (s, 3H), 2.46 (s, 3H), 1.60 (dd, J = 7.1, 1.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 
162.1 (d, 1JC–F = 244.3 Hz, Cq),160.4 (Cq), 138.7 (Cq), 137.4 (d, 4J = 5.0 Hz, Cq), 136.0 (Cq), 
134.1 (Cq), 129.0 (CH), 128.7 (d, 3JC–F = 11.4 Hz, Cq),128.4 (CH), 128.0 (d, 4JC–F = 9.8 Hz, 
CH), 127.1 (CH), 126.1 (d, 4JC–F = 2.6 Hz, CH), 113.9 (d, 2JC–F = 22.6 Hz, CH), 51.7 (CH2), 
42.6 (CH), 20.5 (d, 4JC–F = 3.0 Hz, CH3), 19.6 (d, 4JC–F = 2.5 Hz, CH3), 8.7 (CH3). 19F NMR 
(376 MHz, CDCl3) δ = –116.8 (dd, J = 11.4, 5.6 Hz). IR (ATR): 3425, 2927, 1667, 1507, 
1252, 730, 579 cm–1. MS (ESI) m/z (relative intensity) 375 (100) [M+Na]+, 353 (50) [M+H]+, 






Prepared following the general procedure A by using 178i (76.0 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179i (63.2 mg, 80%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 8.58 (d, J = 9.6 Hz, 1H), 7.33–7.28 
(m, 3H), 7.13–7.10 (m, 2H), 6.34 (dd, J = 20.2, 2.4 Hz, 2H), 5.66 (q, J = 7.0 Hz, 1H), 5.47 
(s, 2H), 3.93 (s, 3H), 3.76 (s, 3H), 2.47 (s, 3H), 2.44 (s, 3H), 1.52 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ = 156.0 (Cq), 159.0 (Cq), 158.9 (Cq), 139.1 (Cq), 136.9 (Cq), 
135.7 (Cq), 134.1 (Cq), 128.9 (CH), 128.3 (CH), 127.0 (CH), 121.8 (Cq), 106.9 (CH), 97.1 
(CH), 55.5 (CH3), 55.2 (CH3), 51.7 (CH2), 42.8 (CH), 20.6 (CH3), 20.5 (CH3), 8.8 (CH3). 
IR (ATR): 3416, 2934, 1661, 1503, 1262, 1153, 731, 461 cm–1. MS (ESI) m/z (relative 
intensity) 417 (100) [M+Na]+, 395 (70) [M+H]+, 243 (80), 217 (10), 179 (30). HR-MS (ESI) 
m/z calcd for C22H27N4O [M+H]+ 395.2083 found 395.2078. 
 






Prepared following the general procedure A by using 178j (67.3 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179j (63.2 mg, 90%) 
as a white solid. M.p. = 83–85 °C. 1H NMR (300 MHz, CDCl3) δ = 7.56 (t, J = 5.6 Hz, 1H), 
7.35–7.28 (m, 3H), 7.18–7.10 (m, 3H), 6.79 (d, J = 7.6 Hz, 1H), 6.75 (d, J = 8.3 Hz, 1H), 
5.47 (s, 2H), 4.67 (d, J = 5.6 Hz, 2H), 3.88 (s, 3H), 2.50 (s, 3H), 2.47 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ = 160.7 (Cq), 158.2 (Cq), 138.9 (Cq), 138.1 (Cq), 135.8 (Cq), 134.0 (Cq), 
128.9 (CH), 128.3 (CH), 128.2 (CH), 127.0 (CH), 124.4 (Cq), 122.7 (CH), 108.0 (CH), 55.5 
(CH3), 51.7 (CH2), 34.6 (CH2), 19.6 (CH3), 8.8 (CH3). IR (ATR): 3423, 2930, 1664, 1511, 
1261, 731, 459 cm–1. MS (ESI) m/z (relative intensity) 373 (100) [M+Na]+, 351 (65) [M+H]+, 





Prepared following the general procedure A by using 178k (65.3 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179k (62.3 mg, 92%) 
as a white solid. M.p. = 107–110 °C. 1H NMR (400 MHz, CDCl3) δ = 7.38–7.29 (m, 4H), 
7.17–7.11 (m, 3H), 6.96 (d, J = 7.6 Hz, 1H), 6.91 (t, J = 9.0 Hz, 1H), 5.48 (s, 2H), 4.67 (dd, 
J = 5.7, 1.7 Hz, 2H), 2.50 (s, 3H), 2.45 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 161.9 (d, 
1JC–F = 245.7 Hz, Cq), 160.9 (Cq), 139.5 (d, 4JC–F = 3.5 Hz, Cq), 138.6 (Cq), 136.1 (Cq), 
134.0 (Cq), 129.0 (CH), 128.9 (d, 4JC–F = 9.3 Hz, CH), 128.4 (CH), 127.1 (CH), 126.0 (d, 
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4JC–F = 3.0 Hz, CH), 123.1 (d, 3JC–F = 14.3 Hz, Cq), 112.9 (d, 2JC–F = 22.5 Hz, CH), 51.7 
(CH2), 33.6 (d, 4JC–F = 5.3 Hz, CH2), 19.1 (d, 4JC–F = 2.6 Hz, CH3), 8.7 (CH3). 19F NMR (376 
MHz, CDCl3) δ = –118.0 (ddt, J = 9.6, 7.6, 1.7 Hz). IR (ATR): 3338, 2961, 1666, 1512, 1253, 
730, 459 cm–1. MS (ESI) m/z (relative intensity) 361 (100) [M+Na]+, 339 (60) [M+H]+, 205 





Prepared following the general procedure A by using 178l (75.0 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179l (62.1 mg, 80%) 
as a white solid. M.p. = 81–82 °C.1H NMR (300 MHz, CDCl3) δ = 7.54 (d, J = 7.7 Hz, 1H), 
7.40 (d, J = 7.2 Hz, 1H), 7.36–7.29 (m, 4H), 7.17–7.12 (m, 3H), 5.48 (s, 2H), 4.78 (d, J = 
5.3 Hz, 2H), 2.52 (s, 3H), 2.45 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 160.7 (Cq), 140.2 
(Cq), 138.4 (Cq), 136.2 (Cq), 134.5 (CH), 134.0 (Cq), 133.4 (d, 3J = 1.3 Hz, Cq), 129.9 (q, 2J 
= 29.4 Hz, Cq), 129.0 (CH), 128.5 (CH), 128.0 (CH), 127.1 (CH), 124.5 (q, 1JC–F = 274.0 
Hz, Cq), 123.8 (q, 3JC–F = 5.8 Hz, CH), 51.7 (CH2), 36.7 (d, 3JC–F = 2.0 Hz, CH2), 19.5 (CH3), 
8.7 (CH3). 19F NMR (376 MHz, CDCl3) δ = –58.1. IR (ATR): 3328, 2974, 1664, 1509, 1254, 
766, 589 cm–1. MS (ESI) m/z (relative intensity) 411 (100) [M+Na]+, 389 (50) [M+H]+, 292 
(10), 163 (10). HR-MS (ESI) m/z calcd for C20H20F3N4O [M+H]+ 389.1589 found 389.1584. 
 
 





Prepared following the general procedure A by using 178m (317 mg, 0.93 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179m (226 mg, 66%) 
as a yellow solid. M.p. = 139–140 °C. 1H NMR (300 MHz, CDCl3) δ = 9.60 (brs, 1H), 7.91 
(dd, J = 7.5, 0.8 Hz, 1H), 7.76–7.70 (m, 2H), 7.47 (t, J = 8.0 Hz, 1H), 7.41–7.32 (m, 4H), 
7.30–7.27 (m, 1H), 7.24–7.20 (m, 2H), 5.53 (s, 2H), 3.01 (s, 3H), 2.58 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ = 159.8 (Cq), 139.1 (Cq), 136.9 (Cq), 135.9 (Cq), 134.0 (Cq), 132.7 (Cq), 
132.7 (Cq), 130.2 (CH), 129.2 (CH), 128.7 (CH), 128.4 (Cq), 127.7 (CH), 127.7 (CH), 127.4 
(CH), 125.6 (CH), 125.2 (CH), 124.4 (CH), 52.0 (CH2), 25.1 (CH3), 8.9 (CH3). IR (ATR): 
3426, 2974, 1666, 1487, 813, 726 cm–1. MS (ESI) m/z (relative intensity) 379 (100) [M+Na]+, 






Prepared following the general procedure A by using 178n (70.2 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179n (56.4 mg, 75%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 7.72 (d, J = 7.6 Hz, 1H), 7.36–7.29 
(m, 3H), 7.14–7.11 (m, 2H), 6.55 (s, 2H), 5.62 (q, J = 7.3 Hz, 1H), 5.48 (s, 2H), 3.74 (s, 
3H), 2.52 (s, 6H), 2.46 (s, 3H), 1.59 (d, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 
160.2 (Cq), 157.6 (Cq), 138.7 (Cq), 136.8 (Cq), 135.8 (Cq), 134.0 (Cq), 131.5 (Cq), 128.9 
(CH), 128.4 (CH), 127.0 (CH), 114.6 (CH), 55.0 (CH3), 51.7 (CH2), 44.8 (CH), 21.3 (CH3), 
20.1 (CH3), 8.8 (CH3). IR (ATR): 3423, 2934, 1663, 1497, 1151, 727, 574 cm–1. MS (ESI) 
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m/z (relative intensity) 401 (100) [M+Na]+, 379 (50) [M+H]+, 163 (10). HR-MS (ESI) m/z 





Prepared following the general procedure A by using 178o (72.7 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179o (48.5 mg, 62%) 
as a yellow liquid. 1H NMR (300 MHz, CDCl3) δ = 7.73 (d, J = 7.7 Hz, 1H), 7.37–7.29 (m, 
3H), 7.14–7.11 (m, 2H), 6.42 (s, 2H), 5.63 (q, J = 7.2 Hz, 1H), 5.48 (s, 2H), 2.90 (s, 6H), 
2.52 (s, 6H), 2.46 (s, 3H), 1.62 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 160.1 
(Cq), 148.9 (Cq), 138.8 (Cq), 136.2 (Cq), 135.7 (Cq), 134.0 (Cq), 131.5 (Cq), 128.9 (CH), 
128.3 (CH), 127.0 (CH), 113.7 (CH), 51.7 (CH2), 44.7 (CH), 40.6 (CH3), 21.6 (CH3), 20.4 
(CH3), 8.8 (CH3). IR (ATR): 3423, 2928, 1662, 1593, 1497, 1356, 726, 551 cm–1. MS (ESI) 
m/z (relative intensity) 414 (100) [M+Na]+, 392 (50) [M+H]+, 176 (10). HR-MS (ESI) m/z 





Prepared following the general procedure A by using 178p (80.1 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179p (69.4 mg, 80%) 
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as a yellow liquid. 1H NMR (300 MHz, CDCl3) δ = 7.76 (d, J = 7.9 Hz, 1H), 7.37–7.30 (m, 
3H), 7.14–7.11 (m, 2H), 6.83 (s, 2H), 5.68 (q, J = 7.2 Hz, 1H), 5.49 (s, 2H), 2.52 (s, 6H), 
2.46 (s, 3H), 2.44–2.34 (m, 1H), 1.84–1.71 (m, 5H), 1.60 (d, J = 7.2 Hz, 3H), 1.41–1.24 (m, 
5H). 13C NMR (126 MHz, CDCl3) δ = 160.2 (Cq), 146.2 (Cq), 138.8 (Cq), 136.3 (Cq), 135.8 
(Cq), 135.1 (Cq), 134.0 (Cq), 128.9 (CH), 128.4 (CH), 127.9 (CH), 127.0 (CH), 51.8 (CH2), 
45.0 (CH), 44.0 (CH), 34.4 (CH2) and 34.3 (CH2), 27.0 (CH2), 26.2 (CH2), 21.2 (CH3), 20.0 
(CH3), 8.8 (CH3). IR (ATR): 3431, 2921, 1670, 1501, 1246, 726, 542 cm–1. MS (ESI) m/z 
(relative intensity) 453 (50) [M+Na]+, 431 (60) [M+H]+, 243 (100), 217 (20), 200 (20). HR-





Prepared following the general procedure A by using 178q (75.0 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179q (62.3 mg, 77%) 
as a white solid. M.p. = 84–85 °C. 1H NMR (300 MHz, CDCl3) δ = 7.77 (d, J = 7.9 Hz, 1H), 
7.37–7.28 (m, 3H), 7.15–7.12 (m, 2H), 6.78 (s, 2H), 5.69 (q, J = 7.3 Hz, 1H), 5.48 (s, 2H), 
2.52 (s, 6H), 2.46 (s, 3H), 2.35 (d, J = 7.1 Hz, 2H), 1.89–1.76 (m, 1H), 1.60 (d, J = 7.3 Hz, 
3H), 0.89 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ = 160.1 (Cq), 139.9 (Cq), 138.7 
(Cq), 136.2 (Cq), 135.8 (Cq), 134.9 (Cq), 134.0 (Cq), 130.1 (CH), 128.9 (CH), 128.3 (CH), 
127.0 (CH), 51.7 (CH2), 45.0 (CH), 44.8 (CH2), 30.0 (CH), 22.5 (CH3), 21.0 (CH3), 20.0 
(CH3), 8.8 (CH3). IR (ATR): 3426, 2957, 1665, 1502, 1253, 729, 574 cm–1. MS (ESI) m/z 
(relative intensity) 427 (100) [M+Na]+, 405 (45) [M+H]+, 243 (80), 189 (6). HR-MS (ESI) 
m/z calcd for C25H33N4O [M+H]+ 405.2654 found 405.2649. 
 






Prepared following the general procedure A by using 178r (79.6 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179r (71.2 mg, 84%) 
as a white solid. M.p. = 89–92 °C. 1H NMR (300 MHz, CDCl3) δ = 7.80 (d, J = 7.7 Hz, 1H), 
7.57–7.53 (m, 2H), 7.44–7.28 (m, 6H), 7.24 (s, 2H), 7.16–7.12 (m, 2H), 5.73 (q, J = 7.3 Hz, 
1H), 5.50 (s, 2H), 2.62 (s, 6H), 2.47 (s, 3H), 1.66 (d, J = 7.3 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ = 160.3 (Cq), 140.7 (Cq), 139.4 (Cq), 138.7 (Cq), 138.1 (Cq), 135.9 (Cq), 135.8 (Cq), 
134.0 (Cq), 129.0 (CH), 128.5 (CH), 128.4 (CH), 128.2 (CH), 127.0 (CH), 126.9 (CH), 126.9 
(CH), 51.8 (CH2), 45.1 (CH), 21.2 (CH3), 19.8 (CH3), 8.8 (CH3). IR (ATR): 3425, 2968, 2929, 
1668, 1505, 1198, 731, 564 cm–1. MS (ESI) m/z (relative intensity) 447 (100) [M+Na]+, 425 






Prepared following the general procedure A by using 178s (77.7 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179s (70.3 mg, 84%) 
as a white solid. M.p. = 97–100 °C.1H NMR (300 MHz, CDCl3) δ = 7.73 (d, J = 7.3 Hz, 1H), 
7.37–7.29 (m, 3H), 7.23 (s, 2H), 7.15–7.12 (m, 2H), 5.67 (p, J = 7.3 Hz, 1H), 5.49 (s, 2H), 
2.58 (s, 6H), 2.45 (s, 3H), 1.61 (d, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 160.3 
(Cq), 142.9 (Cq), 138.4 (Cq), 136.2 (Cq), 136.0 (Cq), 133.9 (Cq), 128.9 (CH), 128.4 (CH), 
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127.7 (d, 2JC–F = 112.9 Hz, Cq), 127.0 (CH), 126.0 (q, 3JC–F = 3.3 Hz, CH), 124.0 (q, 1JC–F 
= 271.6 Hz, Cq), 51.8 (CH2), 45.2 (CH), 21.1 (CH3), 19.2 (CH3), 8.7 (CH3). 19F NMR (282 
MHz, CDCl3) δ = -62.6. IR (ATR): 3373, 2983, 1647, 1581, 1513, 1323, 734, 611, 476    
cm–1. MS (ESI) m/z (relative intensity) 439 (100) [M+Na]+, 417 (70) [M+H]+, 217 (40). HR-





Prepared following the general procedure A by using 178t (72.9 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179t (70.8 mg, 90%) 
as a white solid. M.p. = 87–88 °C. 1H NMR (400 MHz, CDCl3) δ = 7.70 (d, J = 7.4 Hz, 1H), 
7.35–7.30 (m, 3H), 7.14–7.12 (m, 2H), 6.49 (s, 1H), 5.86 (s, 2H), 5.56 (dq, J = 7.3, 7.4 Hz, 
1H), 5.48 (s, 2H), 2.45 (s, 3H), 2.45 (s, 3H), 2.39 (s, 3H), 1.58 (d, J = 7.3 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 160.4 (Cq), 145.1 (Cq), 145.2 (Cq), 138.7 (Cq), 136.0 (Cq), 134.0 (Cq), 
132.6 (Cq), 129.0 (CH), 128.6 (Cq), 128.5 (CH), 127.1 (CH), 117.1 (Cq), 109.0 (CH), 100.4 
(CH2), 51.7 (CH2), 45.1 (CH), 20.94 (CH3), 20.0 (CH3), 12.7 (CH3), 8.7 (CH3). IR (ATR): 
3311, 2883, 1647, 1512, 1247, 743, 462 cm–1. MS (ESI) m/z (relative intensity) 415 (100) 
[M+Na]+, 393 (60) [M+H]+, 217 (30). HR-MS (ESI) m/z calcd for C22H25N4O3 [M+H]+ 
393.1927 found 393.1921. 
 
 





Prepared following the general procedure A by using 178u (69.8 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179u (67.5 mg, 89%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 7.79 (d, J = 7.7 Hz, 1H), 7.36–7.29 
(m, 3H), 7.14–7.11 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 6.67 (d, J = 8.3 Hz, 1H), 5.70 (q, J = 
7.3 Hz, 1H), 5.48 (s, 2H), 3.78 (s, 3H), 2.48 (s, 3H), 2.45 (s, 3H), 2.41 (s, 3H), 1.62 (d, J = 
7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 160.2 (Cq), 156.30 (Cq), 140.0 (Cq), 138.7 
(Cq), 135.8 (Cq), 134.0 (Cq), 128.9 (CH), 128.4 (CH), 127.2 (Cq), 127.0 (CH), 124.1 (Cq), 
109.0 (CH), 55.6 (CH3), 51.7 (CH2), 45.5 (CH), 20.6 (CH3), 19.9 (CH3), 12.5 (CH3), 8.8 
(CH3). IR (ATR): 3351, 2935, 1644, 1580, 1450, 731, 472 cm–1. MS (ESI) m/z (relative 
intensity) 401 (100) [M+Na]+, 379 (50) [M+H]+, 243 (10), 217 (20), 163 (25). HR-MS (ESI) 





Prepared following the general procedure A by using 178v (64.0 mg, 0.20 mmol). 
Purification by column chromatography (EtOAc/n-hexane 1:1 to EtOAc) yielded 179v (36.3 
mg, 52%) as a yellow liquid. 1H NMR (500 MHz, CDCl3) δ = 8.21 (s, 2H), 7.65 (d, J = 7.1 
Hz, 1H), 7.33–7.27 (m, 3H), 7.13–7.11 (m, 2H), 5.51 (q, J = 7.4 Hz, 1H), 5.47 (s, 2H), 2.46 
(s, 6H), 2.40 (s, 3H), 1.56 (d, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 160.5 (Cq), 
149.4 (CH), 148.9 (Cq), 138.1 (Cq), 136.2 (Cq), 133.8 (Cq), 130.6 (Cq), 129.0 (CH), 128.5 
(CH), 127.1 (CH), 51.8 (CH2), 45.0 (CH), 18.4 (CH3), 17.3 (CH3), 8.6 (CH3). IR (ATR): 3419, 
2931, 1663, 1503, 1252, 730, 596 cm–1. MS (ESI) m/z (relative intensity) 372 (10) [M+Na]+, 
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350 (100) [M+H]+, 336 (10), 117 (8). HR-MS (ESI) m/z calcd for C20H24N5O [M+H]+ 





Prepared following the general procedure A by using 178w (69.3 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179w (60.3 mg, 83%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 7.37–7.29 (m, 4H), 7.18–7.15 (m, 2H), 
7.12 (d, J = 7.5 Hz, 1H), 7.01 (t, J = 7.1 Hz, 2H), 5.50 (s, 2H), 5.35–5.31 (m, 1H), 2.92–
2.72 (m, 2H), 2.54 (s, 3H), 2.28 (s, 3H), 2.27–2.25 (m, 1H), 1.91–1.79 (m, 3H). 13C NMR 
(126 MHz, CDCl3) δ = 159.9 (Cq), 138.5 (Cq), 137.9 (Cq), 137.7 (Cq), 136.0 (Cq), 133.9 (Cq), 
133.3 (Cq), 128.9 (CH), 128.4 (CH), 128.1 (CH), 127.4 (CH), 127.1 (CH), 51.8 (CH2), 44.1 
(CH), 29.8 (CH2), 29.6 (CH2), 18.8 (CH3), 18.0 (CH2), 8.9 (CH3). IR (ATR): 3412, 2930, 
1660, 1497, 1249, 774, 574 cm–1. MS (ESI) m/z (relative intensity) 383 (100) [M+Na]+, 361 






Prepared following the general procedure A by using 178x (74.3 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 179x (71.2 mg, 91%) 
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as a white solid. M.p. = 65–71 °C. 1H NMR (300 MHz, CDCl3) δ = 7.87 (s, 1H), 7.81–7.72 
(m, 2H), 7.63 (s, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.44–7.38 (m, 2H), 7.36–7.30 (m, 3H), 7.16–
7.12 (m, 2H), 5.59 (q, J = 6.8 Hz, 1H), 5.47 (s, 2H), 2.6 (s, 3H), 2.48 (s, 3H), 1.68 (d, J = 
6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 160.2 (Cq), 140.2 (Cq), 138.6 (Cq), 136.1 (Cq), 
133.9 (Cq), 133.7 (Cq), 132.7 (Cq), 132.1 (Cq), 128.9 (CH), 128.6 (CH), 128.4 (CH), 127.4 
(CH), 127.0 (CH), 126.7 (CH), 125.7 (CH), 125.1 (CH), 123.7 (CH), 51.7 (CH2), 45.2 (CH), 
21.7 (CH3), 19.6 (CH3), 8.8 (CH3). IR (ATR): 3410, 2974, 1662, 1504, 1251, 732, 540   
cm–1. MS (ESI) m/z (relative intensity) 407 (100) [M+Na]+, 385 (40) [M+H]+, 258 (10), 212 





Prepared following the general procedure B by using 178h (68.2 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 196h (63.7 mg, 81%) 
as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ = 7.91 (d, J = 8.9 Hz, 1H), 7.26–7.20 
(m, 3H), 7.09–7.03 (m, 3H), 6.88–6.80 (m, 2H), 5.64–5.57 (m, 1H), 5.40 (d, J = 2.6 Hz, 2H), 
2.88 (dq, J = 15.0, 7.6 Hz, 1H), 2.72 (dq, J = 15.0, 7.6 Hz, 1H), 2.38 (s, 3H), 1.55 (d, J = 
6.0 Hz, 3H), 1.20 (t, J = 7.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 162.3 (d, 1JC–F = 244.3 
Hz, Cq), 160.3 (Cq), 143.5 (d, 4JC–F = 4.5 Hz, Cq), 138.8 (Cq), 136.1 (Cq), 134.1 (Cq), 129.0 
(CH), 128.4 (CH), 128.3 (d, 3JC–F = 9.8 Hz, CH), 128.2 (d, 3JC–F = 11.3 Hz, Cq), 127.08 (CH), 
124.6 (d, 4JC–F = 2.6 Hz, CH), 113.8 (d, 2JC–F = 22.7 Hz, CH), 51.7 (CH2), 42.1 (CH), 29.6 
(CH2), 26.4 (d, 4JC–F = 2.2 Hz, CH2), 21.2 (d, 4JC–F = 3.4 Hz, CH3), 15.7 (CH3), 8.7 (CH3). 
19F NMR (376 MHz, CDCl3) δ = –116.1 (dd, J = 11.5, 5.6 Hz). IR (ATR): 3421, 2968, 1665, 
1505, 730, 579 cm–1. MS (ESI) m/z (relative intensity) 389 (100) [M+Na]+, 367 (60) [M+H]+, 
217 (40). HR-MS (ESI) m/z calcd for C21H24FN4O [M+H]+ 367.1934 found 367.1929. 







Prepared following the general procedure B by using 178h (67.9 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 197a (66.7 mg, 75%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 7.83 (d, J = 8.9 Hz, 1H), 7.28–7.20 
(m, 5H), 7.16–7.10 (m, 1H), 7.06–6.88 (m, 6H), 5.45–5.33 (m, 3H), 3.76 (s, 3H), 2.36 (s, 
3H), 1.44 (dd, J = 7.0, 0.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 162.1 (d, 1JC–F = 245.2 
Hz, Cq), 160.1 (Cq), 159.1 (Cq), 142.9 (d, 3J C–F = 5.2 Hz, Cq), 139.0 (Cq), 136.0 (Cq), 134.2 
(Cq), 132.2 (Cq), 130.4 (CH), 129.1 (CH), 128.5 (CH), 128.3 (Cq), 128.0 (d, 3J C–F = 9.9 Hz, 
CH), 127.1 (CH), 126.5 (d, 3J C–F = 2.7 Hz, CH), 115.0 (d, 2J C–F = 22.7 Hz, CH), 113.8 (CH), 
55.3 (CH3), 51.8 (CH2), 43.9 (CH), 21.6 (d, 3J C–F = 2.6 Hz, CH3), 8.8 (CH3). 19F NMR (282 
MHz, CDCl3) δ = –115.9. IR (ATR): 3422, 2930, 1668, 1509, 1248, 730, 569 cm–1. MS (ESI) 
m/z (relative intensity) 467 (100) [M+Na]+, 445 (60) [M+H]+, 288 (10), 217 (25), 177 (20). 





Prepared following the general procedure B by using 178h (67.9 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 197b (72.1 mg, 83%) 
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as a white solid. M.p. = 134–136 °C. 1H NMR (300 MHz, CDCl3) δ = 7.81 (d, J = 8.6 Hz, 
1H), 7.33–7.18 (m, 5H), 7.16–7.11 (m, 1H), 7.07–6.95 (m, 5H), 6.90–6.87 (m, 1H), 5.38 (d, 
J = 3.6 Hz, 2H), 5.3–5.25 (m, 1H), 2.35 (s, 3H), 1.43 (dd, J = 7.0, 0.9 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ = 163.9 (d, 1J C–F = 25.7 Hz, Cq), 160.6 (d, 1J C–F = 24.8 Hz, Cq), 160.2 
(Cq), 142.1 (d, 2J C–F = 5.2 Hz, Cq), 138.9 (Cq), 136.0 (Cq), 135.8 (t, 2J C–F = 3.0 Hz, Cq), 
134.2 (Cq), 131.0 (d, 2J = 8.1 Hz, CH), 129.1 (CH), 128.5 (CH), 128.4 (Cq), 128.1 (d, 2J = 
9.9 Hz, CH), 127.2 (CH), 126.3 (d, 2J C–F = 2.6 Hz, CH), 115.5 (d, 1J C–F = 22.7 Hz, CH), 
115.3 (d, 1J C–F = 21.4 Hz, CH), 51.8 (CH2), 43.8 (CH), 21.5 (d, 2J = 2.6 Hz, CH3), 8.8 (CH3). 
19F NMR (282 MHz, CDCl3) δ = –114.82(s,), –115.7(s,). IR (ATR): 3421, 2930, 1667, 1508, 
1226, 729, 550 cm–1. MS (ESI) m/z (relative intensity) 455 (100) [M+Na]+, 433 (45) [M+H]+, 






Prepared following the general procedure B by using 178l (450 mg, 1.2 mmol). Purification 
by column chromatography (n-hexane/EtOAc 2:1) yielded 197c (515 mg, 89%) as a 
colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 7.67–7.61 (m, 1H), 7.40–7.36 (m, 2H), 
7.30–7.12 (m, 5H), 7.08–7.05 (m, 2H), 6.97 (t, J = 4.4 Hz, 1H), 6.82–6.77 (m, 2H), 5.39 (s, 
2H), 4.58 (d, J = 4.4 Hz, 2H), 3.70 (s, 3H), 2.36 (s, 3H). 13C NMR (126 MHz, CDCl3) δ = 
159.9 (Cq), 159.0 (Cq), 145.5 (Cq), 138.4 (Cq), 135.9 (Cq), 134.5 (CH), 134.0 (Cq), 133.0 
(Cq), 131.8 (Cq), 130.1 (q, 2JC–F = 29.8 Hz, Cq), 129.9 (CH), 129.0 (CH), 128.4 (CH), 127.7 
(CH), 127.1 (CH), 125.4 (q, 3JC–F = 6.0 Hz, CH), 124.3 (q, 1JC–F = 273.8 Hz, Cq), 113.8 (CH), 
55.2 (CH3), 51.8 (CH2), 37.7 (CH2), 8.7 (CH3). 19F NMR (282 MHz, CDCl3) δ = –58.67. 
IR (ATR): 3288, 2958, 1662, 1510, 1253, 693, 589 cm–1. MS (ESI) m/z (relative intensity) 
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503 (100) [M+Na]+, 481 (60) [M+H]+, 217 (30). HR-MS (ESI) m/z calcd for C26H24F3N4O2 





Prepared following the general procedure B by using 178w (69.3 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded 197d (63.9 mg, 76%) 
as a colorless liquid. 1H NMR (300 MHz, CDCl3) δ = 7.31–7.23 (m, 3H), 7.17–6.99 (m, 11H), 
5.37 (s, 2H), 5.17–5.12 (m, 1H), 2.89–2.71 (m, 2H), 2.24 (s, 3H), 2.08–2.00 (m, 1H), 1.83–
1.72 (m, 3H). 13C NMR (75 MHz, CDCl3) δ = 159.2 (Cq), 143.7 (Cq), 141.0 (Cq), 138.7 (Cq), 
138.3 (Cq), 135.7 (Cq), 134.3 (Cq), 133.4 (Cq), 129.1 (CH), 128.8 (CH), 128.7 (CH), 128.5 
(CH), 128.3 (CH), 127.7 (CH), 127.33 (CH), 127.1 (CH), 126.5 (CH), 51.7 (CH2), 44.4 (CH), 
29.8 (CH2), 29.7 (CH2), 18.3 (CH2), 8.6 (CH3). IR (ATR): 3414, 2933, 1665, 1496, 1251, 
730, 541 cm–1. MS (ESI) m/z (relative intensity) 445 (100) [M+Na]+, 423 (60) [M+H]+, 217 
(40), 158 (20). HR-MS (ESI) m/z calcd for C27H27N4O [M+H]+ 423.2185 found 423.2179. 
5.3.2 Iron-catalyzed C–H methylation of chiral benzamide (S)-178a 
 
Prepared following the general procedure A by using (S)-1a (64.0 mg, 0.20 mmol). 
Purification by column chromatography (n-hexane/EtOAc 2:1) yielded (S)-2a (58.9 mg, 
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86%) as a white solid. M.p. = 72–73 °C. Chiral HPLC analysis (Chiralcel IC, i-PrOH/n-
hexane 30:70, flow rate = 1.0 mL/min, λ = 254 nm), tr (minor) = 8.7 min, tr (major) = 9.8 min.  
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5.3.3 Parallel Experiments for KIE 
 
Ten independent reactions with 178k or deuterated substrate [D1]-178k under the standard 
conditions were performed. To a schlenk tube charged with amide (0.20 mmol), 
TMEDA.ZnCl2 (152 mg, 0.60 mmol, 3.0 equiv) and 1.0 mL THF was added MeMgBr (457 
ul, 1.4 mmol, 3.0 M in ether, 7.0 equiv) in one portion at room temperature under nitrogen 
gas. Five minutes later, dppen (11.9 mg, 0.030 mmol, 15 mol %) and FeCl3 (4.9 mg, 0.030 
mmol, 15 mol %) were added successively. Stirring at room temperature for another one 
minute, 2,3-dichloridebutane was added and the reaction was moved to 65 oC oil bath 
stirring for 5 min, 10 min, 15 min, 20 min, 25 min respectively. The yields of the products 
179k were monitored by 19F NMR using benzotrifluoride as the internal standard. 
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t [min] 5 10 15 20 25 
179k [%] 6 17 24 39 48 
[D1]-179k [%] 5 8 15 22 30 
5.3.4 The Removal of Directing Group 
 
A solution of amide 179m (178 mg, 0.50 mmol) in 3.0 ml concentrated hydrochloride and 
1.5 ml 1,4-dioxane under nitrogen was stirred at 130 oC for 16 hours. Basified the mixture 
to pH = 12 by 3M KOH aqueous solution and extracted with mixed solvent (MeOH/DCM 
1:8) for three times. Combined the organic layers, washed with brine and removed the 
solvent. The resulting crude material was purified by column chromatography (n-
hexane/EtOAc 1:4) yielding amine 198m as a brown solid (59.4 mg, 76%). M.p. = 68–69 
oC.1H NMR (300 MHz, CDCl3) δ = 7.58 (d, J = 8.2 Hz, 1H), 7.26–7.16 (m, 3H), 7.09 (d, J = 
7.0 Hz, 1H), 6.64 (dd, J = 7.2, 1.5 Hz, 1H), 4.24 (brs, 2H), 2.97 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ = 144.9 (Cq), 136.5 (Cq), 133.6 (Cq), 128.2 (CH), 127.5 (CH), 126.0 (CH), 125.4 
(CH), 124.3 (Cq), 120.0 (CH), 111.9 (CH), 25.2 (CH3). IR (ATR): 3363, 2963, 1618, 1463, 
814, 759, 671 cm–1. MS (ESI) m/z (relative intensity) 180 (100) [M+Na]+, 158 (40) [M+H]+, 
141 (30). HR-MS (ESI) m/z calcd for C11H12N [M+H]+ 158.0970 found 158.0964. The 1H-
1H COSY confirmed the structure of 198m is 1-Amino–8-methylnaphthalene rather than 
reported compound 1-Amino–2-methylnaphthalene.[177] 
The aqueous layer was acidified to pH = 3 and extracted with mixed solvent 
(Methanol/DCM 1:8) for three times. Combined the organic layers, washed with brine and 
removed the solvent. The resulting residue was washed with very little amount of ether to 
afford the acid 199a as a yellow solid (82.2 mg, 76%). M.p. = 133–134 °C. 1H NMR (300 
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MHz, D6-acetone) δ = 7.45–7.31 (m, 3H), 7.28–7.25 (m, 2H), 5.67 (s, 2H), 2.52 (s, 3H). 
13C NMR (75 MHz, D6-acetone) δ = 167.2 (Cq), 143.8 (Cq), 141.7 (Cq), 140.5 (Cq), 134.1 
(CH), 133.4 (CH), 132.6 (CH), 56.4 (CH2), 13.4 (CH3). IR (ATR): 3443, 2923, 2854, 1716, 
1570, 1183, 798, 747 cm–1. MS (ESI) m/z (relative intensity) 240 (100) [M+Na]+, 218 (60) 















A solution of amide 179s (215 mg, 0.5 mmol) in 3.0 ml concentrated hydrochloride and 1.5 
mL dioxane under nitrogen was stirred at 130 oC for 12 hours. Basified the mixture to pH 
= 12 by 3M KOH aqueous solution and extracted with mixed solvent (Methanol/DCM 1:8) 
for three times. Combined the organic layers, washed with brine and removed the solvent. 
The resulting crude material was purified by column chromatography (gradient elution    
n-hexane/EtOAc 1:1 to EtOAc) yielding amine 198s as a yellow liquid (77.3 mg, 72%). 
1H NMR (300 MHz, CDCl3) δ = 7.22 (s, 2H), 4.67 (q, J = 7.0 Hz, 1H), 2.51 (s, 6H), 1.53 
(brs, 2H), 1.45 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 146.2 (Cq), 136.6 (Cq), 
128.2 (q, 2JC–F = 31.9 Hz, Cq), 126.0 (q, 3JC–F = 2.9 Hz, CH), 124.2 (q, 1JC–F = 271.8 Hz, 
Cq), 47.4 (CH), 21.8 (CH3), 21.2 (CH3). 19F NMR (282 MHz, CDCl3) δ = -62.62. IR (ATR): 
3425, 2969, 2929, 1339, 1227, 1116, 881 cm–1. MS (ESI) m/z (relative intensity) 240 (100) 
[M+Na]+, 218 (40) [M+H]+, 201 (80), 161 (6). HR-MS (ESI) m/z calcd for C11H15F3N [M+H]+ 
218.1157 found 218.1152. 
The aqueous layer was acidified to pH = 3 and extracted with mixed solvent 
(Methanol/DCM 1:8) for three times. Combined the organic layers, washed with brine and 
removed the solvent. The resulting residue was washed with very little amount of ether to 
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5.4 Pyridinyl C–H Alkylation Catalyzed by Manganese(II) 
5.4.1 Experimental Procedure and Analytical Data 
 
3-cyclohexyl-N-(1-phenylethyl)picolinamide (181aa) 
Prepared following the general procedure C using N-(1-phenylethyl)picolinamide 88a 
(45.2 mg, 0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 181aa (48.7 mg, 79%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ = 8.35 (brs, 1H), 8.33 (dd, J = 4.5, 1.5 Hz, 1H), 
7.74 (dd, J = 8.1, 1.5 Hz, 1H), 7.42–7.38 (m, 2H), 7.35–7.29 (m, 3H), 7.26–7.20 (m, 1H), 
5.29 (dq, J = 6.9, 6.4 Hz, 1H), 4.07 (tt, J = 11.7, 3.0 Hz, 1H), 1.93–1.72 (m, 5H), 1.59 (d, J 
= 6.9 Hz, 3H), 1.54–1.16 (m, 5H). 13C NMR (100 MHz, CDCl3) δ = 165.3 (Cq), 146.9 (Cq), 
144.9 (CH), 144.8 (Cq), 143.6 (Cq), 136.0 (CH), 128.6 (CH), 127.1 (CH), 126.1 (CH), 125.6 
(CH), 48.5 (CH), 37.7 (CH), 34.2 (CH2), 34.0 (CH2), 26.7 (CH2), 26.7 (CH2), 26.2 (CH2), 
22.3 (CH3). IR (ATR): 3376, 2922, 2850, 1665, 1497, 806, 699, 625 cm–1. MS (ESI) m/z 
(relative intensity): 331 (100) [M+Na]+, 309 (30) [M+H]+, 188 (30). HR-MS (ESI) m/z calcd 




Prepared following the general procedure C using N-phenethylpicolinamide 88b (45.2 mg, 
0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by column 
5 Experimental Section 
133 
 
chromatography (n-hexane/EtOAc 8:1) yielded 181ba (58.0 mg, 94%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.22 (dd, J = 4.5, 1.5 Hz, 1H), 8.01 (brs, 1H), 7.67 (dd, J = 
8.1, 1.5 Hz, 1H), 7.25–7.11 (m, 6H), 3.97 (tt, J = 11.8, 3.0 Hz, 1H), 3.69–3.54 (m, 2H), 2.86 
(t, J = 7.2 Hz, 2H), 1.78–1.67 (m, 5H), 1.55–1.07 (m, 5H). 13C NMR (100 MHz, CDCl3) δ = 
166.2 (Cq), 147.0 (Cq), 144.9 (CH), 144.6 (Cq), 139.1 (CH), 135.9 (CH), 128.7 (CH), 128.45 
(CH), 126.3 (CH), 125.6 (CH), 40.6 (CH2), 37.8 (CH), 35.9 (CH2), 34.1 (CH2), 26.7 (CH2), 
26.2 (CH2). IR (ATR): 3384, 2923, 2850, 1664, 1506, 1000, 806, 698, 497 cm–1. MS (ESI) 
m/z (relative intensity): 331 (40) [M+Na]+, 309 (100) [M+H]+, 284 (10), 188 (10). HR-MS 




Prepared following the general procedure C using N-phenethylpicolinamide 88c (42.4 mg, 
0.20 mmol) and 180a cyclohexylchloride (71 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181ca (45.2 mg, 77%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.36 (brs, 1H), 8.31 (dd, J = 4.5, 1.5 Hz, 1H), 7.76 (dd, J = 
8.1, 1.5 Hz, 1H), 7.37–7.30 (m, 5H), 7.27–7.23 (m, 1H), 4.62 (d, J = 6.0 Hz, 2H), 4.10 (tt, 
J = 11.8, 3.3 Hz, 1H), 1.92–1.89 (m, 2H), 1.84–1.75 (m, 3H), 1.52 (qt, J = 12.8, 3.3 Hz, 2H), 
1.35 (qd, J = 12.4, 3.0 Hz, 2H), 1.24 (qt, J = 13.0, 3.6 Hz, 1H). 13C NMR (100 MHz, CDCl3) 
δ = 166.1 (Cq), 146.8 (Cq), 145.0 (CH), 144.9 (Cq), 138.4 (Cq), 136.0 (CH), 128.6 (CH), 
127.7 (CH), 127.3 (CH), 125.7 (CH), 43.3 (CH2), 37.8 (CH), 34.1 (CH2), 26.7 (CH2), 26.2 
(CH2). IR (ATR): 3381, 2922, 2849, 1665, 1505, 805, 698 cm–1. MS (ESI) m/z (relative 
intensity): 317 (100) [M+Na]+, 295 (40) [M+H]+, 188 (20), 106 (10). HR-MS (ESI) m/z calcd 
for C19H23N2O [M+H]+ 295.1800 found 295.1805. 
 





Prepared following the general procedure C using N-(4-fluorobenzyl)picolinamide 88d 
(46.1 mg, 0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 181da (52.3 mg, 84%) as a white 
solid. M.p. = 72–73 °C. 1H NMR (300 MHz, CDCl3) δ = 8.32 (brs, 1H), 8.25 (dd, J = 4.5, 
1.5 Hz, 1H), 7.70 (dd, J = 8.0, 1.5 Hz, 1H), 7.28–7.23 (m, 3H), 6.97–6.90 (m, 2H), 4.51 (d, 
J = 6.0 Hz, 2H), 4.02 (tt, J = 11.8, 3.0 Hz, 1H), 1.85–1.67 (m, 5H), 1.51–1.10 (m, 5H). 
13C NMR (125 MHz, CDCl3) δ = 166.0 (Cq), 161.9 (d, 1JC–F = 245.0 Hz, Cq), 146.6 (Cq), 
144.9 (CH), 144.8 (Cq), 135.9 (CH), 134.2 (d, 4JC–F = 3.1 Hz, Cq), 129.2 (d, 3JC–F = 8.1 Hz, 
CH), 125.7 (CH), 115.3 (d, 2JC–F = 21.4 Hz, CH), 42.6 (CH2), 37.9 (CH), 34.2 (CH2), 26.8 
(CH2), 26.3 (CH2). 19F NMR (275 MHz, CDCl3) δ = -115.4–-115.5 (m). IR (ATR): 3187, 2925, 
2851, 1655, 1505, 1221, 838, 728, 429 cm–1. MS (ESI) m/z (relative intensity): 335 (100) 
[M+Na]+, 313 (15) [M+H]+, 244 (8). HR-MS (ESI) m/z calcd for C19H22FN2O [M+H]+ 




Prepared following the general procedure C using N-(2-fluorobenzyl)picolinamide 88e 
(46.0 mg, 0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 181ea (51.7 mg, 83%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.38 (t, J = 6.4 Hz, 1H) , 8.32 (dd, J = 4.4, 1.6 
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Hz, 1H), 7.75 (dd, J = 8.0, 1.6 Hz, 1H), 7.40 (td, J = 7.6, 1.8 Hz, 1H), 7.31 (ddd, J = 8.0, 
4.4, 0.4 Hz, 1H), 7.25–7.20 (m, 1H), 7.08 (td, J = 7.6, 1.2 Hz, 1H), 7.06–7.00 (m, 1H), 4.67 
(d, J = 6.4 Hz, 2H), 4.07 (tt, J = 11.6, 3.0 Hz, 1H), 1.90–1.73 (m, 5H), 1.56–1.45 (m, 2H), 
1.39–1.20 (m, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.1 (Cq), 161.0 (d, 1JC–F = 246.0 Hz, 
Cq), 146.7 (Cq), 145.0 (CH), 144.9 (Cq), 136.0 (CH), 130.0 (d, 3JC–F = 4.3 Hz, CH), 129.0 
(d, 3JC–F = 8.1 Hz, CH), 125.8 (CH), 125.5 (d, 2JC–F = 14.9 Hz, Cq), 124.2 (d, 4JC–F = 3.6 Hz, 
CH), 115.3 (d, 2JC–F = 21.3 Hz, CH), 37.8 (CH), 37.1 (d, 3JC–F = 4.2 Hz, CH2), 34.1 (CH2), 
26.7 (CH2), 26.2 (CH2). 19F NMR (275 MHz, CDCl3) δ = -118.7–-118.8 (m). IR (ATR): 3382, 
2922, 2850, 1668, 1501, 1227, 805, 757, 625 cm–1. MS (ESI) m/z (relative intensity): 335 
(100) [M+Na]+, 313 (20) [M+H]+, 244 (15). HR-MS (ESI) m/z calcd for C19H22FN2O [M+H]+ 




Prepared following the general procedure C using N-(4-methoxybenzyl)picolinamide 88f 
(48.4 mg, 0.20 mmol) and cyclohexylchloride 181fa (71 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 181fa (57.1 mg, 88%) as a yellow 
solid. M.p. = 107–108 °C. 1H NMR (400 MHz, CDCl3) δ = 8.29 (dd, J = 4.4, 1.6 Hz, 1H), 
8.27 (brs, 1H), 7.74 (dd, J = 8.0, 1.6 Hz, 1H), 7.30 (ddd, J = 8.0, 4.4, 0.4 Hz, 1H), 7.27 (d, 
J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 4.54 (d, J = 6.0 Hz, 2H), 4.09 (tt, J = 11.6, 3.1 Hz, 
1H), 3.76 (s, 3H), 1.93–1.72 (m, 5H), 1.52 (qt, J = 12.4, 3.2 Hz, 2H), 1.34 (qd, J = 12.4, 3.2 
Hz, 2H), 1.23 (qt, J = 12.8, 3.6 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ = 166.0 (Cq), 158.9 
(Cq), 146.9 (Cq), 144.9 (CH), 144.8 (Cq), 136.0 (CH), 130.5 (Cq), 129.1 (CH), 125.7 (CH), 
114.0 (CH), 55.2 (CH3), 42.8 (CH2), 37.8 (CH), 34.1 (CH2), 26.7 (CH2), 26.2 (CH2). IR (ATR): 
3306, 2925, 2848, 1652, 1513, 1242, 994, 807, 685 cm–1. MS (ESI) m/z (relative intensity): 
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347 (100) [M+Na]+, 325 (50) [M+H]+, 188 (15), 121 (10). HR-MS (ESI) m/z calcd for 




Prepared following the general procedure C using N-cyclohexylpicolinamide 88g (40.8 mg, 
0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181ga (45.9 mg, 80%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.30 (dd, J = 4.4, 1.6 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.72 
(dd, J = 8.0, 1.6 Hz, 1H), 7.28 (dd, J = 8.0, 4.4 Hz, 1H), 4.04 (tt, J = 11.6, 3.2 Hz, 1H), 3.94–
3.85 (m, 1H), 2.00–1.93 (m, 9H), 1.63–1.16 (m, 11H). 13C NMR (100 MHz, CDCl3) δ = 
165.3 (Cq), 147.2 (Cq), 144.8 (CH), 144.7 (Cq), 135.9 (CH), 125.5 (CH), 48.0 (CH), 37.9 
(CH), 34.1 (CH2), 33.1 (CH2), 26.7 (CH2), 26.2 (CH2), 25.6 (CH2), 24.9 (CH2). IR (ATR): 
3378, 2922, 2850, 1663, 1502, 805, 625 cm–1. MS (ESI) m/z (relative intensity): 309 (30) 
[M+Na]+, 287 (100) [M+H]+, 202 (20), 188 (10). HR-MS (ESI) m/z calcd for C18H27N2O 
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Prepared following the general procedure C using N-(1,2,3,4-tetrahydronaphthalen-1-
yl)picolinamide 88h (50.4 mg, 0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). 
Purification by column chromatography (n-hexane/EtOAc 8:1) yielded 181ha (55.1 mg, 
82%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.33 (d, J = 8.8 Hz, 1H), 8.28 (dd, 
J = 4.4, 1.6 Hz, 1H), 7.76 (dd, J = 7.6, 1.6 Hz, 1H), 7.36–7.33 (m, 1H), 7.31 (ddd, J = 8.0, 
4.4, 0.4 Hz, 1H), 7.17–7.09 (m, 3H), 5.37–5.32 (m, 1H), 4.15 (tt, J = 12.0, 3.2 Hz, 1H), 
2.94–2.71 (m, 2H), 2.22–2.09 (m, 1H), 1.96–1.77 (m, 8H), 1.63–1.46 (m, 2H), 1.43–1.22 
(m, 3H). 13C NMR (100 MHz, CDCl3) δ = 165.5 (Cq), 146.9 (Cq), 144.92 (CH), 144.8 (Cq), 
137.5 (Cq), 137.0 (Cq), 135.9 (CH), 129.0 (CH), 128.7 (CH), 127.0 (CH), 126.1 (CH), 125.6 
(CH), 47.3 (CH), 37.9 (CH), 34.2 (CH2), 34.1 (CH2), 30.3 (CH2), 29.3 (CH2), 26.8 (CH2), 
26.3 (CH2), 20.2 (CH2). IR (ATR): 3376, 2923, 2851, 1664, 1493, 1445, 805, 734, 624   
cm–1. MS (ESI) m/z (relative intensity): 357 (100) [M+Na]+, 335 (25) [M+H]+, 188 (30), 147 




Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 0.20 
mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181ia (47.7 mg, 92%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.31 (dd, J = 4.4, 1.6 Hz, 1H), 7.97 (brs, 1H), 7.72 (dd, J = 
8.0, 1.6 Hz, 1H), 7.29 (dd, J = 8.0, 4.4 Hz, 1H), 4.04 (tt, J = 12.0, 3.2 Hz, 1H), 3.39 (td, J = 
7.2, 6.0 Hz, 2H), 1.88–1.76 (m, 5H), 1.62–1.18 (m, 9H), 0.92 (t, J = 7.2 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 166.2 (Cq), 147.2 (Cq), 144.9 (CH), 144.7 (Cq), 136.0 (CH), 125.5 
(CH), 39.1 (CH2), 37.8 (CH), 34.1 (CH2), 31.7 (CH2), 26.7 (CH2), 26.2 (CH2), 20.2 (CH2), 
13.8 (CH3). IR (ATR): 3382, 2922, 2850, 1663, 1504, 694, 498 cm–1. MS (ESI) m/z (relative 
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intensity): 283 (40) [M+Na]+, 261 (100) [M+H]+,188 (15), 160 (10). HR-MS (ESI) m/z calcd 




Prepared following the general procedure C using N-(4-methoxyphenyl)picolinamide 88j 
(45.6 mg, 0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 181ja (28.7 mg, 46%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ = 10.05 (brs, 1H), 8.41 (dd, J = 4.5, 1.5 Hz, 1H), 
7.85–7.80 (dd, J = 8.1, 1.5 Hz, 1H), 7.64 (d, J = 9.0 Hz, 2H), 7.39 (dd, J = 8.1, 4.5 Hz, 1H), 
6.91 (d, J = 9.0 Hz, 2H), 4.24–4.16 (m, 1H), 3.81 (s, 3H), 1.95–1.76 (m, 5H), 1.57–1.24 (m, 
5H). 13C NMR (125 MHz, CDCl3) δ = 163.5 (Cq), 156.1 (Cq), 146.4 (Cq), 145.4 (Cq), 144.7 
(CH), 136.3 (CH), 131.3 (Cq), 125.9 (CH), 121.5 (CH), 114.1 (CH), 55.5 (CH3), 37.9 (CH), 
34.2 (CH2), 26.8 (CH2), 26.3 (CH2). IR (ATR): 3319, 2922, 2847, 1673, 1513, 1240, 825, 
689, 559 cm–1. MS (ESI) m/z (relative intensity): 333 (35) [M+Na]+, 211 (100) [M+H]+, 188 




Prepared following the general procedure C using N-phenethylpicolinamide 88k (48.4 mg, 
0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by column 
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chromatography (n-hexane/EtOAc 8:1) yielded 181ka (16.7 mg, 26%) as a white solid.   
M.p. = 92–93 °C. 1H NMR (400 MHz, CDCl3) δ = 8.28 (t, J = 5.6 Hz, 1H), 8.20 (brs, 1H), 
8.12–8.07 (m, 2H), 7.70 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H), 7.58 (ddd, J = 8.4, 6.8, 1.6 Hz, 1H), 
3.51 (td, J = 7.1, 6.0 Hz, 2H), 3.33 (tt, J = 11.6, 3.0 Hz, 1H), 2.00–1.80 (m, 4H), 1.85–1.80 
(m, 1H), 1.69–1.28 (m, 9H), 0.96 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 164.8 
(Cq), 155.1 (Cq), 149.8 (Cq), 146.8 (Cq), 130.6 (CH), 129.3 (CH), 127.8 (Cq), 127.3 (CH), 
123.1 (CH), 115.2 (CH), 39.3 (CH), 33.4 (CH2), 31.8 (CH2), 26.9 (CH2), 26.2 (CH2), 20.2 
(CH2), 13.8(CH3). IR (ATR): 3322, 2928, 2855, 1669, 1529, 762 cm–1. MS (ESI) m/z 
(relative intensity): 333 (30) [M+Na]+, 311 (100) [M+H]+, 238 (20). HR-MS (ESI) m/z calcd 




Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 0.20 
mmol) and cyclopentylchloride 180b (63 μL, 0.60 mmol) under stirring for 36 h. Purification 
by column chromatography (n-hexane/EtOAc 8:1) yielded 181ib (28.1 mg, 57%) as a 
yellow oil. 1H NMR (300 MHz, CDCl3) δ = 8.31 (dd, J = 4.5, 1.5 Hz, 1H), 7.90 (brs, 1H), 
7.74 (dd, J = 8.1, 1.5 Hz, 1H), 7.30 (dd, J = 8.1, 4.5 Hz, 1H), 4.39 (tt, J = 9.6, 7.5 Hz, 1H), 
3.40 (td, J = 7.1, 6.0 Hz, 2H), 2.17–2.07 (m, 2H), 1.77–1.70 (m, 4H), 1.62–1.36 (m, 6H), 
0.93 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 166.3 (Cq), 147.9 (Cq), 144.8 (CH), 
143.3 (Cq), 136.0 (CH), 125.5 (CH), 39.7 (CH), 39.2 (CH2), 34.7 (CH2), 31.8 (CH2), 25.8 
(CH2), 20.3 (CH2), 13.9 (CH3). IR (ATR): 3385, 2947, 2859, 1660, 1508, 804, 654 cm–1. 
MS (ESI) m/z (relative intensity): 269 (100) [M+Na]+, 247 (25) [M+H]+, 174 (15). HR-MS 
(ESI) m/z calcd for C15H23N2O [M+H]+ 247.1803 found 247.1805. 
 





Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 
0.20 mmol) and 4-chlorotetrahydro-2H-pyran 180c (65 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 181ic (31.5 mg, 60%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) δ = 8.36 (dd, J = 4.5, 1.5 Hz, 1H), 8.09 (brs, 1H), 
7.75 (dd, J = 8.1, 1.5 Hz, 1H), 7.36 (dd, J = 8.1, 4.5 Hz, 1H), 4.45–4.35 (m, 1H), 4.06–4.01 
(m, 2H), 3.68–3,56 (m, 2H), 3.40 (td, J = 7.2, 6.0 Hz, 2H), 1.81–1.55 (m, 4H), 1.65–1.54 
(m, 2H), 1.47–1.34 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 165.8 
(Cq), 146.9 (Cq), 145.3 (CH), 142.6 (Cq), 136.0 (CH), 125.7 (CH), 68.4 (CH2), 39.2 (CH2), 
35.4 (CH), 33.6 (CH2), 31.7 (CH2), 20.3 (CH2), 13.9 (CH3). IR (ATR): 3386, 2951, 2928, 
2843, 1661, 1512, 1502, 1437, 1124, 630, 597 cm–1. MS (ESI) m/z (relative intensity): 285 
(100) [M+Na]+, 263 (10) [M+H]+, 224 (30), 190 (15). HR-MS (ESI) m/z calcd for C15H23N2O2 




Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 0.20 
mmol) and 1-allylpiperidine 180d (94 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181id (46.4 mg, 77%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 4.4, 1.6 Hz, 1H), 8.04 (brs, 1H), 7.76 (dd, J = 
8.0, 1.6 Hz, 1H), 7.30 (dd, J = 8.0, 4.4 Hz, 1H), 5.88 (ddt, J = 16.8, 10.0, 6.8 Hz, 1H), 5.19–
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5.11 (m, 2H), 4.11 (tt, J = 12.0, 3.6 Hz, 1H), 3.37 (td, J = 7.2, 6.0 Hz, 2H), 3.03 (dt, J = 6.8, 
1.2 Hz, 4H), 2.18 (td, J = 11.8, 2.4 Hz, 2H), 1.93–1.80 (m, 2H), 1.75 (qd, J = 12.4, 3.6 Hz, 
2H), 1.65–1.48 (m, 2H), 1.45–1.25 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ = 166.0 (Cq), 147.1 (Cq), 145.2 (CH), 143.0 (Cq), 136.0 (CH), 134.5 (CH), 125.7 
(CH), 118.4 (CH2), 61.9 (CH2), 53.9 (CH2), 39.1 (CH2), 35.9 (CH), 32.7 (CH2), 31.6 (CH2), 
20.2 (CH2), 13.7 (CH3). IR (ATR): 3385, 2927, 2789, 1662, 1512, 1438, 994, 918, 626   
cm–1. MS (ESI) m/z (relative intensity): 318 (10) [M+Na]+, 302 (100) [M+H]+, 229 (30). HR-




Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 0.20 
mmol)and isopropylchloride 180e (53 μL, 0.60 mmol) with stirring for 24 h. Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 181ie (27.3 mg, 62%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 4.4, 1.6 Hz, 1H), 7.92 (brs, 1H), 
7.75 (dd, J = 8.0, 1.6 Hz, 1H), 7.31 (dd, J = 8.0, 4.4 Hz, 1H), 4.40 (p, J = 6.8 Hz, 1H), 3.39 
(td, J = 7.2, 6.0 Hz, 2H), 1.62–1.55 (m, 2H), 1.44–1.35 (m, 2H), 1.23 (d, J = 6.8 Hz, 6H), 
0.92 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 166.2 (Cq), 147.2 (Cq), 145.6 (Cq), 
145.0 (CH), 135.4 (CH), 125.6 (CH), 39.1 (CH2), 31.7 (CH2), 27.5 (CH), 23.6 (CH3), 20.2 
(CH2), 13.8 (CH3). IR (ATR): 3386, 2958, 2866, 1662, 1511, 855, 655 cm–1. MS (ESI) m/z 
(relative intensity): 243 (100) [M+Na]+, 221 (20) [M+H]+, 148 (15). HR-MS (ESI) m/z calcd 
for C13H21N2O [M+H]+ 221.1646 found 2212.1648. 
 
 





Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 
0.20 mmol) and isobutylchloride 180f (64 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181if (35.7 mg, 75%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.28 (dd, J = 4.5, 1.5 Hz, 1H), 7.88 (brs, 1H), 7.66 (dd, J = 
8.0, 1.5 Hz, 1H), 7.27 (dd, J = 8.0, 4.5 Hz, 1H), 4.23–4.11 (m, 1H), 3.35 (td, J = 7.2, 6.0 Hz, 
2H), 1.60–1.48 (m, 4H), 1.41–1.29 (m, 2H), 1.16 (d, J = 6.9 Hz, 3H), 0.88 (t, J = 7.2 Hz, 
3H), 0.78 (t, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 166.1 (Cq), 147.7 (Cq), 144.9 
(CH), 144.5 (Cq), 135.8 (CH), 125.4 (CH), 39.1 (CH2), 34.0 (CH), 31.7 (CH2), 30.8 (CH2), 
21.4 (CH3), 20.3 (CH2), 13.8 (CH3), 12.1 (CH3). IR (ATR): 3394, 2958, 2865, 1669, 1514, 
146, 805, 398 cm–1. MS (ESI) m/z (relative intensity): 257 (100) [M+Na]+, 235 (20) [M+H]+, 




Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 
0.20 mmol) and 2-chlorohexane 181g (83 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181ig (47.6 mg, 82%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.33 (dd, J = 4.4, 1.6 Hz, 1H), 7.88 (brs, 1H), 7.72 (dd, J = 
8.0, 1.6 Hz, 1H), 7.32 (ddd, J = 8.0, 4.4, 0.4 Hz, 1H), 4.30 (h, J = 7.2 Hz, 1H), 3.43–3.39 
(m, 2H), 1.63–1.48 (m, 4H), 1.45–1.35 (m, 2H), 1.30–1.19 (m, 3H), 1.21 (d, J = 6.8 Hz, 3H), 
1.16–1.08 (m, 1H), 0.93 (t, J = 7.2 Hz, 3H), 0.81 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, 
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CDCl3) δ = 166.3 (Cq), 147.7 (Cq), 145.0 (CH), 144.9 (Cq), 136.0 (CH), 125.6 (CH), 39.1 
(CH2), 37.7 (CH2), 32.3 (CH), 31.7 (CH2), 29.8 (CH2), 22.8 (CH2), 22.0 (CH3), 20.2 (CH2), 
14.0 (CH3), 13.8 (CH3). IR (ATR): 3387, 2955, 2925, 2863, 1665, 1511, 1457, 806, 708, 
659 cm–1. MS (ESI) m/z (relative intensity): 285 (30) [M+Na]+, 263 (100) [M+H]+, 190 (10), 




Prepared following the general procedure C using N-butylpicolinamide 88ii (35.6 mg, 0.20 
mmol) and (1-chloroethyl)benzene 180h (80 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181ih (20.9 mg, 37%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.38 (dd, J = 5.2, 0.8 Hz, 1H), 8.11–8.10 (m, 1H), 8.03 (brs, 
1H), 7.30–7.24 (m, 2H), 7.21–7.16 (m, 4H), 4.17 (q, J = 7.2 Hz, 1H), 3.44 (td, J = 7.2, 6.0 
Hz, 2H), 1.65 (d, J = 7.2 Hz, 3H), 1.61–1.55 (m, 2H), 1.43–1.35 (m, 2H), 0.93 (t, J = 7.2 
Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 164.3 (Cq), 156.9 (Cq), 150.1 (Cq), 148.0 (CH), 
144.0 (Cq), 128.7 (CH), 127.6 (CH), 126.7 (CH), 125.3 (CH), 121.3 (CH), 44.5 (CH), 39.1 
(CH2), 31.7 (CH2), 20.9 (CH3), 20.1 (CH2), 13.8 (CH3). IR (ATR): 3387, 2960, 2868, 1668, 
1523, 701, 585 cm–1. MS (ESI) m/z (relative intensity): 305 (100) [M+Na]+, 283 (55) [M+H]+, 
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Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 
0.20 mmol) and (3-chlorobutyl)benzene 180i (101 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181ii (32.4 mg, 52%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.36 (dd, J = 4.5, 1.5 Hz, 1H), 7.93 (s, 1H), 7.76 (dd, J = 
8.1, 1.5 Hz, 1H), 7.34 (ddd, J = 8.1, 4.5, 0.6 Hz, 2H), 7.24–7.08 (m, 4H), 4.45 (h, J = 7.2 
Hz, 1H), 3.42 (td, J = 7.2, 6.0 Hz, 2H), 2.70–2.57 (m, 1H), 2.50–2.37 (m, 1H), 1.99–1.82 
(m, 2H), 1.66–1.56 (m, 2H), 1.49–1.36 (m, 2H), 1.29 (d, J = 6.9 Hz, 3H), 0.95 (t, J = 7.2 Hz, 
3H). 13C NMR (125 MHz, CDCl3) δ = 166.1 (Cq), 147.7 (Cq), 145.10 (CH), 144.2 (Cq), 142.5 
(Cq), 135.8 (CH), 128.1 (CH), 128.1 (CH), 125.6 (CH), 125.5 (CH), 40.1 (CH2), 39.2 (CH2), 
34.2 (CH2), 32.8 (CH), 31.8 (CH2), 22.18 (CH3), 20.3 (CH2), 13.9 (CH3). IR (ATR): 3388, 
2926, 2863, 1664, 1510, 1455, 807, 700 cm–1. MS (ESI) m/z (relative intensity): 333 (30) 
[M+Na]+, 311 (100) [M+H]+, 238 (10). HR-MS (ESI) m/z calcd for C20H27N2O [M+H]+ 




Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 
0.20 mmol) and (1-chloropropyl)benzene 180j (100 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181ij (36.7 mg, 59%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.37 (dd, J = 5.1, 0.9 Hz, 1H), 8.11 (dt, J = 1.8, 0.6 Hz, 1H), 
8.02 (brs, 1H), 7.29–7.17 (m, 6H), 3.82 (t, J = 7.8 Hz, 1H), 3.43 (td, J = 7.2, 6.3 Hz, 2H), 
2.14–2.04 (m, 2H), 1.63–1.54 (m, 2H), 1.46–1.33 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H), 0.88 (t, 
J = 7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 164.2 (Cq), 155.7 (Cq), 150.0 (Cq), 147.9 
(CH), 142.7 (Cq), 128.6 (CH), 127.8 (CH), 126.6 (CH), 125.5 (CH), 121.5 (CH), 52.9 (CH2), 
39.2 (CH2), 31.8 (CH2), 27.9 (CH2), 20.2 (CH2), 13.8 (CH3), 12.6 (CH3). IR (ATR): 3388, 
2959, 2928, 2868, 1668, 1522, 700, 593 cm–1. MS (ESI) m/z (relative intensity): 319 (30) 
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[M+Na]+, 297 (100) [M+H]+, 223 (10). HR-MS (ESI) m/z calcd for C19H25N2O [M+H]+ 




Prepared following the general procedure C using N-butylpicolinamide 88i (35.6 mg, 
0.20 mmol) and 5-chlorohex-1-ene 180k (80 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 181k (30.7 mg, 59%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.29 (dd, J = 4.5, 1.5 Hz, 1H), 7.85 (brs, 1H), 7.68 (dd, J = 
8.1, 1.5 Hz, 1H), 7.28 (ddd, J = 8.1, 4.5, 0.6 Hz, 1H), 5.72 (ddt, J = 16.8, 10.2, 6.6 Hz, 1H), 
4.90–4.80 (m, 2H), 4.31 (h, J = 7.2 Hz, 1H), 3.39–3.32 (m, 2H), 2.06–1.80 (m, 2H), 1.66–
1.50 (m, 4H), 1.44–1.27 (m, 2H), 1.19 (d, J = 6.9 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H). 13C NMR 
(125 MHz, CDCl3) δ = 166.1 (Cq), 147.7 (Cq), 145.0 (CH), 144.3 (Cq), 138.6 (CH), 135.9 
(CH), 125.5 (CH), 114.1 (CH2), 39.2 (CH2), 37.2 (CH2), 32.2 (CH), 31.9 (CH2), 31.8 (CH2), 
22.0 (CH3), 20.3 (CH2), 13.9 (CH3). IR (ATR): 3385, 2924, 2864, 1664, 1512, 1373, 807, 
654 cm–1. MS (ESI) m/z (relative intensity): 383 (40) [M+Na]+, 261 (100) [M+H]+, 188 (10). 
HR-MS (ESI) m/z calcd for C16H25N2O [M+H]+ 261.1963 found 261.1961. 
 
 
Butyl-N-(1-phenylethyl)picolinamide (200aa)  
Prepared following the general procedure D using N-(1-phenylethyl)picolinamide 88a (45.2 
mg, 0.20 mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column 
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chromatography (n-hexane/EtOAc 8:1) yielded 200aa (39.0 mg, 69%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.41 (brs 1H), 8.35 (dd, J = 4.6, 1.7 Hz, 1H), 7.56 (dd, J = 
7.8, 1.7 Hz, 1H), 7.42–7.37 (m, 2H), 7.36–7.20 (m, 4H), 5.35–5.19 (m, 1H), 3.25–3.06 (m, 
2H), 1.66–1.51 (m, 5H), 1.44–1.32 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, 
CDCl3) δ = 164.9 (Cq), 147.1 (Cq), 145.3 (CH), 143.7 (Cq), 140.2 (Cq), 139.9 (CH), 128.6 
(CH), 127.1 (CH), 126.1 (CH), 125.5 (CH), 48.5 (CH), 33.5 (CH2), 32.7 (CH2), 22.7 (CH2), 
22.3 (CH3), 14.0 (CH3). IR (ATR): 2958, 2864, 1669, 1496, 1208, 698 cm–1. MS (ESI) m/z 
(relative intensity) 305 (100) [M+Na]+, 283 (50) [M+H]+, 236 (10). HR-MS (ESI) m/z calcd 




Prepared following the general procedure D using N-benzylpicolinamide 88b (42.4 mg, 
0.20 mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 6:1) yielded 200ba (34.8 mg, 65%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ = 8.44 (brs 1H), 8.34 (brs,1H), 7.58 (d, J = 7.8 Hz, 1H), 7.46–
7.15 (m, 6H), 4.62 (d, J = 4.8 Hz, 2H), 3.19 (t, J = 7.5 Hz, 2H), 1.70–1.56 (m, 2H), 1.51–
1.34 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 165.6 (Cq), 147.0 
(Cq), 145.3 (CH), 140.2 (Cq), 139.9 (CH), 138.5 (Cq), 128.5 (CH), 127.7 (CH), 127.2 (CH), 
125.5 (CH), 43.3 (CH2), 33.7 (CH2), 32.9 (CH2), 22.9 (CH2), 14.1 (CH3). IR (ATR): 2926, 
2862, 1668, 1505, 1433, 1127, 697, 602 cm–1. MS (ESI) m/z (relative intensity) 291 (100) 
[M+Na]+, 269 (30) [M+H]+, 236 (10). HR-MS (ESI) m/z calcd for C17H20N2O [M+Na]+ 
291.1468, found 291.1463. 
 





Prepared following the general procedure D using N-(2-fluorobenzyl)picolinamide 88c 
(46.0 mg, 0.20 mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 6:1) yielded 200ca (32.0 mg, 56%) as a white solid. M.p. 
= 55–57 oC. 1H NMR (300 MHz, CDCl3) δ = 8.45 (brs 1H), 8.34 (dd, J = 4.6, 1.7 Hz, 1H), 
7.57 (dd, J = 7.8, 1.7 Hz, 1H), 7.39 (td, J = 7.5, 1.8 Hz, 1H), 7.29 (dd, J = 7.8, 4.6 Hz, 1H), 
7.26–7.16 (m, 1H), 7.13–6.96 (m, 2H), 4.67 (d, J = 6.3 Hz, 2H), 3.24–3.10 (m, 2H), 1.68–
1.55 (m, 2H), 1.46–1.32 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 
165.6 (Cq), 160.9 (d, 1JC–F = 243.7 Hz, Cq), 146.9 (Cq), 145.3 (CH), 140.2 (Cq), 139.9 (CH), 
129.9 (d, 3JC–F = 3.8 Hz, CH), 128.9 (d, 3JC–F = 7.5 Hz, CH), 125.5 (CH), 125.4 (Cq), 124.1 
(d, 4JC–F = 3.7 Hz, CH), 115.2 (d, 2JC–F = 21.3 Hz, CH), 37.2 (d, 3JC–F = 4.9 Hz, CH), 33.6 
(CH2), 32.8 (CH2), 22.8 (CH2), 14.1 (CH3). 19F NMR (275 MHz, CDCl3) δ = –118.0-–117.9 
(m). IR (ATR): 2927, 2862, 1671, 1502, 1229, 754, 607 cm–1. MS (ESI) m/z (relative 
intensity) 309 (100) [M+Na]+, 287 (30) [M+H]+. HR-MS (ESI) m/z calcd for C17H19FN2O 




Prepared following the general procedure D using N-(4-methoxybenzyl)picolinamide 88d 
(48.5 mg, 0.20 mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 6:1) yielded 200da (41.2 mg, 69%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.35 (brs, 1H), 8.31 (dd, J = 4.6, 1.7 Hz, 1H), 7.57 (dd, J = 
7.8, 1.7 Hz, 1H), 7.30–7.25 (m, 3H), 6.85 (d, J = 8.8 Hz, 2H), 4.54 (d, J = 5.9 Hz, 2H), 3.77 
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(s, 3H), 3.23–3.14 (m, 2H), 1.68–1.56 (m, 2H), 1.46–1.34 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 165.6 (Cq), 158.8 (Cq), 147.0 (Cq), 145.3 (CH), 140.2 (Cq), 
140.1 (CH), 140.0 (Cq), 130.6 (CH), 129.1 (CH), 125.5 (CH), 114.0 (CH), 113.9 (CH), 55.2 
(CH3), 42.7 (CH2), 33.6 (CH2), 32.8 (CH2), 22.8 (CH2), 14.0 (CH3). IR (ATR): 2927, 2863, 
1667, 1505, 1033, 813, 579 cm–1. MS (ESI) m/z (relative intensity) 321 (100) [M+Na]+, 299 




Prepared following the general procedure D using N-butylpicolinamide 88i (35.6 mg, 0.20 
mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column chromatography 
(n-hexane/EtOAc 8:1) yielded 200ia (34.5 mg, 74%) as a colorless oil. 1H NMR (300 MHz, 
CDCl3) δ = 8.34 (dd, J = 4.6, 1.7 Hz, 1H), 8.05 (brs 1H), 7.56 (dd, J = 7.8, 1.7 Hz, 1H), 7.27 
(dd, J = 7.8, 4.6 Hz, 1H), 3.40 (td, J = 7.1, 6.0 Hz, 2H), 3.14 (t, J = 7.7 Hz, 2H), 1.64–1.54 
(m, 4H), 1.45–1.34 (m, 4H), 0.92 (td, J = 7.3, 6.3 Hz, 6H). 13C NMR (125 MHz, CDCl3) δ = 
165.7 (Cq), 147.4 (Cq), 145.2 (CH), 139.9 (Cq), 139.8 (CH), 125.3 (CH), 39.1 (CH2), 33.7 
(CH2), 32.9 (CH2), 31.8 (CH2), 22.9 (CH2), 20.3 (CH2), 14.1 (CH3), 13.9 (CH3). IR (ATR): 
2927, 2864, 1667, 1511, 1434, 807, 605 cm–1. MS (ESI) m/z (relative intensity) 257 (100) 
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Prepared following the general procedure D using N-(2-phenylethyl)picolinamide 88f (45.2 
mg, 0.20 mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 200fa (42.3 mg, 75%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 4.6, 1.7 Hz, 1H), 8.16 (brs 1H), 7.57 (dd, J = 
7.8, 1.7 Hz, 1H), 7.33–7.18 (m, 6H), 3.68 (td, J = 7.3, 6.0 Hz, 2H), 3.16 (t, J = 7.3 Hz, 2H), 
2.92 (t, J = 7.3 Hz, 2H), 1.65–1.55 (m, 2H), 1.46–1.34 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 
13C NMR (100 MHz, CDCl3) δ = 165.8 (Cq), 147.2 (Cq), 145.3 (CH), 140.1 (Cq), 140.0 (CH), 
139.2 (Cq), 128.8 (CH), 128.5 (CH), 126.3 (CH), 125.5 (CH), 40.6 (CH2), 36.0 (CH2), 33.6 
(CH2), 32.8 (CH2), 22.8 (CH2), 14.0 (CH3). IR (ATR): 2927, 2862, 1667, 1506, 1435, 745, 
698 cm–1. MS (ESI) m/z (relative intensity) 305 (100) [M+Na]+, 283 (30) [M+H]+, 236 (10). 




Prepared following the general procedure D using N-cyclohexylpicolinamide 88g (40.8 mg, 
0.20 mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 200ga (39.8 mg, 77%) as a colorless oil. 
1H NMR (500 MHz, CDCl3) δ = 8.33 (dd, J = 4.6, 1.7 Hz, 1H), 7.96 (brs 1H), 7.54 (dd, J = 
7.8, 1.7 Hz, 1H), 7.26 (dd, J = 7.8, 4.6 Hz, 1H), 3.95–3.78 (m, 1H), 3.13 (t, J = 7.3 Hz, 2H), 
2.02–1.93 (m, 2H), 1.77–1.69 (m, 2H), 1.64–1.53 (m, 3H), 1.45–1.33 (m, 4H), 1.30–1.13 
(m, 3H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ = 164.8 (Cq), 147.5 (Cq), 
145.2 (CH), 140.1 (Cq), 140.0 (CH), 125.3 (CH), 47.9 (CH), 33.7 (CH2), 33.1 (CH2), 32.9 
(CH2), 25.6 (CH2), 24.9 (CH2), 22.8 (CH2), 14.0 (CH3). IR (ATR): 2927, 2854, 1667, 1503, 
1440, 1122, 808, 590 cm–1. MS (ESI) m/z (relative intensity) 283 (100) [M+Na]+, 261 (50) 
[M+H]+, 133 (5). HR-MS (ESI) m/z calcd for C16H24N2O [M+H]+ 261.1961, found 261.1960. 





Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and n-butylbromide 86a (64 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 8:1) yielded 200ea (35.5 mg, 75%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.31 (dd, J = 4.6, 1.7 Hz, 1H), 7.83 (brs 1H), 7.54 (dd, J = 
7.8, 1.7 Hz, 1H), 7.24 (dd, J = 7.8, 4.6 Hz, 1H), 3.13 (t, J = 7.3 Hz, 2H), 1.65–1.52 (m, 2H), 
1.45 (s, 9H), 1.32 (d, J = 7.3 Hz, 2H), 0.90 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3) 
δ = 165.4 (Cq), 148.6 (Cq), 145.0 (CH), 139.8 (CH), 139.5 (Cq), 125.1 (CH), 50.7 (Cq), 33.4 
(CH2), 32.6 (CH2), 28.7 (CH3), 22.6 (CH2), 14.0 (CH3). IR (ATR): 2960, 2865, 1674, 1508, 
1450, 1227, 805, 603 cm–1. MS (ESI) m/z (relative intensity) 257 (100) [M+Na]+, 235 (80) 




Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and n-pentylbromide 86b (74 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 200eb (35.3 mg, 71%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 4.6, 1.6 Hz, 1H), 7.83 (brs 1H), 7.54 (dd, J = 
7.8, 1.6 Hz, 1H), 7.25 (dd, J = 7.8, 4.6 Hz, 1H), 3.13 (t, J = 7.3 Hz, 2H), 1.66–1.54 (m, 2H), 
1.45 (s, 9H), 1.38–1.26 (m, 4H), 0.89–0.81 (m, 3H). 13C NMR (100 MHz, CDCl3) δ = 165.4 
(Cq), 148.6 (Cq), 145.0 (CH), 140.0 (CH), 139.5 (Cq), 125.1 (CH), 50.7 (Cq), 32.8 (CH2), 
31.8 (CH2), 30.9 (CH2), 28.7 (CH3), 22.6 (CH2), 14.0 (CH3). MS (ESI) m/z (relative intensity) 
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271 (100) [M+Na]+, 249 (70) [M+H]+, 149 (10). HR-MS (ESI) m/z calcd for C15H24N2O 




Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and 1-bromoundecane 86c (94 μL, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 200ec (35.3 mg, 53%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 4.6, 1.6 Hz, 1H), 7.83 (brs 1H), 7.54 (dd, J = 
7.8, 1.6 Hz, 1H), 7.25 (dd, J = 7.8, 4.6 Hz, 1H), 3.13 (t, J = 7.6 Hz, 2H), 1.63–1.54 (m, 2H), 
1.45 (s, 9H), 1.39–1.20 (m, 16H), 0.85 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ = 
165.4 (Cq), 148.6 (Cq), 145.0 (CH), 140.0 (CH), 139.6 (Cq), 125.1 (CH), 50.7 (Cq), 32.9 
(CH2), 31.9 (CH2), 31.2 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 
29.3 (CH2), 28.7 (CH3), 22.7 (CH2), 14.1 (CH3). IR (ATR): 2922, 2853, 1676, 1509, 1455, 
1228, 803, 604 cm–1. MS (ESI) m/z (relative intensity) 355 (100) [M+Na]+, 333 (60) [M+H]+, 





Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and (3-bromopropyl)benzene 86d (119.4 mg, 0.60 mmol). Purification by 
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column chromatography (n-hexane/EtOAc 7:1) yielded 200ed (43.8 mg, 74%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.33 (dd, J = 4.6, 1.6 Hz, 1H), 7.90 (brs 1H), 
7.52 (dd, J = 7.8, 1.6 Hz, 1H), 7.29–7.21 (m, 3H), 7.20–7.11 (m, 3H), 3.22 (t, J = 7.5 Hz, 
2H), 2.70 (t, J = 7.3 Hz, 2H), 2.01–1.91 (m, 2H), 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3) 
δ = 165.3 (Cq), 148.5 (Cq), 145.2 (CH), 142.4 (Cq), 139.9 (CH), 139.0 (Cq), 128.4 (CH), 
128.2 (CH), 125.6 (CH), 125.2 (CH), 50.7 (Cq), 35.7 (CH2), 32.8 (CH2), 32.6 (CH2), 28.7 
(CH3). IR (ATR): 2963, 1672, 1508, 1448, 1227, 1096, 745, 700, 607 cm–1. MS (ESI) m/z 
(relative intensity) 319 (100) [M+Na]+, 297 (70) [M+H]+, 271 (20), 236 (15), 149 (20). HR-




Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and 1-bromo-6-chlorohexane 86e (119.7 mg, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded 200ee (43.5 mg, 73%) as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.33 (dd, J = 4.6, 1.7 Hz, 1H), 7.87 (brs 1H), 
7.54 (dd, J = 7.8, 1.7 Hz, 1H), 7.26 (dd, J = 7.8, 4.6 Hz, 1H), 3.50 (t, J = 6.8 Hz, 2H), 3.14 
(t, J = 7.5 Hz, 2H), 1.78–1.70 (m, 2H), 1.66–1.57 (m, 2H), 1.45 (s, 9H), 1.49–1.32 (m, 4H). 
13C NMR (100 MHz, CDCl3) δ = 165.3 (Cq), 148.5 (Cq), 145.1 (CH), 139.9 (CH), 139.3 (Cq), 
125.2 (CH), 50.7 (Cq), 45.1 (CH2), 32.8 (CH2), 32.5 (CH2), 31.0 (CH2), 28.8 (CH2), 28.7 
(CH3), 26.7 (CH2). IR (ATR): 2928, 2858, 1672, 1509, 1447, 1361, 1227, 711, 610 cm–1. 
MS (ESI) m/z (relative intensity) 319 (100) (35Cl) [M+Na]+, 297 (80) (35Cl) [M+H]+, 249 (10), 
149 (20). HR-MS (ESI) m/z calcd for C16H2535ClN2O [M+H]+ 297.1728, found 297.1729. 
 





Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and 4-bromobut-1-ene 86f (81.0 mg, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 200ef (24.1 mg, 52%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.33 (dd, J = 4.6, 1.7 Hz, 1H), 7.90 (brs 1H), 7.53 (dd, J = 
7.8, 1.7 Hz, 1H), 7.26 (dd, J = 7.8, 4.6 Hz, 1H), 5.84 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.03–
4.86 (m, 2H), 3.25 (t, J = 6.8, Hz, 2H), 2.44–2.33 (m, 2H), 1.46 (s, 9H). 13C NMR (100 MHz, 
CDCl3) δ = 165.2 (Cq), 148.6 (Cq), 145.3 (CH), 140.2 (CH), 138.5 (Cq), 138.0 (CH), 125.1 
(CH), 115.1 (CH2), 50.8 (Cq), 35.1 (CH2), 32.5 (CH2), 28.8 (CH3). IR (ATR): 2966, 1672, 
1509, 1441, 1225, 911, 804, 601 cm–1. MS (ESI) m/z (relative intensity) 255 (100) [M+Na]+, 




Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and 6-bromohex-1-ene 86h (97.2 mg, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 200eh (35.6 mg, 68%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ = 8.32 (dd, J = 4.6, 1.7 Hz, 1H), 7.85 (brs 1H), 7.54 (dd, J = 
7.8, 1.7 Hz, 1H), 7.26 (dd, J = 7.8, 4.6 Hz, 1H), 5.78 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.00–
4.86 (m, 2H), 3.15 (t, J = 7.3 Hz, 2H), 2.14–1.99 (m, 2H), 1.68–1.57 (m, 2H), 1.51–1.40 (m, 
11H). 13C NMR (100 MHz, CDCl3) δ = 165.3 (Cq), 148.6 (Cq), 145.1 (CH), 139.9 (CH), 139.3 
(Cq), 138.9 (CH), 125.2 (CH), 114.3 (CH2), 50.8 (Cq), 33.7 (CH2), 32.7 (CH2), 30.7 (CH2), 
28.8 (CH2), 28.7 (CH3). IR (ATR): 2924, 2858, 1673, 1509, 1445, 1227, 910, 607 cm–1. 
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MS (ESI) m/z (relative intensity) 283 (10) [M+Na]+, 261 (100) [M+H]+, 205 (10). HR-MS 
(ESI) m/z calcd for C16H24N2O [M+H]+ 261.1961, found 261.1961. 
 
5.4.2 Racemization Free Alkylation of 88a 
 
Prepared following the general procedure B using N-(1-phenylethyl)picolinamide (S)-88a 
(45.2 mg, 0.20 mmol) and cyclohexylchloride 180a (71 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 8:1) yielded (S)-181aa (49.8 mg, 81%) as a 
colorless oil. Chiral HPLC analysis (Chiralcel IC, i-PrOH/n-hexane 30:70, flow rate = 1.0 
mL/min, λ = 254 nm), tr (major) = 4.3 min, tr (minor) = 4.9 min. 
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5.4.3 Mechanistic Studies 
Control experiments 
 
Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and (bromomethyl)cyclopropane 86g (58 μL, 0.60 mmol). Purification by 
column chromatography (n-hexane/EtOAc 10:1) yielded 200eg (21.2 mg, 45%) as a 
colorless oil, while no cyclopropane product (200eg’) was detected. 
 
Prepared following the general procedure D using N-(tert-butyl)picolinamide 88e (35.6 mg, 
0.20 mmol) and 6-bromohex-1-ene 86h (97.2 mg, 0.60 mmol). Purification by column 
chromatography (n-hexane/EtOAc 10:1) yielded 200eh (35.6 mg, 68%) as a colorless oil, 
while no cyclopentane product (200eh’) was detected. 
KIE Experiments 
 
Twelve independent reactions with 88i and deuterated substrate [D]–88i under the 
standard conditions were performed: To a schlenk tube charged with amide 88i (45.0 mg, 
0.20 mmol), TMEDA (30 µL, 0.20 mmol), MnCl2 (2.7 mg, 0.02 mmol) and THF (0.6 mL), 
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EtMgBr (250 µL, 0.70 mmol, 2.8 M in THF) was added dropwise at ambient temperature 
under N2 atmosphere. After stirring for 5 min, alkyl chloride (0.60 mmol) was added and 
the reaction mixture stirred at 65 oC for 16 h. Then, to the reaction mixture sat. aqueous 
NH4Cl (5.0 mL) and H2O (10 mL) were subsequently added. The aqueous layer was 
extracted with EtOAc (3 x 15 mL). The combined organic extracts were washed with brine 
and dried over Na2SO4, and the reaction mixture stirred at 60 oC for 10 min, 20 min, 30 min, 
40 min, 50 min, 60 min respectively. The conversion of the product 181ia was monitored 
by 1H NMR using CH2Br2 as the internal standard. 
T (min) 10 20 30 40 50 60 
Yield [H] (%) 6.1 14.0 19.0 25.5 29.7 36.9 







y = 0.2249x - 1.1533
R² = 0.9885
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5.5 Rhodaelectro-Catalyzed Domino Alkyne Annulations to 
Access Aza-Polycyclic Aromatic Hydrocarbons 
5.5.1 Experimental Procedure and Analytical Data 
 
2,3,7,12,13-Pentaphenylbenzo[de]isoquinolino[2,1-a][1,8]naphthyridine (183aa) 
The general procedure E was followed using 182a (30.0 mg, 0.20 mmol) and 113a 
(124.6 mg, 0.70 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183aa (116.6 mg, 90%) as a red solid. M.p. = 295–
296 °C. 1H NMR (400 MHz, CDCl3) δ = 7.62–7.42 (m, 6H), 7.37–7.23 (m, 9H), 7.21–7.02 
(m, 11H), 7.00–6.94 (m, 3H), 6.86 (ddd, J = 8.3, 7.1, 1.5 Hz, 1H), 6.60–6.56 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ = 150.1 (Cq), 149.5 (Cq), 140.7 (Cq), 138.8 (Cq), 137.9 (Cq), 
137.8 (Cq), 137.5 Cq), 137.1 (Cq), 137.0 (Cq), 135.8 (Cq), 135.4 (Cq), 134.7 (Cq), 132.0 (CH), 
131.9 (CH), 131.4 (CH), 131.1 (CH), 130.4 (CH, overlapped), 130.2 (CH), 129.9 (CH), 
128.6 (CH, overlapped), 128.4 (CH), 128.1 (CH), 128.0 (CH), 127.5 (Cq), 127.1 (CH), 126.9 
(CH, overlapped), 126.8 (CH, overlapped), 126.7 (CH), 126.0 (CH), 125.7 (Cq), 125.0 (CH), 
123.3 (Cq), 122.0 (Cq), 119.1 (CH), 117.7 (CH). IR (ATR): 1738, 1610, 1536, 1342, 1234, 
757, 699 cm−1. HR-MS (ESI) m/z calcd for C49H33N2 [M+H]+ 649.2638, found 649.2635.  
 
 






The general procedure E was followed using 182b (36.0 mg, 0.20 mmol) and 113a 
(124.6 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183da (103.0 mg, 76%) as a red solid. M.p. > 300 °C. 
1H NMR (400 MHz, CDCl3) δ = 7.54–7.40 (m, 5H), 7.29–7.16 (m, 8H), 7.13–7.05 (m, 6H), 
7.06–6.95 (m, 5H), 6.92–6.87 (m, 2H), 6.79 (ddd, J = 8.4, 6.6, 1.9 Hz, 1H), 6.61 (d, J = 2.2 
Hz, 1H), 6.51–6.45 (m, 3H), 3.64 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 162.0 (Cq), 150.7 
(Cq), 149.0 (Cq), 140.7 (Cq), 139.8 (Cq), 138.6 (Cq), 138.1 (Cq), 137.4 (Cq), 137.3 (Cq), 137.0 
(Cq), 136.4 (Cq, overlapped, 2C 134.6 (Cq), 131.9 (CH), 131.7 (CH), 131.2 (CH), 130.3 (CH, 
overlapped, 2C), 130.1 (CH), 129.9 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 128.0 (CH), 
127.9 (CH), 127.3 (Cq), 127.0 (CH), 126.7 (CH, overlapped, 2C), 126.6 (CH), 126.5 (CH), 
125.9 (CH), 125.4 (Cq), 124.9 (CH), 122.8 (Cq), 118.5 (Cq), 117.8 (Cq), 107.2 (CH), 100.2 
(CH), 55.1(CH3). IR (ATR): 1610, 1574, 1537, 1401, 1346, 1208, 759, 701 cm−1.        
HR-MS (ESI) m/z calcd for C50H35N2O [M+H]+ 679.2744, found 679.2733. 
 
 






The general procedure E was followed using 182c (41.6 mg, 0.20 mmol) and 113a 
(124.6 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183ca (81.0 mg, 57%) as a red solid. M.p. = 193–
194 °C. 1H NMR (400 MHz, CDCl3) δ = 7.97 (d, J = 1.2 Hz, 1H), 7.59–7.50 (m, 6H), 7.33–
7.26 (m, 8H), 7.17–6.99 (m, 11H), 6.97–6.91 (m, 2H), 6.86 (ddd, J = 8.4, 6.6, 1.9 Hz, 1H), 
6.53 (d, J = 7.1 Hz, 2H), 3.84 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 167.4 (Cq), 151.1 
(Cq), 149.4 (Cq), 140.4 (Cq), 138.3 (Cq), 137.6 (Cq), 137.3 (Cq), 137.3 (Cq), 136.9 (Cq), 136.8 
(Cq), 136.8 (Cq), 136.6 (Cq), 135.9 (Cq), 134.7 (Cq), 132.6 (Cq), 132.0 (CH), 131.8 (CH), 
131.4 (CH), 130.4 (CH), 130.3 (CH), 130.2 (CH), 128.8 (CH), 128.7 (CH), 128.7 (CH), 
128.5 (CH), 128.1 (CH), 128.1 (CH), 7.4 (Cq), 127.3 (CH), 127.2 (CH), 127.0 (CH), 127.0 
(CH), 126.9 (CH), 126.2 (CH), 125.2 (CH), 124.2 (Cq), 123.4 (Cq), 120.8 (CH), 119.2 (Cq), 
117.5 (CH), 52.5 (CH). IR (ATR): 3058, 2919, 1725, 1609, 1541, 1339, 1229, 764, 669  
cm–1. MS (ESI) m/z (relative intensity): 707 (100) [M+H]+, 739 (15) [M+Na]+. HR-MS (ESI) 
m/z calcd for C51H34N2O2+ [M+H]+ 707.2693, found 707.2695. 
 






The general procedure E was followed using 182d (33.6 mg, 0.20 mmol) and 113a 
(124.6 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183da (98.0 mg, 73%) as a red solid. M.p. = 278–
280 °C. 1H NMR (300 MHz, CDCl3) δ = 7.60–7.49 (s, 5H), 7.34–7.22 (m, 8H), 7.18–7.01 
(m, 11H), 6.95 (t, J = 7.4 Hz, 2H), 6.89–6.82 (m, 2H), 6.62 (dd, J = 10.6, 1.9 Hz, 1H), 6.53 
(d, J = 7.3 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ = 165.1 (Cq, 1JC–F = 247.1 Hz), 151.2 
(Cq), 149.2 (Cq), 140.4 (Cq), 140.31 (Cq, 3JC–F = 11.2 Hz), 138.7 (Cq, 3J = 11.0 Hz), 138.4 
(Cq), 137.7 (Cq), 137.4 (Cq), 137.2 (Cq), 137.1 (Cq), 136.9 (Cq), 134.7 (Cq), 131.9 (CH), 
131.8 (CH), 131.8 (CH), 131.2 (CH), 130.4 (CH), 130.2 (CH), 130.2 (CH), 128.8 (CH), 
128.8 (CH) 128.7 (CH), 128.4 (CH), 128.1 (CH), 127.2 (CH), 127.2 (Cq), 127.1 (CH), 127.0 
(CH), 127.0 (CH), 126.8 (CH), 126.2 (CH), 126.1 (Cq), 125.3 (CH), 123.32 (Cq, 4JC–F = 4.7 
Hz), 119.2 (Cq), 118.5 (Cq), 105.9 (CH, 2JC–F = 27.3 Hz), 103.72 (CH, 2JC–F = 24.6 Hz). 
19F NMR (282 MHz, CDCl3) δ = –105.93 (t, J = 10.7 Hz). IR (ATR): 3051, 2961, 2161, 1609, 
1572, 1342, 1021, 696 cm–1. MS (ESI) m/z (relative intensity): 649 (100), 667 (15) [M+H]+. 
HR-MS (ESI) m/z calcd for C49H32FN2 [M+H]+ 667.2544, found 667.2531.   
 






The general procedure E was followed using 182a (30.0 mg, 0.20 mmol) and 113b 
(144.4 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183ab (118.6 mg, 81%) as a red solid. M.p. = 198–
199 °C. 1H NMR (400 MHz, CDCl3) δ = 7.48–7.33 (m, 5H), 7.22–7.10 (m, 7H), 7.04 (d, J = 
7.6 Hz, 4H), 7.00–6.90 (m, 3H), 6.87 (d, J = 8.0 Hz, 2H), 6.80 (d, J = 7.9 Hz, 2H), 6.69 (d, 
J = 8.3 Hz, 1H), 6.49 (d, J = 8.0 Hz, 2H), 2.51 (s, 3H), 2.40 (s, 3H), 2.38 (s, 3H), 2.27 (s, 
3H), 2.24 (s, 3H), 2.20 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 145.0 (Cq), 149.5 (Cq), 
138.10 (Cq, overlapped 3C), 138.0 (Cq), 137.6 (Cq), 137.5 (Cq), 136.1 (Cq), 136.0 (Cq), 
136.0 (Cq, overlapped, 4C), 135.7 (Cq), 135.2 (Cq), 135.0 (Cq), 134.34 (Cq, overlapped, 2C), 
131.8 (CH), 131.7 (CH), 131.2 (CH), 130.8 (CH), 130.6 (CH), 130.3 (CH), 130.1 (CH), 
129.1 (CH), 128.6 (CH), 128.5 (CH), 127.7 (CH), 127.5 (CH) 127.0 (CH), 125.2 (Cq), 125.2 
(CH), 122.8 (Cq), 121.7 (Cq), 118.7 (CH), 118.1 (Cq), 117.1 (CH), 21.5 (CH3, overlapped, 
2C), 21.4 (CH3), 21.3 (CH3, overlapped, 2C) 21.2 (CH3). IR (ATR): 2919, 1606, 1541, 1508, 
1340, 907, 815, 730 cm−1. HR-MS (ESI) m/z calcd for C55H45N2 [M+H] 733.3577, 
found 733.3568. 
 





a][1,8]naphthyridine (183ac)  
The general procedure E was followed using 182a (7.5 mg, 0.05 mmol), 113c (49.6 mg, 
0.175 mmol) and [Cp*Rh(CH3CN)3](SbF6)2 (4.2 mg, 10 mol %) at 35 °C for 3 h. Purification 
by column chromatography on silica gel (n-hexane/EtOAc 50:1) yielded 183ac (38.2, 92%) 
as a red solid. M.p. = 177–178 °C. 1H NMR (400 MHz, CDCl3) δ = 7.45–7.39 (m, 3H), 7.22–
7.14 (m, 3H), 7.11–6.97 (m, 7H), 6.91–6.82 (m, 5H), 6.64 (d, J = 2.7 Hz, 1H), 6.60 (dd, J = 
8.7, 5.3 Hz, 4H), 6.52 (d, J = 8.8 Hz, 2H), 6.48–6.42 (m, 1H), 3.93 (s, 3H), 3.84 (s, 3H), 
3.82 (s, 3H), 3.73 (s, 3H), 3.71 (s, 3H), 3.65 (s, 3H). 13C NMR (100 MHz, CDCl3) δ = 159.2 
(Cq, overlapped, 2C), 158.3 (Cq, overlapped, 2C), 158.2 (Cq), 158.1 (Cq), 149.6 (Cq), 149.4 
(Cq), 138.1 (Cq), 137.9 (Cq), 137.0 (Cq), 135.9 (Cq), 135.8 (Cq), 133.6 (Cq), 133.0 (CH), 
132.8 (CH), 132.4 (CH), 131.6 (CH, overlapped, 2C), 131.4 (CH), 131.0 (Cq), 130.9 (CH), 
130.5 (Cq), 130.1 (CH), 129.7 (Cq), 129.4 (Cq), 124.5 (Cq), 122.1 (Cq), 121.3 (Cq), 121.0 
(Cq), 118.4 (CH), 116.9 (Cq), 116.8 (CH), 115.3 (CH), 113.9 (CH), 113.5 (CH), 112.5 (CH), 
112.3 (CH), 109.2 (CH), 55.3 (CH3, overlapped, 2C), 55.2 (CH3, overlapped, 2C), 55.1 
(CH3), 55.0 (CH3). IR (ATR): 2928, 1602, 1570, 1507, 1284, 1241, 1172, 1030, 826, 540 
cm−1. HR-MS (ESI) m/z calcd for C55H45N2O6 [M+H]+ 829.3272, found 829.3268. 
 





a][1,8]naphthyridine (183ad)  
The general procedure E was followed using 182a (30.0 mg, 0.20 mmol) and 113d 
(203.4 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183ad (88.6 mg, 45%) as a red solid. M.p. = 205–
206 °C. 1H NMR (400 MHz, CDCl3) δ = 7.58 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 
7.43 (t, J = 7.9 Hz, 1H), 7.30 (dd, J = 12.8, 4.1 Hz, 6H), 7.21–7.11(m, 2H), 7.10–7.00 (m, 
6H), 6.97–6.88 (m, 4H), 6.85 (dd, J = 8.7, 2.0 Hz, 1H), 6.47–6.45 (m, 2H), 1.48 (s, 9H), 
1.37 (s, 9H), 1.35 (s, 9H), 1.26 (s, 9H), 1.22 (s, 9H), 1.18 (s, 9H). 13C NMR (100 MHz, 
CDCl3) δ = 151.0 (Cq), 150.8 (Cq), 150.1 (Cq), 149.5 (Cq), 149.4 (Cq), 149.3 (Cq), 149.0 (Cq), 
148.9 (Cq), 138.0 (Cq), 137.9 (Cq), 137.5 (Cq), 136.0 (Cq), 135.9 (Cq), 135.8 (Cq), 135.2 (Cq), 
134.5 (Cq), 134.4 (Cq), 134.3 (Cq), 131.6 (CH), 131.4 (CH), 130.9 (CH), 130.7 (CH), 130.0 
(CH), 129.9 (Cq), 128.2 (CH), 126.7 (CH), 125.6 (Cq), 125.3 (Cq), 125.1 (CH), 124.4 (CH), 
123.7 (CH), 123.5 (CH), 123.1 (CH), 122.6 (Cq), 121.6 (CH), 121.5 (CH), 118.5 (CH), 117.8 
(Cq), 117.0 (CH), 34.8 (Cq), 34.6 (Cq), 34.5 (Cq, overlapped, 2C), 34.4 (Cq), 34.2 (Cq), 31.5 
(CH3), 31.4 (CH3, overlapped, 2C), 31.3 (CH3, overlapped, 2C), 31.0 (CH3). IR (ATR): 2959, 
2902, 1611, 1577, 1507, 1339, 1268, 1110, 1018, 823 cm−1. HR-MS (ESI) m/z calcd for 
C73H81N2 [M+H]+ 985.6394, found 985.6379.  
 






The general procedure E was followed using 182a (30.0 mg, 0.20 mmol) and 113e 
(225.0 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183ae (145.0 mg, 67%) as a red solid. M.p. = 219–
220 °C. 1H NMR (400 MHz, CDCl3) δ = 7.68 (d, J = 7.8 Hz, 2H), 7.51 (d, J = 7.5 Hz, 2H), 
7.42–7.38 (m, 5H), 7.31 (s, 1H), 7.23–7.15 (m, 5H), 7.09–7.01 (m, 6H), 6.94 (s, 2H), 6.87 
(d, J = 7.6 Hz, 1H), 6.40 (d, J = 8.1 Hz, 2H), 0.37 (s, 9H), 0.28 (s, 9H), 0.26 (s, 9H), 0.18 
(s, 9H), 0.14 (s, 9H), 0.10 (s, 9H). 13C NMR (100 MHz, CDCl3) δ = 150.1 (Cq), 149.6 (Cq), 
141.1 (Cq), 140.9 (Cq), 140.2 (Cq), 139.5 (Cq), 138.6 (Cq), 138.5 (Cq), 138.5 (Cq), 138.4 (Cq), 
138.2 (Cq), 137.8 (Cq), 137.6 (Cq), 137.6 (Cq), 137.5 (Cq), 135.9 (Cq), 135.6 (Cq), 134.9 
(CH), 133.5 (Cq), 133.4 (CH), 132.6 (CH), 132.0 (CH), 131.9 (CH), 131.4 (CH), 131.1 (CH), 
131.0 (CH), 130.8 (CH), 130.7 (CH), 130.2 (CH), 129.6 (CH), 129.6 (CH), 128.0 (Cq), 127.6 
(CH), 125.9 (Cq), 123.2 (Cq), 122.0 (Cq), 119.1 (CH), 119.0 (Cq), 117.7 (CH), -0.8 (CH3), -
0.9 (CH3), -0.9 (CH3), –1.0 (CH3), –1.1 (CH3), –1.3 (CH3). IR (ATR): 2954, 2203, 1548, 
1342, 1249, 1108, 840 cm–1. MS (ESI) m/z (relative intensity): 1081 (98) [M+H]+, 1082 (100) 
[M(13C,29Si)+H]+, 1010 (10). HR-MS (ESI) m/z calcd for C67H80N2Si6 [M+H]+ 1081.5010, 
found 1081.5017.  
 






The general procedure E was followed using 182a (30.0 mg, 0.20 mmol) and 113f 
(144.0 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 50:1) yielded 183af (104.0mg, 71%) as a red solid. M.p. = 153–
154 °C. 1H NMR (400 MHz, CDCl3) δ = 7.51–7.44 (m, 2H), 7.42–7.33 (m, 3H), 7.29–7.19 
(m, 3H), 7.11–7.03 (m, 7H), 7.00–6.91 (m, 6H), 6.88–6.82 (m, 3H), 6.47 (s, 2H), 2.47 (s, 
3H), 2.35 (s, 3H), 2.34 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 2.00 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 150.1 (Cq), 149.6 (Cq), 140.7 (Cq), 139.5 (Cq), 139.1 (Cq), 138.1 (Cq), 137.8 (Cq), 
137.7 (Cq), 137.3 (Cq), 137.3 (Cq), 137.0 (Cq) 136.7 (Cq), 136.4 (Cq, overlapped, 2C), 135.8 
(Cq), 135.5 (Cq), 135.3 (Cq), 132.6 (CH), 132.4 (Cq, overlapped, 2C), 132.2 (CH), 131.9 
(CH), 131.5 (CH), 130.9 (CH), 130.8 (CH), 129.7 (CH), 129.3 (CH), 129.3 (CH), 129.0 (CH), 
128.9 (CH), 128.6 (CH), 128.5 (CH), 128.3 (CH), 128.3 (CH), 127.7 (CH), 127.7 (CH), 
127.5 (CH), 127.4 (CH), 127.4 (CH), 127.2 (CH), 127.0 (CH), 126.7 (CH), 125.7 (Cq), 125.0 
(CH), 123.3 (Cq), 122.0 (Cq, overlapped, 2C), 118.9 (CH), 117.5 (CH), 21.6 (CH3), 21.5 
(CH3), 21.5 (CH3), 21.4 (CH3), 21.3 (CH3), 21.3 (CH3).. IR (ATR): 3023, 2914, 2091, 1997, 
1606, 1538, 1337, 1289, 703 cm–1. MS (ESI) m/z (relative intensity): 733 (100) [M+H]+, 765 
(10) [M+Na]+. HR-MS (ESI) m/z calcd for C55H45N2O+ [M+H]+ 733.3577, found 733.3578. 
 






The general procedure was G followed using 182a (30.0 mg, 0.20 mmol) and 113g 
(101.0 mg, 0.7 mmol) at 35 °C for 12 h. Purification by column chromatography on silica 
gel (n-hexane/EtOAc 100 : 1) yielded two regioisomers 183ag (55.5 mg ) and 183ag’ (20.5 
mg) (76.0 mg, 70%, 183ag: 183ag’ = 2.7 : 1). Characterization data for 183ga: red solid. 
M.p. = 175–176 °C. 1H NMR (400 MHz, CDCl3) δ = 7.70 (t, J = 8.0 Hz, 2H), 7.54 (dd, J = 
8.0, 1.1 Hz, 1H), 7.47–7.41 (m, 2H), 7.37–7.31 (m, 2H), 7.28–7.10 (m, 8H), 6.77–6.72 (m, 
2H), 3.08–2.96 (m, 2H), 2.67–2.55 (m, 4H), 1.96–1.84 (m, 2H), 1.56–1.43 (m, 4H), 1.18 (t, 
J = 7.3 Hz, 3H), 0.73 (t, J = 7.4 Hz, 3H), 0.69 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ = 150.8 (Cq), 147.7 (Cq), 141.5 (Cq), 137.9 (Cq), 137.6 (Cq), 137.4 (Cq), 136.4 (Cq), 134.5 
(Cq), 134.2 (Cq), 130.8 (CH), 129.6 (CH, overlapped, 2C), 128.8 (Cq), 128.7 (CH), 127.7 
(CH), 127.3 (CH, overlapped, 2C), 127.1 (CH), 126.9 (CH), 126.1 (CH), 123.2 (CH), 122.5 
(Cq), 121.0 (Cq), 120.9 (Cq), 117.5 (CH), 116.7 (Cq), 115.3 (CH), 30.9 (CH2), 30.4 (CH2), 
29.8 (CH2), 22.8 (CH2, overlapped, 2C), 21.2 (CH2), 14.5 (CH3), 14.1 (CH3), 13.9 (CH3). IR 
(ATR): 3065, 2957, 2866, 1611, 1547, 1334, 1281, 757 cm–1. MS (ESI) m/z (relative 
intensity): 547 (100) [M+H]+, 579 (40) [M+Na]+. HR-MS (ESI) m/z calcd for C40H39N2 [M+H]+ 
547.3108, found 547.3108. 
 






Characterization data for 183ag’: 1H NMR (400 MHz, CDCl3) δ = 7.74 (t, J = 7.9 Hz, 1H), 
7.65 (d, J = 7.5 Hz, 1H), 7.54 (d, J = 8.3 Hz, 1H), 7.49–7.37 (m, 6H), 7.41–7.30 (m, 5H), 
7.27–7.15 (m, 2H), 6.75 (dd, J = 7.6, 1.4 Hz, 1H), 3.19–3.01 (m, 2H), 3.03–2.98 (m, 2H), 
2.85–2.79 (m, 2H), 1.94–1.81 (m, 2H), 1.65 (dq, J = 14.9, 7.3 Hz, 2H), 1.17 (t, J = 7.3 Hz, 
3H), 0.87 (t, J = 7.3 Hz, 3H), 0.73 (p, J = 7.4 Hz, 2H), 0.45 (t, J = 7.3 Hz, 3H). 13C NMR 
(100 MHz, CDCl3) δ = 151.0 (Cq), 148.0 (Cq), 142.1 (Cq), 139.6 (Cq), 138.8 (Cq), 137.5 (Cq), 
136.5 (Cq), 135.5 (Cq), 133.9 (Cq), 131.5 (CH), 131.1 (CH), 129.4 (CH), 128.6 (CH), 128.6 
(CH), 128.1 (CH), 127.5 (Cq), 127.4 (CH), 127.2 (CH), 126.7 (CH), 125.5 (CH), 124.9 (CH), 
123.4 (Cq), 122.1 (Cq), 122.1 (Cq), 117.6 (CH), 117.6 (Cq), 115.7 (CH), 31.0 (CH2), 30.7 
(CH2), 30.7 (CH2), 23.1 (CH2), 21.3 (CH2), 20.0 (CH2), 14.5 (CH3), 14.3 (CH3), 13.5 (CH3). 
IR (ATR): 3063, 2959, 2870, 1614, 1549, 1340, 1257, 767 cm–1. MS (ESI) m/z (relative 
intensity): 547 (100) [M+H]+, 579 (20) [M+Na]+. HR-MS (ESI) m/z calcd for C40H39N2 [M+H]+ 
547.3108, found 547.3110. 
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5.5.2 Mechanistic Studies  
 
The electrocatalysis was carried out in an undivided cell with a graphite felt anode (10 mm 
× 15 mm × 6 mm) and a Pt cathode (10 mm × 15 mm × 0.25 mm). The cell was charged 
with imidate 182a (0.20 mmol), alkyne 113a (0.7 mmol), KOAc (39.3 mg, 0.4 mmol), AdOH 
(3.6 mg, 10 mol %), 202 (4.5 mg, 5.0 mol %) and MeOH (4.0 mL). Electrocatalysis was 
performed at 35 °C with a constant current of 2.0 mA maintained for 12 h. The graphite felt 
anode was washed with CH2Cl2 (8 × 5.0 mL) in an ultrasonic bath. Evaporation of the 
solvents and subsequent column chromatography on silica gel (n-hexane/EtOAc 50:1) 
afforded the corresponding product 183aa (112.0 mg, 86%). 
 
 
The electrocatalysis was carried out in an undivided cell with a graphite felt anode (10 mm 
× 15 mm × 6 mm) and a Pt cathode (10 mm × 15 mm × 0.25 mm). The cell was charged 
with imidate 182a (0.20 mmol), alkyne 113a (0.70 mmol), KOAc (39.3 mg, 0.40 mmol), 
5 Experimental Section 
173 
 
AdCO2H (3.6 mg, 10 mol %), 203 (6.2 mg, 5.0 mol %) and MeOH (4.0 mL). Electrocatalysis 
was performed at 35 °C with a constant current of 2.0 mA maintained for 12 h. The graphite 
felt anode was washed with CH2Cl2 (8 × 5.0 mL) in an ultrasonic bath. Evaporation of the 
solvents and subsequent column chromatography on silica gel (n-hexane/EtOAc 50:1) 
afforded the corresponding product 183ab (75.2 mg, 51%). 
5.5.3 Derivatiztion of 183aa and 183aj 
 
1-methyl–2,3,7,12,13-pentaphenylbenzo[de]isoquinolino[2,1-a][1,8]naphthyridin-1-
ium iodide (204) 
To a 25 mL Schlenk tube was added 183aa (65.2 mg, 0.10 mmol), MeI (85 mg, 0.6 mmol, 
20 µL) and 1.0 mL DCE. The reaction was stirred at 80 oC for 6 hours. Then the solvent 
was removed and purification of the residue by column chromatography (DCM/MeOH, 50:1) 
yielded the product 204 (73.4 mg, 93%) as a red solid. M.p. = 229–230 °C. 1H NMR (400 
MHz, CDCl3) δ = 7.93 (t, J = 8.0 Hz, 1H), 7.81 (d, J = 7.7 Hz, 1H), 7.74 (t, J = 7.2 Hz, 1H), 
7.61 (t, J = 7.4 Hz, 1H), 7.54–7.50 (m, 3H), 7.45–7.35 (m, 7H), 7.32–7.27 (m, 3H), 7.26–
6.98 (m, 13H), 6.55 (d, J = 7.6 Hz, 1H), 5.51 (d, J = 7.7 Hz, 1H), 3.63 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ = 151.9 (Cq), 144.3 (Cq), 136.0 (CH), 135.8 (Cq), 135.5 (Cq), 135.4 (Cq, 
overlapped, 2C), 135.1 (Cq), 135.0 (Cq), 134.6 (Cq), 134.1 (Cq), 133.6 (Cq), 132.5 (Cq), 
132.0 (CH), 131.7 (Cq), 131.7 (Cq), 131.6 (CH), 130.9 (CH), 130.7 (CH), 130.4 (CH), 130.3 
(CH), 130.0 (CH), 129.7 (CH), 129.5 (CH), 129.1 (CH), 129.0 (CH), 128.8 (CH), 128.7 (CH), 
128.4 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 127.6 (Cq), 126.8 (CH), 125.4 
(Cq), 123.6 (CH), 122.6 (CH), 122.6 (Cq), 46.9 (CH3). IR (ATR): 3031, 3004, 1619, 1549, 
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1439, 1328, 1246, 758, 697 cm–1. HR-MS (ESI) m/z calcd for C50H34N2 [M-I]+: 663.2795, 
found: 663.2799. 
 
5.6 Rhodaelectro-catalyzed switchable Indole dienylation/ 
cyclopropylation 
5.6.1 Experimental procedure and analytical data 
 
(Z)-2-(1-Phenylbuta-1,3-dien–2-yl)-1-(pyrimidin-2-yl)-1H-indole (184aa) 
The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.6 mg, 0.32 mmol) for 3.0 h. 
Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184aa (57.6 mg, 89%, 
Z/E = 7.0/1 determined by 1H NMR) as a yellow solid. M.p. = 137–139 °C. 1H NMR (400 
MHz, CDCl3): δ = 8.71 (d, J = 4.8 Hz, 0.29H, E isomer), 8.62 (d, J = 4.8 Hz, 2H, Z isomer), 
8.33 (d, J = 8.3 Hz, 1H), 7.60 (dd, J = 7.8, 1.2 Hz, 1H), 7.32 (td, J = 7.7, 1.2 Hz, 1H), 7.24 
(t, J = 6.6 Hz, 1H), 7.08–7.06 (m, 3H), 7.03–6.99 (m, 3H), 6.69 (dd, J = 17.4, 10.6 Hz, 1H), 
6.68 (s, 1H), 6.57 (s, 1H), 5.06 (d, J = 10.6 Hz, 1H), 5.02 (d, J = 17.4 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ = 157.9 (CH), 157.5 (Cq), 140.6 (CH), 136.7 (Cq), 136.7 (Cq), 135.4 
(Cq), 134.0 (Cq), 133.0 (CH), 129.5 (Cq), 129.1 (CH), 128.1 (CH), 127.2 (CH), 123.4 (CH), 
122.0 (CH), 120.8 (CH), 117.0 (CH), 115.7 (CH), 114.2 (CH), 108.7 (CH2). IR (ATR): 3000, 
2201, 1564, 1437, 1419, 1360, 1256, 1075, 812, 769 cm−1. MS (ESI) m/z (relative intensity): 









The general procedure F was followed using 3-methyl-1-(pyrimidin-2-yl)-1H-indole 71b 
(41.9 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.6 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ba (46.5 
mg, 69%, Z/E = 9.6/1 determined by 1H NMR) as a yellow solid. M.p. = 102–104 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.69 (d, J = 4.8 Hz, 0.18H, E isomer), 8.65 (d, J = 4.7 Hz, 
2H, Z isomer), 8.44 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.39–7.24 (m, 3H), 7.17– 
7.10 (m, 4H), 7.01 (t, J = 4.8 Hz, 1H), 6.81 (s, 1H), 6.65 (ddd, J = 17.2, 10.4, 0.7 Hz, 1H), 
4.97 (d, J = 10.5 Hz, 1H), 4.81 (d, J = 17.2 Hz, 1H), 2.00 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 157.9 (CH), 157.8 (Cq), 140.3 (CH), 137.2 (Cq), 136.5 (Cq), 133.6 (Cq), 133.5 
(CH), 132.0 (Cq), 130.7 (Cq), 128.8 (CH), 128.2 (CH), 127.2 (CH), 123.6 (CH), 121.6 (CH), 
119.0 (CH), 116.6 (CH), 115.2 (CH2), 114.9 (Cq), 114.4 (CH), 9.0 (CH3). IR (ATR): 3048, 
2920, 1565, 1425, 1354, 1223, 1017, 988, 801, 748, 697 cm−1. MS (ESI) m/z (relative 
intensity): 360 (68) [M+Na]+, 338 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H20N3 [M+H]
+ 




The general procedure F was followed using 4-methoyl-1-(pyrimidin-2-yl)-1H-indole 71c 
(45.1 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.6 mg, 0.32 mmol) 
for 2.8 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ca (67.1 
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mg, 95%, Z/E = 3.3/1 determined by 1H NMR) as a yellow solid. M.p. = 98–99 °C. 1H NMR 
(400 MHz, CDCl3) δ = 8.72 (d, J = 4.8 Hz, 0.6H, E isomer), 8.61 (d, J = 4.8 Hz, 2H, Z 
isomer), 7.90 (d, J = 8.5 Hz, 1H), 7.25 (t, J = 8.1 Hz, 1H), 7.09–7.05 (m, 3H), 7.02–6.98(m, 
3H), 6.73 (s, 1H), 6.71 (dd, J = 16.5, 10.2 Hz, 1H), 6.70 (d, J = 7.9 Hz, 1H), 6.66 (s, 1H), 
5.09 (d, J = 16.5 Hz, 1H), 5.09 (d, J = 10.6 Hz, 1H), 3.98 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ = 157.8 (CH), 157.5 (Cq), 153.1 (Cq), 140.6 (CH), 138.0 (Cq), 136.7 (Cq), 133.9 
(Cq), 133.8 (Cq), 133.0 (CH), 129.1 (CH), 128.0 (CH), 127.1 (CH), 124.2 (CH), 120.0 (Cq), 
117.1 (CH), 115.8 (CH2), 107.4 (CH), 105.7 (CH), 102.1 (CH), 55.5 (CH3). IR (ATR): 3026, 
2918, 1693, 1564, 1420, 1336, 1240, 1149, 910, 805, 740, 698 cm−1. MS (ESI) m/z (relative 
intensity): 376 (100) [M+Na]+, 354 (50) [M+H]+. HR-MS (ESI) m/z calcd for C23H20N3O 
[M+H]+
 




The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole-4-carbonitrile 
71d (44.1 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.6 mg, 0.32 
mmol) for 5.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 
184da (41.8 mg, 60%, Z/E = 2.0/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 
MHz, CDCl3) δ = 8.76 (d, J = 4.8 Hz, 1H, E isomer), 8.65 (d, J = 4.8 Hz, 2H, Z isomer), 
8.49 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.45–7.43 (m, 1H), 7.35 (dd, J = 8.5, 7.4 
Hz, 1H), 7.11 (t, J = 4.8 Hz, 1H), 7.09–7.04 (m, 3H), 6.94–6.92 (m, 1H), 6.82 (s, 1H), 6.73 
(s, 1H), 6.71 (dd, J = 17.2, 10.6 Hz, 1H), 5.13 (d, J = 10.6 Hz, 1H), 5.02 (d, J = 17.2 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ = 158.0 (CH), 156.7 (Cq), 139.8 (CH), 138.4 (Cq), 136.7 
(Cq), 136.1 (Cq), 133.9 (CH), 132.7 (Cq), 130.8 (Cq), 128.8 (CH), 128.1 (CH), 127.5 (CH), 
126.8 (CH), 122.9 (CH), 118.7 (CH), 118.4 (Cq), 117.9 (CH), 115.9 (CH2), 106.6 (CH), 
103.1 (Cq). IR (ATR): 3050, 2221, 1693, 1567, 1425, 1318, 1263, 1234, 1078, 913, 813, 
5 Experimental Section 
177 
 
786, 739, 698 cm−1. MS (ESI) m/z (relative intensity): 371 (40) [M+Na]+, 349 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C23H17N4 [M+H]




The general procedure F was followed using 5-methyl-1-(pyrimidin-2-yl)-1H-indole 71e 
(45.1 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ea (50.6 
mg, 75%, Z/E = 8.6/1 determined by 1H NMR) as a yellow oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.70 (d, J = 4.8 Hz, 0.23H, E isomer), 8.61 (d, J = 4.8 Hz, 1.97H, Z isomer), 8.25 (d, J 
= 8.6 Hz, 1H), 7.40 (s, 1H), 7.15 (d, J = 8.2 Hz, 1H), 7.10–6.98 (m, 6H), 6.72 (d, J = 17.6, 
10.6 Hz, 1H), 6.68 (s, 1H), 6.50 (s, 1H), 5.06 (d, J = 10.6 Hz, 1H), 5.01 (d, J = 17.6 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ = 157.8 (CH), 157.5 (Cq), 140.7 (CH), 136.8 (Cq), 135.4 (Cq), 
135.0 (Cq), 134.3 (Cq), 132.8 (CH), 131.4 (CH), 129.8 (Cq), 129.1 (CH), 128.1 (CH), 127.2 
(CH), 124.9 (CH), 120.6 (CH), 116.8 (CH), 115.6 (CH2), 114.1 (CH), 108.5 (CH), 21.5 (CH3). 
IR (ATR): 2919, 2860, 1565, 1423, 1217, 1080, 987, 806, 751, 699 cm−1. MS (ESI) m/z 
(relative intensity): 360 (100) [M+Na]+, 338 (80) [M+H]+. HR-MS (ESI) m/z calcd for 
C23H19N3Na [M+Na]




The general procedure F was followed using 5-fluoro-1-(pyrimidin-2-yl)-1H-indole 71f (42.6 
mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) for 3.5 
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h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184fa (48.5 mg, 
71%, Z/E = 5.0/1 determined by 1H NMR) as a yellow solid. M.p. = 104–106 °C. 1H NMR 
(400 MHz, CDCl3) δ = 8.67 (d, J = 4.8 Hz, 0.40H, E isomer), 8.58 (d, J = 4.8 Hz, 2H, Z 
isomer), 8.25 (dd, J = 9.1, 4.7 Hz, 1H), 7.20 (dd, J = 9.0, 2.6 Hz, 1H), 7.07–7.02 (m, 3H), 
7.01–6.94 (m, 4H), 6.67 (dd, J = 17.6, 10.5 Hz, 1H), 6.65 (s, 1H), 6.48 (s, 1H), 5.03 (d, J = 
10.5 Hz, 1H), 4.95 (d, J = 17.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 158.76 (d, J = 
297.2 Hz, Cq), 157.9 (CH), 157.89 (d, J = 2.7 Hz, Cq), 140.4 (CH), 137.1 (Cq), 136.6 (Cq), 
133.9 (Cq), 133.1 (CH), 132.9 (Cq), 130.16 (d, J = 10.0 Hz, Cq),129.1 (CH), 128.1 (CH), 
127.3 (CH), 117.6 (d, J = 23.3 Hz), 117.2 (CH), 115.7 (CH2), 115.3 (d, J = 9.1 Hz, CH), 
111.3 (d, J = 25.3 Hz, CH), 108.4 (d, J = 4.1 Hz, CH), 105.8 (d, J = 23.5 Hz, CH). 19F NMR 
(377 MHz, CDCl3) δ = –122.3 (td, J = 9.1, 4.6 Hz). IR (ATR): 3053, 2130, 1961, 1710, 1568, 
1427, 1419, 1196, 804, 698 cm−1. MS (ESI) m/z (relative intensity): 364 (95) [M+Na]+, 342 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C22H17N3F [M+H]




The general procedure F was followed using 5-chloro-1-(pyrimidin-2-yl)-1H-indole 71g 
(45.9 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ga (40.8 
mg, 57%, Z/E = 3.6/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
δ = 8.72 (d, J = 4.8 Hz, 0.55H, E isomer), 8.63 (d, J = 4.8 Hz, 2H, Z isomer), 8.28 (d, J = 
8.9 Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.28 (dd, J = 8.7, 2.3 Hz, 1H), 7.15–7.04 (m, 3H), 
7.05 (t, J = 4.8 Hz, 1H), 7.00 (dd, J = 6.7, 3.0 Hz, 2H), 6.71 (s, 1H), 6.70 (dd, J = 17.2, 10.2 
Hz, 1H), 6.52 (s, 1H), 5.09 (d, J = 10.2 Hz, 1H), 5.00 (d, J = 17.2 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ = 158.0 (CH), 157.2 (Cq), 141.8 (Cq), 140.3 (CH), 136.9 (Cq), 136.5 (Cq), 
135.0 (Cq), 133.7 (Cq), 133.3 (CH), 130.6 (Cq), 129.0 (CH), 128.1 (CH), 127.3 (CH), 123.5 
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(CH), 120.1 (CH), 117.3 (CH), 115.7 (CH2), 115.5 (CH), 108.0 (CH). MS (ESI) m/z (relative 
intensity): 380 (40) (35Cl) [M+Na]+, 358 (100) (35Cl) [M+H]+. HR-MS (ESI) m/z calcd for 
C22H17N335Cl [M+H]




The general procedure F was followed using 5-bromo-1-(pyrimidin-2-yl)-1H-indole 71h 
(54.8 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ha (54.7 
mg, 68%, Z/E = 6.9/1 determined by 1H NMR) as a yellow oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.72 (d, J = 4.8 Hz, 0.29H, E isomer), 8.63 (d, J = 4.8 Hz, 2H, Z isomer), 8.23 (d, J = 
8.9 Hz, 1H), 7.73 (d, J = 2.0 Hz, 1H), 7.40 (dd, J = 8.9, 2.0 Hz, 1H), 7.12–7.07 (m, 3H), 
7.05 (t, J = 4.8 Hz, 1H), 7.00–6.97 (m, 2H), 6.71 (dd, J = 17.3, 10.5 Hz, 1H), 6.70 (s, 1H), 
6.51 (s, 1H), 5.08 (d, J = 10.5 Hz, 1H), 4.99 (d, J = 17.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) 
δ = 158.0, 157.2 (Cq), 140.3 (CH), 136.7 (Cq), 136.5 (Cq), 135.3 (Cq), 133.6 (Cq), 133.3 
(CH), 131.2 (Cq), 129.0 (CH), 128.1 (CH), 127.4 (CH), 126.1 (CH), 123.2 (CH), 117.4 (CH), 
115.9 (CH), 115.7 (CH2), 115.2 (Cq), 107.8 (CH). IR (ATR): 3049, 2964, 2927, 1692, 1561, 
1414, 1313, 1264, 1233, 1171, 1076, 1035, 989, 912, 808, 736, 696 cm−1. MS (ESI) m/z 
(relative intensity): 424 (40) (79Br) [M+Na]+, 402 (100) (79Br) [M+H]+. HR-MS (ESI) m/z 
calcd for C22H17N379Br [M+H]
+ 402.0600, found 402.0594. 
  





The general procedure F was followed using 5-methoxyl-1-(pyrimidin-2-yl)-1H-indole 71i 
(45.1 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 2.8 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ia (59.4 
mg, 84%, Z/E = 5.7/1 determined by 1H NMR) as a yellow oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.70 (d, J = 4.8 Hz, 0.36H, E isomer), 8.62 (d, J = 4.8 Hz, 2H, Z isomer), 8.32 (d, J = 
9.1 Hz, 1H), 7.12–7.03 (m, 6H), 7.01–6.96 (m, 2H), 6.73 (d, J = 17.4, 10.5 Hz, 1H), 6.70 
(s, 1H), 6.51 (s, 1H), 5.08 (d, J = 10.5 Hz, 1H), 5.03 (d, J = 17.4 Hz, 1H), 3.91 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ = 157.8 (CH), 157.4 (Cq), 155.5 (Cq), 140.6 (CH), 136.8 (Cq), 
136.0 (Cq), 134.3 (Cq), 132.8 (CH), 131.6 (Cq), 130.3 (Cq), 129.1 (CH), 128.1 (CH), 127.2 
(CH), 116.8 (CH), 115.6 (CH2), 115.4 (CH), 112.8 (CH), 108.6 (CH), 102.7 (CH), 55.8 (CH3). 
IR (ATR): 3044, 2950, 2249, 1717, 1565, 1421, 1280, 1202, 1106, 908, 804, 728 cm−1. 
MS (ESI) m/z (relative intensity): 376 (80) [M+Na]+, 354 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H20N3O [M+H]




The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole–5-carbonitrile 71j 
(44.0 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 5.0 h. Isolation by column chromatography (n-hexane/EtOAc 5:1) yielded 184ja (46.0 
mg, 66%, Z/E = 3.2/1 determined by 1H NMR) as a yellow solid. 1H NMR (300 MHz, CDCl3) 
δ = 8.76 (d, J = 4.8 Hz, 0.63H, E isomer), 8.67 (d, J = 4.8 Hz, 2H, Z isomer), 8.34 (d, J = 
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8.7 Hz, 1H), 7.95 (s, 1H), 7.55 (dd, J = 8.7, 1.7 Hz, 1H), 7.43 (s, 1H), 7.13 (t, J = 4.8 Hz, 
1H), 7.11–7.06 (m, 2H), 6.96 (dd, J = 7.6, 2.2 Hz, 2H), 6.73 (s, 1H), 6.69 (dd, J = 16.9, 10.0 
Hz, 1H), 6.63 (s, 1H), 5.09 (d, J = 10.0 Hz, 1H), 4.97 (d, J = 16.9 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ = 158.2 (CH), 156.8 (Cq), 140.0 (CH), 138.2 (Cq), 138.1 (Cq), 136.3 (Cq), 
133.9 (CH), 132.9 (Cq), 129.2 (Cq), 129.0 (CH), 128.2 (CH), 127.6 (CH) , 126.3 (CH), 125.9 
(CH), 120.4 (Cq), 118.1 (CH), 115.9 (CH2), 115.0 (CH), 108.3 (CH), 105.2 (Cq). IR (ATR): 
3050, 2921, 2221, 1608, 1565, 1415, 1316, 1217, 1030, 986, 886, 809, 735, 698 cm−1. 
MS (ESI) m/z (relative intensity): 371 (100) [M+Na]+, 349 (90) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H17N4 [M+H]




The general procedure F was followed using 6-fluoro-1-(pyrimidin-2-yl)-1H-indole 71k 
(42.6 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene138a (41.9 mg, 0.32 mmol) 
for 5.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ka (42.3 
mg, 62%, Z/E = 2.7/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
δ = 8.73 (d, J = 4.8 Hz, 0.75H, E isomer), 8.64 (d, J = 4.8 Hz, 2H, Z isomer), 8.12 (dd, J = 
10.8, 2.4 Hz, 1H), 7.51 (dd, J = 8.6, 5.5 Hz, 1H), 7.44–7.37 (m, 1H), 7.12–7.07 (m, 3H), 
7.05–6.99 (m, 4H), 6.73 (dd, J = 17.6, 10.8 Hz, 1H), 6.69 (s, 1H), 6.54 (s, 1H), 5.08 (d, J = 
10.8 Hz, 1H), 5.02 (d, J = 17.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 160.6 (d, J = 238.2 
Hz, Cq), 157.9 (CH), 157.3 (Cq), 140.5 (CH), 137.2 (Cq), 136.7 (Cq), 135.8 (d, J = 4.2 Hz, 
Cq), 133.9 (Cq), 133.0 (CH), 129.1 (CH), 128.1 (CH), 127.2 (CH), 125.9 (Cq), 121.3 (d, J = 
10.0 Hz, CH), 117.2 (CH), 115.7 (CH2), 110.5 (d, J = 24.8 Hz, CH), 108.5 (CH), 101.6 (d, 
J = 28.5 Hz, CH). 19F NMR (377 MHz, CDCl3) δ = -118.88 – -118.98 (m). IR (ATR): 3050, 
2925, 2854, 1724, 1566, 1418, 1423, 1261, 1149, 1077, 986, 852, 808, 738, 697 cm−1.   
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MS (ESI) m/z (relative intensity): 364 (20) [M+Na]+, 342 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C22H17N3F [M+H]




The general procedure F was followed using 6-chloro-1-(pyrimidin-2-yl)-1H-indole 71l 
(45.9 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 4.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184la (43.7 
mg, 61%, Z/E = 2.2/1 determined by 1H NMR) as a yellow oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.74 (d, J = 4.8 Hz, 0.91H, E isomer), 8.65 (d, J = 4.8 Hz, 2H, Z isomer), 8.39 (s, 1H), 
7.51 (d, J = 8.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 1H), 7.23 (dd, J = 8.3, 1.9 Hz, 1H), 7.12–7.07 
(m, 3H), 7.06 (d, J = 4.8 Hz, 1H), 7.01–6.98 (m, 1H), 6.69 (s, 1H), 6.69 (dd, J = 17.1, 10.4 
Hz, 1H), 6.53 (s, 1H), 5.07 (d, J = 10.4 Hz, 1H), 4.99 (d, J = 17.1 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ = 158.0 (CH), 157.2 (Cq), 140.4 (CH), 136.9 (Cq), 136.6 (Cq), 136.2 (Cq), 
133.7 (Cq), 133.2 (CH), 129.3 (Cq), 129.1 (CH), 128.1 (CH), 128.0 (Cq), 127.3 (CH), 122.6 
(CH), 121.5 (CH), 117.4 (CH), 115.7 (CH2), 114.5 (CH), 108.4 (CH). IR (ATR): 3051, 1709, 
1567, 1426, 1352, 1315, 1264, 1218, 908, 811, 748 cm−1. MS (ESI) m/z (relative intensity): 
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The general procedure F was followed using 6-methoxyl-1-(pyrimidin-2-yl)-1H-indole 71m 
(45.1 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 10:1) yielded 184ma (43.1 
mg, 61%, Z/E = 3.6/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
δ = 8.72 (d, J = 4.8 Hz, 0.56H, E isomer), 8.63 (d, J = 4.8 Hz, 2H, Z isomer), 7.96 (d, J = 
2.3 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.12–7.06 (m, 5H), 7.02 (t, J = 4.8 Hz, 1H), 6.92 (dd, 
J = 8.5, 2.3 Hz, 1H), 6.71 (d, J = 10.5, 17.3 Hz, 1H), 6.66 (s, 1H), 6.49 (s, 1H), 5.05 (d, J = 
10.5 Hz, 1H), 5.02 (d, J = 17.3 Hz, 1H), 3.92 (s, 3H). 13C NMR (126 MHz, CDCl3) δ = 157.9 
(CH), 157.6 (Cq), 157.3 (Cq), 140.8 (CH), 137.6 (Cq), 136.9 (Cq), 134.3 (Cq), 134.2 (Cq), 
132.6 (CH), 129.2 (CH), 128.1 (CH), 127.1 (CH), 123.7 (Cq), 121.2 (CH), 116.9 (CH), 115.6 
(CH2), 111.3 (CH), 108.6 (CH), 98.7 (CH), 55.9 (CH3). IR (ATR): 2924, 2855, 2245, 2200, 
1948, 1612, 1565, 1484, 1418, 1265, 1159, 1030, 906, 808, 728 cm−1. MS (ESI) m/z 
(relative intensity): 376 (80) [M+Na]+, 354 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C23H20N3O [M+H]
+ 354.1606, found 354.1590. 
 
 
Methyl (Z)-2-(1-phenylbuta-1,3-dien–2-yl)-1-(pyrimidin-2-yl)-1H-indole-6-carboxy late 
(184na) 
The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole-6-carboxylate 
71n (50.7 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 
mmol) for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 5:1) yielded 184na 
(59.5 mg, 78%, Z/E = 3.8/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, 
CDCl3) δ = 9.00 (s, 1H), 8.77 (d, J = 4.8 Hz, 0.53H, E isomer), 8.68 (d, J = 4.8 Hz, 2H, Z 
isomer), 7.96 (d, J = 8.3 Hz, 1H), 7.63 (d, J = 8.3 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.11–
7.06 (m, 3H), 7.03–6.98 (m, 2H), 6.72 (s, 1H), 6.70 (dd, J = 17.2, 10.5 Hz, 1H), 6.61 (s, 
1H), 5.08 (d, J = 10.5 Hz, 1H), 5.00 (d, J = 17.2 Hz, 1H), 3.97 (s, 3H). 13C NMR (101 MHz, 
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CDCl3) δ = 168.2 (Cq), 158.1 (CH), 157.1 (Cq), 140.1 (CH), 138.8 (Cq), 136.4 (Cq), 136.0 
(Cq), 133.6 (CH), 133.4 (Cq), 133.1 (Cq), 129.0 (CH), 128.2 (CH), 127.4 (CH), 125.1 (Cq), 
123.1 (CH), 120.4 (CH), 117.6 (CH), 116.3 (CH), 115.8 (CH2), 108.4 (CH), 52.1 (CH3). 
IR (ATR): 3052, 2950, 2844, 1709, 1566, 1421, 1361, 1276, 1217, 1092, 990, 907, 804, 
732, 696 cm−1. MS (ESI) m/z (relative intensity): 404 (75) [M+Na]+, 382 (100) [M+H]+.   
HR-MS (ESI) m/z calcd for C24H20N3O2 [M+H]




The general procedure F was followed using 7-methyl-1-(pyrimidin-2-yl)-1H-indole 71o 
(41.6 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184na (41.2 
mg, 61%, Z/E = 3.6/1 determined by 1H NMR) as a yellow oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.78 (d, J = 4.8 Hz, 0.55H, E isomer), 8.64 (d, J = 4.8 Hz, 2H, Z isomer), 7.55 (d, J = 
7.8 Hz, 1H), 7.39–7.35 (m, 1H), 7.19 (d, J = 7.8 Hz, 1H), 7.15–7.11 (m, 5H), 7.10 (t, J = 
4.8 Hz, 1H), 6.69 (s, 1H), 6.59 (d, J = 1.6 Hz, 1H), 6.58 (dd, J = 17.0, 10.6 Hz, 1H), 5.07 
(d, J = 10.6 Hz, 1H), 5.00 (dd, J = 17.0, 1.5 Hz, 1H), 2.14 (s, 3H). 13C NMR (75 MHz, CDCl3) 
δ = 158.1 (Cq), 157.6 (CH), 140.2 (CH), 136.4 (Cq), 136.2 (Cq), 136.2 (Cq), 135.1 (CH), 
132.7 (Cq), 129.9 (Cq), 129.3 (CH), 128.1 (CH), 127.5 (CH), 125.9 (CH), 122.7 (Cq), 121.5 
(CH), 118.8 (CH), 118.5 (CH), 116.5 (CH2), 106.6 (CH), 20.7 (CH3). IR (ATR): 3051, 1691, 
1567, 1422, 1309, 1208, 1058, 913, 868, 802, 733, 697 cm−1. MS (ESI) m/z (relative 
intensity): 360 (25) [M+Na]+, 338 (80) [M+H]+. HR-MS (ESI) m/z calcd for C23H20N3 [M+H]
+ 
338.1652, found 338.1647. 
 






The general procedure F was followed using 1-(pyrimidin-2-yl)-1,5,6,7-tetrahydro-4H-
indol-4-one 71p (42.4 mg, 0.20 mmol) and (cyclopropylidenemethyl)benzene 138a (41.9 
mg, 0.32 mmol) for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 3:1) 
yielded (Z)-184pa (38.7 mg, 57%) as a yellow solid and (E)-184pa (19.2 mg, 28%) as a 
yellow solid. (Z)-184pa: M.p. = 148–150 °C. 1H NMR (400 MHz, CDCl3) δ = 8.54 (d, J = 
4.8 Hz, 2H), 7.13–7.05 (m, 4H), 6.88–6.82 (m, 2H), 6.64 (s, 1H), 6.60 (dd, J = 17.2, 10.5 
Hz, 1H), 6.49 (s, 1H), 5.24 (d, J = 17.2 Hz, 1H), 5.14 (d, J = 10.5 Hz, 1H), 3.02 (t, J = 6.0 
Hz, 2H), 2.60 (t, J = 6.4 Hz, 2H), 2.18 (tt, J = 6.0, 6.4 Hz, 2H). 13C NMR (101 MHz, CDCl3) 
δ = 195.2 (Cq), 157.9 (CH), 156.2 (Cq), 145.6 (Cq), 140.1 (CH), 136.4 (Cq), 133.4 (CH), 
132.3 (Cq), 130.1 (Cq), 128.8 (CH), 128.1 (CH), 127.3 (CH), 122.3 (Cq), 118.7 (CH), 116.1 
(CH2), 109.4 (CH), 38.1 (CH2), 24.3 (CH2), 24.0 (CH2). IR (ATR): 3051, 2945, 1657, 1562, 
1413, 1261, 1179, 996, 903, 821, 730, 695 cm−1. MS (ESI) m/z (relative intensity): 1048 
(10), 705 (15), 683(25), 364(20) [M+Na]+, 342 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C22H20N3O [M+H]
+ 342.1601, found 342.1601. 
(E)-184pa: M.p. = 129–131 °C. 1H NMR (400 MHz, CDCl3) δ = 8.73 (d, J = 4.8 Hz, 2H), 
7.35 (d, J = 4.4 Hz, 3H), 7.32–7.25 (m, 2H), 7.22 (t, J = 4.9 Hz, 1H), 6.79 (s, 1H), 6.73 (s, 
1H), 6.64 (dd, J = 17.5, 10.8 Hz, 1H), 5.05 (d, J = 17.5 Hz, 1H), 4.94 (d, J = 10.8 Hz, 1H), 
3.02 (t, J = 6.1 Hz, 2H), 2.58 (t, J = 6.4 Hz, 2H), 2.19 (tt, J = 6.1, 6.4 Hz, 2H). 13C NMR 
(101 MHz, CDCl3) δ = 194.9 (Cq), 158.5 (CH), 157.1 (Cq), 145.8 (Cq), 137.1 (Cq), 135.8 
(Cq), 134.2 (CH), 132.5 (Cq), 131.4 (CH), 129.7 (CH), 128.3 (CH), 127.4 (CH), 121.9 (Cq), 
119.2 (CH), 118.0 (Cq), 109.3 (CH), 38.1 (CH2), 24.1 (CH2), 23.9 (CH2). IR (ATR): 3051, 
2926, 1727, 1658, 1564, 1418, 1265, 1182, 1000, 910, 733, 700 cm−1. MS (ESI) m/z 
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(relative intensity): 364 (70) [M+Na]+, 342 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C22H20N3O [M+H]




The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 4-(cyclopropylidenemethyl)-1,1'-biphenyl 138b (66.0 mg, 0.32 mmol) for 
3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ab (64.7 
mg, 81%, Z/E = 3.4/1 determined by 1H NMR) as a yellow solid. M.p. = 127–128 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J = 4.8 Hz, 0.59H, E isomer), 8.65 (d, J = 4.8 Hz, 
2H, Z isomer), 8.40 (d, J = 8.3 Hz, 1H), 7.64 (d, J = 5.7 Hz, 1H), 7.53 (d, J = 8.0 Hz, 2H), 
7.41–7.27 (m, 7H), 7.15 (d, J = 8.0 Hz, 2H), 7.04 (t, J = 4.8 Hz, 1H), 6.75 (s, 1H), 6.72 (dd, 
J = 17.3, 10.6 Hz, 1H), 6.61 (s, 1H), 5.07 (d, J = 10.6 Hz, 1H), 5.00 (d, J = 17.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ = 158.0 (CH), 157.6 (Cq), 140.7 (CH), 140.6 (Cq), 139.7 (Cq), 
136.7 (Cq), 135.8 (Cq), 135.5 (Cq), 134.2 (Cq), 132.7 (CH), 129.6 (CH), 129.6 (Cq), 128.8 
(CH), 127.3 (CH), 126.9 (CH), 126.7 (CH), 123.4 (CH), 122.1 (CH), 120.8 (CH), 117.1 (CH), 
115.7 (CH2), 114.4 (CH), 108.6 (CH). IR (ATR): 3032, 2243, 1716, 1688, 1564, 1420, 1347, 
1305, 1212, 904, 804, 727 cm−1. MS (ESI) m/z (relative intensity):, 422 (90) [M+Na]+,400 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C28H22N3 [M+H]
+ 400.1808, found 400.1806. 
 





The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-4-methylbenzene 138c (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ac (58.0 
mg, 86%, Z/E = 4.7/1 determined by 1H NMR) as a yellow oil. 1H NMR (400 MHz, CDCl3) 
δ = 8.73 (d, J = 4.8 Hz, 0.43H, E isomer), 8.65 (d, J = 4.8 Hz, 2H, Z isomer), 8.39 (d, J = 
8.4 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.37–7.33 (m, 1H), 7.31–7.23 (m, 1H), 7.02 (t, J = 
4.8 Hz, 1H), 6.98 (d, J = 8.2 Hz, 2H), 6.92 (d, J = 8.2 Hz, 2H), 6.70 (dd, J = 17.2, 10.6 Hz, 
1H), 6.70 (s, 1H), 6.59 (s, 1H), 5.04 (d, J = 10.6 Hz, 1H), 4.98 (d, J = 17.2 Hz, 1H), 2.26 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ = 157.9 (CH), 157.5 (Cq), 140.8 (CH), 137.1 (Cq), 136.6 
(Cq), 135.7 (Cq), 133.9 (Cq), 133.2 (Cq), 133.2 (CH), 129.6 (CH), 129.1 (Cq), 128.9 (CH), 
123.3 (CH), 122.0 (CH), 120.8 (CH), 117.0 (CH), 115.1 (CH2), 114.2 (CH), 108.4 (CH), 
21.3 (CH3). IR (ATR): 3043, 2919, 1710, 1590, 1510, 1421, 1351, 1307, 1214, 1179, 985, 
899, 804, 744 cm−1. MS (ESI) m/z (relative intensity): 360 (100) [M+Na]+, 338 (80) [M+H]+. 
HR-MS (ESI) m/z calcd for C23H20N3 [M+H]
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The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-4-fluorobenzene 138c (46.1 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ad (51.9 
mg, 76%, Z/E = 4.7/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
δ = 8.73 (d, J = 4.8 Hz, 0.39H, E isomer), 8.66 (d, J = 4.8 Hz, 2H, Z isomer), 8.36 (d, J = 
8.2, 1H), 7.64 (d, J = 7.2, 1H), 7.36 (dd, J = 8.5, 7.2 Hz, 1H), 7.28 (dd, J = 8.5, 6.8 Hz, 1H), 
7.06–6.99 (m, 3H), 6.79 (t, J = 8.8 Hz, 2H), 6.69 (dd, J = 17.0, 10.6 Hz, 1H), 6.66 (s, 1H), 
6.58 (s, 1H), 5.08 (d, J = 10.6 Hz, 1H), 5.03 (s, d, J = 17.0 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ = 161.9 (d, 1JC–F = 247.7 Hz, Cq), 157.9 (CH), 157.4 (Cq), 140.3 (CH), 136.7 (Cq), 
135.2 (Cq), 133.85 (d, 4JC–F = 2.0 Hz, Cq), 132.9 (d, 4JC–F = 3.5 Hz, Cq), 131.7 (CH), 130.7 
(d, 3JC–F = 7.9 Hz, CH), 129.4 (Cq), 123.5 (CH), 122.1 (CH), 120.8 (CH), 117.1 (CH), 115.8 
(CH2), 115.1 (d, 2JC–F = 21.3 Hz, CH), 114.2 (CH), 108.7 (CH). 19F NMR (282 MHz, CDCl3) 
δ = (-114.1) – (-114.2) (m). IR (ATR): 3044, 2245, 1717, 1690, 1565, 1503, 1420, 1347, 
1307, 1220, 1153, 985,906, 805, 729 cm−1. MS (ESI) m/z (relative intensity): 364 (70) 
[M+Na]+, 342 (100) [M+H]+. HR-MS (ESI) m/z calcd for C22H17N3F [M+H]






The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-4-bromobenzene 138e (66.9 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ae (48.3 
mg, 60%, Z/E = 1.8/1 determined by 1H NMR) as a yellow solid. M.p. = 100–102 °C. 
1H NMR (300 MHz, CDCl3) δ = 8.72 (d, J = 4.8 Hz, 1.09H, E isomer), 8.66 (d, J = 4.8 Hz, 
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2H, Z isomer), 8.36 (d, J = 8.2 Hz, 1H), 7.62 (d, J = 7.7 Hz, 1H), 7.35–7.28 (m, 2H), 7.21 
(d, J = 8.5 Hz, 2H), 7.05 (t, J = 4.8 Hz, 1H), 6.93 (d, J = 8.5 Hz, 2H), 6.66 (d, J = 17.2, 10.6 
Hz, 1H), 6.62 (s, 1H), 6.54 (s, 1H), 5.08 (d, J = 10.6 Hz, 1H), 5.01 (d, J = 17.2 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ = 156.0 (CH), 157.5 (Cq), 140.3 (CH), 140.2 (Cq), 136.7 (Cq), 
135.7 (Cq), 134.9 (Cq), 131.6 (CH), 131.2 (CH), 130.6 (CH), 129.4 (Cq), 123.6 (CH), 122.1 
(CH), 121.1 (CH), 120.9 (Cq), 117.2 (CH), 116.3 (CH2), 114.3 (CH), 108.7 (CH). IR (ATR): 
3044, 1711, 1561, 1487, 1451, 1421, 1346, 1302, 1070, 1008, 906, 802, 727 cm−1. 
MS (ESI) m/z (relative intensity): 364 (75) (79Br) [M+Na]+, 342 (75) (79Br) [M+H]+. HR-MS 
(ESI) m/z calcd for C22H14N379Br [M+H]





The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-4-trifluoromethylbenzene 138f (63.1 mg, 0.32 
mmol) for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184af 
(40.7 mg, 52%, Z/E = 3.6/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, 
CDCl3) δ = 8.74 (d, J = 4.8 Hz, 0.56H, E isomer), 8.66 (d, J = 4.8 Hz, 2H, Z isomer), 8.42 
(d, J = 8.2 Hz, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.37 (d, J = 8.2 Hz, 2H), 7.35–7.27 (m, 2H), 
7.20 (d, J = 8.2 Hz, 2H), 7.05 (t, J = 4.8 Hz, 1H), 6.73 (s, 1H), 6.72 (dd, J = 17.3, 10.7 Hz, 
1H) ,6.58 (s, 1H), 5.14 (d, J = 10.7 Hz, 1H), 5.07 (d, J = 17.3 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ = 158.0 (CH), 157.5 (Cq), 140.4 (q, J = 1.4 Hz, Cq), 140.1 (CH), 136.7 (Cq), 136.4 
(Cq), 134.8 (Cq), 131.1 (CH), 129.4 (Cq), 129.2 (CH), 128.7 (q, J = 32.3 Hz, Cq), 125.0 (q, 
J = 3.9 Hz, CH), 124.3 (q, J = 271.9 Hz, Cq), 123.7 (CH), 122.2 (CH), 120.9 (CH), 117.2 
5 Experimental Section 
190 
 
(CH), 117.1 (CH2), 114.4 (CH), 109.0 (CH). 19F NMR (377 MHz, CDCl3) δ = -62.48. IR 
(ATR): 3048, 1573, 1562, 1453, 1423, 1352, 1322, 1124, 1067, 827, 742 cm−1. MS (ESI) 
m/z (relative intensity): 414 (100) [M+Na]+, 392 (90) [M+H]+. HR-MS (ESI) m/z calcd for 




The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 4-(cyclopropylidenemethyl)benzonitrile 138g (49.7 mg, 0.32 mmol) for 3.0 
h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ag (62.7 mg, 
90%, Z/E = 1.4/1 determined by 1H NMR) as a yellow solid. M.p. = 140–141 °C. 1H NMR 
(400 MHz, CDCl3) δ = 8.72 (d, J = 4.8 Hz, 1.46H, E isomer), 8.65 (d, J = 4.8 Hz, 2H, Z 
isomer), 8.37 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 8.4 Hz, 2H), 7.28 (t, 
J = 7.4 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 7.06 (t, J = 4.8 Hz, 1H), 6.68 (dd, J = 17.3, 11.3 
Hz, 1H), 6.67 (s, 1H), 6.54 (s, 1H), 5.15 (d, J = 11.3 Hz, 1H), 5.08 (d, J = 17.3 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ = 158.0 (CH), 157.4 (Cq), 141.6 (Cq), 139.8 (CH), 137.4 (Cq), 
136.7 (Cq), 134.4 (Cq), 131.8 (CH), 130.2 (CH), 129.5 (CH), 129.3 (Cq), 123.9 (CH), 122.3 
(CH), 120.9 (CH), 119.2 (Cq), 117.9 (CH2), 117.2 (CH), 114.4 (CH), 110.1 (CH), 109.2 (Cq). 
IR (ATR): 2221, 2135, 2023, 1701, 1563, 1420, 1346, 1307, 905, 800, 735 cm−1. MS (ESI) 
m/z (relative intensity): 371 (100) [M+Na]+, 349 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C23H17N4 [M+H]
+ 349.1448, found 349.1446. 
 





The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-3-fluorobenzene 138h (47.4 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ah (53.9 
mg, 79%, Z/E = 4.4/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
δ = 8.73 (d, J = 4.8 Hz, 0.45H, E isomer), 8.66 (d, J = 4.8 Hz, 2H, Z isomer), 8.37 (dd, J = 
8.3, 1.0 Hz, 1H), 7.63 (d, J = 7.4 Hz, 1H), 7.36 (t, J = 8.4 Hz, 1H), 7.33–7.21 (m, 1H), 7.05 
(d, J = 5.0 Hz, 1H), 7.02 (t, J = 4.2 Hz, 1H), 6.84 (s, 1H), 6.83–6.75 (m, 2H), 6.69 (dd, J = 
17.5, 11.2 Hz, 1H), 6.66 (s, 1H), 6.59 (s, 1H), 5.11 (d, J = 11.2 Hz, 1H), 5.06 (d, J = 17.5 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 162.5 (d, 1JC–F = 244.5 Hz, Cq), 157.9 (CH), 157.4 
(Cq), 140.2 (CH), 139.1 (d, 3JC–F  = 8.0 Hz, Cq), 136.7 (Cq), 135.4 (Cq), 134.8 (Cq), 131.4 
(d, 4JC–F = 2.6 Hz, CH), 129.4, 129.1 (Cq), 124.8 (d, 4JC–F = 2.8 Hz, CH), 123.6 (CH), 122.1 
(CH), 120.8 (CH), 117.1 (CH), 116.6 (CH2), 115.7 (d, 2JC–F = 22.0 Hz), 114.3 (CH), 114.0 
(d, 2JC–F = 21.4 Hz, CH), 109.0 (CH). 19F NMR (282 MHz, CDCl3) δ = –113.79 (td, J = 9.5, 
6.4 Hz). IR (ATR): 3045, 1998, 1718, 1566, 1420, 1347, 1307, 1244, 1143, 905, 803, 729 
cm−1. MS (ESI) m/z (relative intensity): 364( [M+Na]+, 342 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C22H17N3F [M+H]
+ 342.1712, found 342.1400. 
  






The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-3-trifluoromethylbenzene 138i (63.1 mg, 0.32 
mmol) for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ai 
(64.2 mg, 82%, Z/E = 5.7/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, 
CDCl3) δ = 8.74 (d, J = 4.8 Hz, 0.35H, E isomer), 8.63 (d, J = 4.8 Hz, 2H, Z isomer), 8.32 
(d, J = 8.2 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.37–7.32 (m, 2H), 7.29 (dd, J = 7.5, 1.2 Hz, 
1H), 7.25–7.23 (m, 1H), 7.15–7.12 (m, 2H), 7.04 (t, J = 4.8 Hz, 1H), 6.73 (d, J = 16.8, 11.0 
Hz, 1H), 6.69 (s, 1H), 6.61 (s, 1H), 5.18 (d, J = 11.0 Hz, 1H), 5.17 (d, J = 16.8 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ = 157.9 (CH), 157.3 (Cq), 139.9 (CH), 137.6 (Cq), 136.7 (Cq), 
135.9 (Cq), 134.5 (Cq), 131.7 (CH), 130.9 (CH), 130.3 (q, 2JC–F = 32.1 Hz, Cq), 128.5 (CH), 
125.9 (CH), 125.9 (q, 3JC–F = 3.8 Hz, CH), 124.1 (q, 1JC–F = 273.7 Hz, CH), 123.7 (CH), 
123.6 (q, 3JC–F = 3.8 Hz, CH), 122.2 (CH), 120.8 (CH), 117.1 (CH), 117.1 (CH2), 114.2 (CH), 
109.1 (CH). 19F NMR (282 MHz, CDCl3) δ = -62.9. IR (ATR): 3045, 1720, 1594, 1420, 1347, 
1224, 1090, 908, 800, 731 cm−1. MS (ESI) m/z (relative intensity): 414 (80) [M+Na]+, 392 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C23H17N3F3 [M+H]
+ 392.1369, found 392.1365. 
 
 
Methyl (Z)-3-{2-[1-(pyrimidin-2-yl)-1H-indol–2-yl]buta-1,3-dien-1-yl}benzoate (184aj) 
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The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and methyl-3-(cyclopropylidenemethyl)benzoate 138j (59.9 mg, 0.32 mmol) for 
3.0 h. Isolation by column chromatography (n-hexane/EtOAc 8:1) yielded 184aj (58.7 mg, 
77%, Z/E = 4.5/1 determined by 1H NMR) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 
8.73 (d, J = 4.8 Hz, 0.44H, E isomer), 8.62 (d, J = 4.8 Hz, 2H, Z isomer), 8.34 (d, J = 8.4 
Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.65 (s, 1H), 7.64–7.57 (m, 1H), 7.34 (t, J = 8.4 Hz, 1H), 
7.27 (d, J = 7.8 Hz, 1H), 7.21–7.12 (m, 1H), 7.10 (t, J = 7.6 Hz, 1H), 7.01 (t, J = 4.8 Hz, 
1H), 6.73 (dd, J = 17.2, 10.4 Hz, 1H), 6.71 (s, 1H), 6.59 (s, 1H), 5.14 (d, J = 10.4 Hz, 1H), 
5.12 (d, J = 17.2 Hz, 1H), 3.75 (s, 3H). 13C NMR (126 MHz, CDCl3) δ = 167.0 (Cq), 157.9 
(CH), 157.3 (Cq), 140.2 (CH), 137.0 (Cq), 136.7 (Cq), 135.2 (Cq), 134.9 (Cq), 133.0 (CH), 
131.6 (CH), 130.5 (CH), 129.9 (Cq), 129.4 (Cq), 128.2 (CH), 128.1 (CH), 123.5 (CH), 122.0 
(CH), 120.8 (CH), 117.1 (CH), 116.6 (CH2), 114.3 (CH), 108.9 (CH). IR (ATR): 3045, 1720, 
1594, 1420, 1347, 1224, 1090, 908, 800, 731 cm−1. MS (ESI) m/z (relative intensity): 414 






The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-3-phenoxybenzene 138k (70.8 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184ak (70.6 
mg, 85%, Z/E = 7.0/1 determined by 1H NMR) as a yellow solid. M.p. = 86–88 °C. 1H NMR 
(300 MHz, CDCl3) δ = 8.72 (d, J = 4.8 Hz, 0.28H, E isomer), 8.63 (d, J = 4.8 Hz, 2H, Z 
isomer), 8.34 (d, J = 8.2 Hz, 1H), 7.61 (d, J = 7.7 Hz, 1H), 7.37–7.25 (m, 2H), 7.14–7.02 
(m, 2H), 7.03 (t, J = 5.1 Hz, 2H), 6.93 (t, J = 7.3 Hz, 1H), 6.83–6.73 (m, 5H), 6.66 (s, 1H), 
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6.65 (d, J = 17.3, 10.8 Hz, 1H), 6.54 (s, 1H), 5.06 (d, J = 10.8 Hz, 1H), 5.00 (d, J = 17.3 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ = 157.8 (CH), 157.4 (Cq), 157.2 (Cq), 156.5 (Cq), 140.2 
(CH), 138.6 (Cq), 136.7 (Cq), 135.1 (Cq), 134.9 (Cq), 132.1 (CH), 129.5 (CH), 129.4 (Cq), 
129.3 (CH), 123.6 (CH), 123.4 (CH), 123.2 (CH), 122.0 (CH), 120.8 (CH), 119.2 (CH), 
119.2 (CH), 118.8 (CH), 117.6 (CH), 117.0 (CH), 116.1 (CH2), 114.3 (CH), 108.9 (CH). 
IR (ATR): 3047, 1692, 1568, 1423, 1244, 1211, 1154, 1023, 1079, 900, 800, 732, 692 cm−1. 
MS (ESI) m/z (relative intensity): 438 (100) [M+Na]+, 416 (70) [M+H]+. HR-MS (ESI) m/z 
calcd for C28H22N3O [M+H]




The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-2-fluorobenzene 138l (47.1 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184al (51.2 
mg, 75%, Z/E = 4.8/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
δ = 8.74 (d, J = 4.8 Hz, 0.42H, E isomer), 8.65 (d, J = 4.8 Hz, 2H, Z isomer), 8.32 (dd, J = 
8.2, 1.2 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.34 (td, J = 8.4, 1.5 Hz, 1H), 7.26 (td, J = 7.2, 
1.2 Hz, 1H), 7.12–7.06 (m, 1H), 7.05 (t, J = 4.8 Hz, 1H), 6.97 (td, J = 7.8, 1.8 Hz, 1H), 6.90 
(td, J = 8.4, 1.2 Hz, 1H), 6.85 (s, 1H), 6.75 (t, J = 7.1 Hz, 1H), 6.74 (dd, J = 18.0, 9.6 Hz, 
1H), 6.61 (s, 1H), 5.13 (d, J = 9.6 Hz, 1H), 5.12 (d, J = 18.0 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ = 160.6 (d, J = 248.3 Hz, Cq), 157.9 (CH), 157.4 (CH), 140.2 (Cq), 136.7 (Cq), 
135.5 (d, J = 1.6 Hz, Cq), 135.1 (Cq), 130.1 (d, J = 2.8 Hz, CH), 129.4 (Cq), 128.7 (d, J = 
8.5 Hz, CH), 124.4 (d, J = 5.1 Hz, Cq), 123.8 (CH), 123.8 (CH), 123.6 (CH), 122.0 (CH), 
120.8 (CH), 117.1 (CH), 116.5 (CH2), 114.8 (d, J = 21.9 Hz, CH), 114.1 (CH), 109.0 (CH). 
19F NMR (282 MHz, CDCl3) δ = –116.86––116.96 (m). IR (ATR): 3044, 2244, 1565, 1437, 
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1421, 1347, 1347, 1071, 1006, 906, 803, 727 cm−1. MS (ESI) m/z (relative intensity): 414 






The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-2-bromobenzene 138m (66.6 mg, 0.32 mmol) 
for 4.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184am (49.1 
mg, 61%, Z/E = 1.3/1 determined by 1H NMR) as a yellow solid. M.p. = 143–145 °C. 
1H NMR (400 MHz, CDCl3) δ = 8.75 (d, J = 4.8 Hz, 1.56H, E isomer), 8.65 (d, J = 4.8 Hz, 
2H, Z isomer), 8.22 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 
7.37–7.30 (m, 2H), 7.17 (t, J = 8.0 Hz, 1H), 7.05 (t, J = 4.8 Hz, 1H), 6.91 (t, J = 7.4, 1H), 
6.80 (s, 1H), 6.80 (s, 1H), 6.68 (dd, J = 17.6, 10.6 Hz, 1H), 6.59 (s, 1H), 5.22 (d, J = 17.3 
Hz, 1H), 5.18 (d, J = 10.6 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.0 (CH), 157.2 (Cq), 
139.8 (CH), 139.4 (Cq), 137.3 (Cq), 136.8 (Cq), 135.3 (Cq), 132.0 (CH), 131.1 (CH), 130.8 
(CH), 129.2 (Cq), 128.5 (CH), 127.1 (CH), 124.3 (Cq), 123.6 (CH), 122.0 (CH), 120.8 (CH), 
117.2 (CH), 116.9 (CH2), 113.9 (CH), 109.6 (CH). IR (ATR): 3049, 2920, 1695, 1565, 1423, 
1349, 1262, 1213, 1013, 987, 805, 741cm−1. MS (ESI) m/z (relative intensity): 424 (70) 
(79Br) [M+Na]+, 402 (100) (79Br) [M+H]+. HR-MS (ESI) m/z calcd for C22H17N379Br [M+H]
+ 
402.0606, found 402.0534. 
 





The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-2-ethoxybenzene 138n (66.6 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 184an (57.3 
mg, 78%, Z/E = 3.0/1 determined by 1H NMR) as a yellow solid. M.p. = 86–89 °C. 1H NMR 
(300 MHz, CDCl3) δ = 8.74 (d, J = 4.8 Hz, 0.66H, E isomer), 8.64 (d, J = 4.8 Hz, 2H, Z 
isomer), 8.29 (d, J = 8.1 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H), 7.25 (t, 
J = 7.6 Hz, 1H), 7.08–6.95 (m, 5H), 6.78 (dd, J = 16.4, 11.2 Hz, 1H), 6.61 (s, 1H), 6.58 (t, 
J = 7.5 Hz, 1H), 5.08 (d, J = 16.4 Hz, 1H), 5.07 (d, J = 11.2 Hz, 1H), 3.99 (q, J = 7.2 Hz, 
2H), 1.46 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ = 157.8 (CH), 157.4 (Cq), 156.7 
(Cq), 140.8 (CH), 136.7 (Cq), 135.9 (Cq), 133.2 (Cq), 129.9 (CH), 129.5 (Cq), 128.4 (CH), 
128.1 (CH), 125.7 (Cq), 123.2 (CH), 121.8 (CH), 120.7 (CH), 120.3 (CH), 116.8 (CH), 114.9 
(CH2), 113.9 (CH), 111.0 (CH), 108.7 (CH), 63.7 (CH2), 15.1 (CH3). IR (ATR): 2978, 2508, 
2162, 2088, 2011, 1957, 1563, 1422, 1239, 1039, 742 cm−1. MS (ESI) m/z (relative 
intensity): 390 (60) [M+Na]+, 368 (50) [M+H]+. HR-MS (ESI) m/z calcd for C24H21N3ONa 
[M+H]+
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The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-3,5-dimethoxybenzene (138o) (60.6 mg, 0.32 
mmol) for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 10:1) yielded 
184ao (69.8 mg, 91%, Z/E = 3.8/1 determined by 1H NMR) as a yellow oil. 1H NMR (300 
MHz, CDCl3) δ = 8.73 (d, J = 4.8 Hz, 0.52H, E isomer), 8.63 (dd, J = 4.8 Hz, 2H, Z isomer), 
8.33 (d, J = 7.8 Hz, 1H), 7.64 (dd, J = 7.8 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H), 7.25 (t, J = 7.2 
Hz, 1H), 7.01 (t, J = 4.8 Hz, 0H), 6.78 (dd, J = 17.2, 10.5 Hz, 1H), 6.66 (s, 1H), 6.59 (s, 1H), 
6.22 (t, J = 2.1 Hz, 1H), 6.07 (d, J = 2.1 Hz, 2H), 5.25 (d, J = 17.2 Hz, 1H), 5.21 (d, J = 10.5 
Hz, 1H), 3.38 (s, 6H). 13C NMR (75 MHz, CDCl3) δ = 160.2 (Cq), 157.8 (CH), 157.2 (Cq), 
140.4 (CH), 138.3 (Cq), 136.6 (Cq), 135.0 (Cq), 134.5 (Cq), 132.8 (CH), 129.4 (Cq), 123.4 
(CH), 122.0 (CH), 120.6 (CH), 117.0 (CH), 116.3 (CH2), 114.3 (CH), 108.7 (CH), 106.5 
(CH), 100.6 (CH), 55.0 (CH). IR (ATR): 3047, 2937, 2835, 1730, 1590, 1423, 1344, 1303, 
1263, 1201, 1152, 1061, 985, 904, 805, 735 cm−1. MS (ESI) m/z (relative intensity): 406 







The general procedure F was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and 1-(cyclopropylidenemethyl)-2-bromo-5-trifluoromethylbenzene 138p (88.3 
mg, 0.32 mmol) for 6.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) 
yielded 184ap (48.0 mg, 78%, Z/E = 10.5/1 determined by 1H NMR) as a yellow solid. M.p. 
= 71–72 °C. 1H NMR (400 MHz, CDCl3) δ = 8.70 (d, J = 4.8 Hz, 0.19H, E isomer), 8.60 (d, 
J = 4.8 Hz, 2H, Z isomer), 8.18 (dq, J = 8.4, 0.8 Hz, 1H), 7.54 (dd, J = 7.7, 1.4 Hz, 1H), 
5 Experimental Section 
198 
 
7.45 (d, J = 8.4 Hz, 1H), 7.28–7.23 (m, 1H), 7.19 (dd, J = 7.7, 2.4 Hz, 1H), 7.11 (dd, 8.4, 
2.3 Hz, 1H), 7.02 (t, J = 4.8 Hz, 1H), 6.73 (ddd, J = 17.3, 10.5, 0.7 Hz, 1H), 6.72 (dd, J = 
17.5, 10.7, 0.8 Hz, 1H ), 6.71 (s, 1H), 6.56 (d, J = 0.8 Hz, 1H), 5.27 (dt, J = 17.5, 0.8 Hz, 
1H), 5.21 (dt, J = 10.7, 0.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ = 158.0 (CH), 157.2 (Cq), 
139.1 (CH), 137.9 (Cq), 137.3 (Cq), 136.9 (Cq), 133.8 (Cq), 132.4 (CH), 129.5 (q, J = 33.5 
Hz, Cq), 129.3 (CH), 129.0 (Cq), 127.9 (q, J = 3.9 Hz, CH), 127.5 (Cq), 124.6 (q, J = 3.6 Hz, 
CH), 123.9 (CH), 123.5 (q, J = 272.5 Hz, Cq), 122.2 (CH), 120.8 (CH), 118.1 (CH2), 117.2 
(CH), 113.9 (CH), 110.1 (CH). 19F NMR (376 MHz, CDCl3) δ = -63.32. IR (ATR): 3048, 
2922, 1701, 1566, 1423, 1324, 1263, 1166, 1123, 1079, 1025, 912, 811, 741 cm−1. MS 
(ESI) m/z (relative intensity): 492 (100) (79Br) [M+Na]+, 472 (30) (79Br) [M+H]+. HR-MS (ESI) 
m/z calcd for C23H16N3
79BrF3 [M+H]




The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (39.0 mg, 
0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) for 3.0 h. 
Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186aa (64.1 mg, 95%) 
as a yellow oil. 1H NMR (300 MHz, CDCl3): δ = 8.77 (d, J = 4.7 Hz, 2H), 8.17 (d, J = 8.1 
Hz, 1H), 7.66 (d, J = 7.2 Hz, 1H), 7.37–7.30 (m, 1H), 7.30–7.26 (m, 1H), 7.25–7.14 (m, 
5H), 7.09 (t, J = 4.8 Hz, 1H), 6.69 (s, 1H), 6.09 (d, J = 16.0 Hz, 1H), 6.00 (d, J = 16.0 Hz, 
1H), 1.50 (dd, J = 4.6, 4.6 Hz, 2H), 1.25 (dd, J = 4.6, 4.6 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ = 158.3 (Cq), 158.1 (CH), 142.7 (Cq), 137.8 (Cq), 137.2 (Cq), 136.8 (CH), 128.8 
(Cq), 128.4 (CH), 127.1 (CH), 126.6 (CH), 125.7 (CH), 123.1 (CH), 121.7 (CH), 120.3 (CH), 
117.6 (CH), 113.4 (CH), 107.4 (CH), 22.7 (Cq), 18.4 (CH2). IR (ATR): 3026, 1643, 1562, 
1452, 1417, 1351, 1298, 1151, 955, 740 cm−1. MS (ESI) m/z (relative intensity): 360 (100) 
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[M+Na]+, 338 (85) [M+H]+. HR-MS (ESI) m/z calcd for C23H20N3 [M+H]





The general procedure G was followed using 3-methyl-1-(pyrimidin-2-yl)-1H-indole 71b 
(41.6 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.5 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ba (51.3 
mg, 73%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.23 (d, 
J = 7.8 Hz, 1H), 7.65 (d, J = 1.7 Hz, 1H), 7.40–7.30 (m, 6H), 7.24–7.19 (m, 1H), 7.13 (td, 
J = 4.8, 1.6 Hz, 1H), 6.37 (d, J = 15.8 Hz, 1H), 6.30 (d, J = 15.8 Hz, 1H), 2.44 (s, 3H), 1.18 
(s, 2H), 1.04 (s, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.1 (Cq), 158.0 (CH), 138.2 (Cq), 
137.2 (Cq), 136.5 (CH), 135.8 (Cq), 130.1 (Cq), 128.5 (CH), 127.2 (CH), 126.5 (CH), 125.9 
(CH), 123.3 (CH), 121.5 (CH), 118.3 (CH), 117.0 (CH), 116.4 (Cq), 113.3 (CH), 21.3 (Cq), 
18.1 (CH2), 9.5 (CH3). IR (ATR): 3029, 2916, 1645, 1563, 1453, 1420, 1347, 1298, 1178, 
956, 736 cm−1. MS (ESI) m/z (relative intensity): 374 (80) [M+Na]+, 352 (100) [M+H]+.   
HR-MS (ESI) m/z calcd for C24H22N3 [M+H]
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The general procedure G was followed using (1-(pyrimidin-2-yl)-1H-indol-3-yl)methanol 
71q (44.8 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 
mmol) for 4.5 h. Isolation by column chromatography (n-hexane/EtOAc 5:1) yielded 186qa 
(33.1 mg, 45%) as a colorless solid. M.p. = 145–146 °C. 1H NMR (400 MHz, CDCl3) δ = 
8.81 (d, J = 4.6 Hz, 2H), 8.11 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 7.4 Hz, 1H), 7.36–7.26 (m, 
6H), 7.21–7.17 (m, 2H), 6.31 (s, 2H), 5.06 (d, J = 5.0 Hz, 2H), 1.56 (t, J = 5.0 Hz, 1H), 
1.23–1.15 (m, 2H), 1.15–1.06 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.3 (CH), 158.0 
(Cq), 139.4 (Cq), 137.8 (Cq), 137.0 (CH), 136.1 (Cq), 128.6 (CH), 128.3 (Cq), 127.7 (CH), 
126.8 (CH), 126.0 (CH), 123.8 (CH), 122.0 (CH), 119.2 (Cq), 118.8 (CH), 117.8 (CH), 113.3 
(CH), 56.4 (CH2), 21.0 (Cq), 17.8 (CH2). IR (ATR): 3492, 3023, 2858, 1562, 1455, 1423, 
1358, 1298, 1100, 953, 746 cm−1. MS (ESI) m/z (relative intensity): 381 (100) [M+Na]+, 368 
(50) [M+H]+. HR-MS (ESI) m/z calcd for C24H22N3O [M+H]




The general procedure G was followed using 4-methoxy-1-(pyrimidin-2-yl)-1H-indole 71c 
(44.8 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ca (55.1 
mg, 75%) as a colorless solid. M.p. = 115–116 °C. 1H NMR (300 MHz, CDCl3) δ = 8.76 (d, 
J = 4.8 Hz, 2H), 7.75 (d, J = 8.4 Hz, 1H), 7.26–7.18 (m, 3H), 7.17–7.12 (m,, 3H), 7.08 (t, J 
= 4.8 Hz, 1H), 6.82 (s, 1H), 6.70 (d, J = 7.9 Hz, 1H), 6.08 (d, J = 16.0 Hz, 1H), 5.97 (d, J = 
16.0 Hz, 1H), 4.03 (s, 3H), 1.53–1.48 (m, 2H), 1.25–1.20 (m, 2H). 13C NMR (75 MHz, CDCl3) 
δ = 158.4 (Cq), 158.1 (CH), 152.8 (Cq), 141.2 (Cq), 138.5 (Cq), 137.8 (Cq), 136.8 (CH), 
128.3 (CH), 127.1 (CH), 126.5 (CH), 125.7 (CH), 123.9 (CH), 119.1 (Cq), 117.7 (CH), 106.7 
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(CH), 104.2 (CH), 101.8 (CH), 55.5 (CH3), 22.6 (Cq), 18.3 (CH2). IR (ATR): 3000, 2201, 
1564, 1437, 1419, 1360, 1256, 1075, 812, 769 cm−1. MS (ESI) m/z (relative intensity): 390 






The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole-4-carbonitrile 
71d (43.8 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 
mmol) for 4.0 h. Isolation by column chromatography (n-hexane/EtOAc 4:1) yielded 186da 
(39.9 mg, 55%) as a white solid. M.p. = 153–155 °C. 1H NMR (400 MHz, CDCl3) δ = 8.80 
(d, J = 4.8 Hz, 2H), 8.28 (d, J = 8.2 Hz, 1H), 7.57 (dd, J = 7.4, 1.1 Hz, 1H), 7.31 (td, J = 
8.1, 7.5, 1.4 Hz, 1H), 7.25–7.15 (m, 3H), 7.15–7.09 (m, 3H), 6.88 (s, 1H), 6.01 (d, J = 16.0 
Hz, 1H), 5.95 (d, J = 16.0 Hz, 1H), 1.53–1.49 (m, 2H), 1.29–1.25 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ = 158.4 (CH), 157.7 (Cq), 145.9 (Cq), 137.4 (Cq), 137.0 (Cq), 135.6 (CH), 
130.5 (Cq), 128.4 (CH), 127.7 (CH), 126.8 (CH), 126.5 (CH), 125.8 (CH), 122.8 (CH), 118.7 
(Cq), 118.5 (CH), 118.0 (CH), 105.4 (CH), 102.7 (Cq), 22.6 (Cq), 18.4 (CH2). IR (ATR): 3037, 
2213, 1646, 1561, 1411, 1361, 1302, 1202, 928, 814, 775, 742 cm−1. MS (ESI) m/z (relative 
intensity): 386 (100) [M+Na]+, 364 (55) [M+H]+. HR-MS (ESI) m/z calcd for C24H19N4 [M+H]
+ 
363.1604, found 363.1603. 
 





The general procedure G was followed using 4-methoxy-1-(pyrimidin-2-yl)-1H-indole 71e 
(41.6 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ea (56.9 
mg, 81%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.72 (d, J = 4.8 Hz, 2H), 8.07 (d, 
J = 8.5 Hz, 1H), 7.41 (s, 2H), 7.22–7.09 (m, 6H), 7.03 (t, J = 4.8 Hz, 1H), 6.59 (s, 1H), 6.04 
(d, J = 16.0 Hz, 1H), 5.98 (d, J = 16.0 Hz, 1H), 2.49 (s, 3H), 1.48–1.36 (m, 2H), 1.23–1.19 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.3 (Cq), 158.0, 142.7 (Cq), 137.9 (Cq), 137.0 
(CH), 135.5 (Cq), 131.1 (Cq), 129.1 (Cq), 128.4 (CH), 127.0 (CH), 126.5 (CH), 125.7 (CH), 
124.6 (CH), 120.1 (CH), 117.3 (CH), 113.4 (CH), 107.3 (CH), 22.9 (Cq), 21.5 (CH3), 18.4 
(CH2). IR (ATR): 3023, 1644, 1564, 1418, 1336, 1215, 1151, 952, 907, 802, 731, 688 cm−1. 
MS (ESI) m/z (relative intensity): 374 (95) [M+Na]+, 352 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C24H22N3 [M+H]




The general procedure G was followed using 5-chloro-1-(pyrimidin-2-yl)-1H-indole 71g 
(45.7 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ga (54.3 
mg, 73%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.76 (d, J = 4.8 Hz, 2H), 8.07 (d, 
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J = 8.9 Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.25–7.18 (m, 3H), 7.14–7.10 (m, 4H), 6.60 (s, 
1H), 6.02 (d, J = 16.0 Hz, 1H), 5.96 (d, J = 16.0 Hz, 1H), 1.47–1.44 (m, 2H), 1.24–1.21 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ = 158.2 (CH), 158.0 (Cq), 144.1 (Cq), 137.7 (Cq), 136.4 
(CH), 135.6 (Cq), 130.0 (Cq), 130.0 (Cq), 128.4 (CH), 127.2 (CH), 126.7 (CH), 125.8 (CH), 
123.2 (CH), 119.7 (CH), 117.9 (CH), 114.7 (CH), 106.8 (CH), 22.8 (Cq), 18.4 (CH2). IR 
(ATR): 3025, 1644, 1564, 1416, 1335, 1186, 1067, 950, 866, 800, 742, 687 cm−1. MS (ESI) 
m/z (relative intensity): 394 (50) (35Cl) [M+Na]+, 372 (100) (35Cl) [M+H]+. HR-MS (ESI) m/z 




The general procedure G was followed using 5-bromo-1-(pyrimidin-2-yl)-1H-indole 71h 
(54.6 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ha (69.1 
mg, 83%) as a yellow solid. M.p. = 153–155 °C. 1H NMR (300 MHz, CDCl3) δ = 8.76 (d, J 
= 4.8 Hz, 2H), 8.03 (d, J = 8.8 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.38 (dd, J = 8.9, 2.0 Hz, 
1H), 7.25–7.18 (m, 2H), 7.16–7.09 (m, 4H), 6.60 (s, 1H), 6.03(d, J = 16.2 Hz, 1H), 5.97 (d, 
J = 16.2 Hz, 1H), 1.49–1.44 (m, 2H), 1.26–1.21 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 
158.2 (Cq), 158.0 (CH), 144.0 (Cq), 137.6 (Cq), 136.4 (CH), 135.9 (Cq), 130.5 (Cq), 128.4 
(CH), 127.2 (CH), 126.7 (CH), 125.8 (CH), 125.7 (CH), 122.8 (CH), 117.9 (CH), 115.1 (CH), 
114.9 (Cq), 106.7 (CH), 22.7 (Cq), 18.4 (CH2). IR (ATR): 3022, 1644, 1563, 1415, 1334, 
1185, 949, 907, 866, 799, 740, 688 cm−1. MS (ESI) m/z (relative intensity): 438 (60) (79Br) 
[M+Na]+, 416 (100) (79Br) [M+H]+. HR-MS (ESI) m/z calcd for C23H19
79BrN3 [M+H]
+ 
416.0762, found 416.0757. 






The general procedure G was followed using 5-iodo-1-(pyrimidin-2-yl)-1H-indole 71r (64.0 
mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) for 4.0 
h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ra (50.0 mg, 
54%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.75 (d, J = 4.8 Hz, 2H), 7.95 (s, 1H), 
7.91 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.24–7.17 (m, 2H), 7.15–7.08 (m, 4H), 
6.57 (s, 1H), 6.00 (d, J = 16.2 Hz, 1H), 5.95 (d, J = 16.0 Hz, 1H), 1.49–1.42 (m, 2H), 1.24–
1.19 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.2 (CH), 143.6 (Cq), 137.6 (Cq), 136.5 
(Cq), 136.4 (Cq), 131.4 (CH), 131.3 (Cq), 129.1 (CH), 128.4 (CH), 127.2 (CH), 126.7 (CH), 
125.8 (CH), 117.9 (CH), 115.6 (CH), 106.4 (CH), 85.4 (Cq), 22.6 (Cq), 18.4 (CH2). IR (ATR): 
3025, 2921, 2849, 1732, 1643, 1563, 1415, 1330, 1183, 1023, 947, 799, 738, 689 cm−1. 
MS (ESI) m/z (relative intensity): 486 (60) [M+Na]+, 464 (100) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H19N3I [M+H]




The general procedure G was followed using 5-methoxyl-1-(pyrimidin-2-yl)-1H-indole 71i 
(44.8 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ia (61.7 
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mg, 54%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.74 (d, J = 4.8 Hz, 2H), 8.16 (d, 
J = 9.0 Hz, 1H), 7.25–7.20 (m, 2H), 7.18–7.14 (m, 3H), 7.12 (d, J = 2.5 Hz, 1H), 7.05 (t, J 
= 4.8 Hz, 1H), 6.98 (dd, J = 9.0, 2.6 Hz, 1H), 6.63 (s, 1H), 6.09 (d, J = 16.0 Hz, 1H), 6.03 
(d, J = 16.0 Hz, 1H), 3.93 (s, 3H), 1.49–1.46 (m, 2H), 1.26–1.23 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ = 158.2 (Cq), 158.0 (CH), 155.4 (Cq), 143.2 (Cq), 137.8 (Cq), 137.0 (CH), 
132.1 (Cq), 129.5 (Cq), 128.4 (CH), 126.9 (CH), 126.5 (CH), 125.7 (CH), 117.2 (CH), 114.7 
(CH), 112.4 (CH), 107.6 (CH), 102.5 (CH), 55.9 (CH3), 23.0 (Cq), 18.4 (CH2). 3002, 1614, 
1564, 1418, 1341, 1214, 1154, 1030, 951, 801, 737, 688 cm−1. MS (ESI) m/z (relative 
intensity) 390 (25) [M+Na]+, 368 (100) [M+H]+. HR-MS (ESI) m/z calcd for C24H22N3O 




The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole–5-carbonitrile 
71j (43.8 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 5:1) yielded 186ja (60.2 
mg, 83%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ = 8.80 (d, J = 4.9 Hz, 2H), 8.09 (d, 
J = 8.7 Hz, 1H), 7.95 (s, 1H), 7.51 (dd, J = 8.6, 1.5 Hz, 1H), 7.23–7.16 (m, 3H), 7.18–7.07 
(m, 3H), 6.69 (s, 1H), 5.99 (d, J = 16.0 Hz, 1H), 5.92 (d, J = 16.0 Hz, 1H), 1.49–1.46 (m, 
2H), 1.26–1.23 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.4 (CH), 157.6 (Cq), 145.3 (Cq), 
138.9 (Cq), 137.3 (Cq), 135.6 (CH), 128.5 (Cq), 128.4 (CH), 127.6 (CH), 126.8 (CH), 126.0 
(CH), 125.7 (CH), 125.4 (CH), 120.6 (Cq), 118.6 (CH), 114.0 (CH), 106.8 (CH), 104.7 (Cq), 
22.4 (Cq), 18.3 (CH2). IR (ATR): 3025, 2221, 1733, 1564, 1463, 1418, 1375, 1309, 1239, 
1040, 952, 808, 743, 690 cm−1. MS (ESI) m/z (relative intensity): 385 (100) [M+Na]+, 363 
(65) [M+H]+. HR-MS (ESI) m/z calcd for C24H19N4 [M+H]
+ 363.1604, found 363.1603. 






The general procedure G was followed using 6-fluoro-1-(pyrimidin-2-yl)-1H-indole 71k 
(42.4 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ka (64.0 
mg, 90%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ = 8.76 (d, J = 4.8 Hz, 2H), 7.96 (dd, 
J = 10.9, 2.4 Hz, 1H), 7.54 (dd, J = 8.6, 5.5 Hz, 1H), 7.26–7.19 (m, 2H), 7.15 –7.13 (m, 
3H), 7.03 (td, J = 8.9, 2.3 Hz, 1H), 6.65 (d, J = 0.8 Hz, 1H), 6.07 (d, J = 16.0 Hz, 1H), 6.00 
(d, J = 16.1 Hz, 1H), 1.51–1.46 (m, 1H), 2.28–1.22 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 
= 160.6 (d, 1JC–F = 237.4 Hz, Cq), 143.2 (d, 4JC–F  = 3.9 Hz, Cq), 137.3 (d, 3JC–F = 12.6 Hz, 
Cq), 120.8 (d, 3JC–F = 10.0 Hz, CH), 110.1 (d, 2JC–F = 24.2 Hz, CH), 100.8 (d, 2JC–F = 28.3 
Hz, CH). 125.1 (d, 5JC–F = 1.4 Hz, Cq) 158.1 (CH), 158.1 (Cq), 137.7 (Cq), 136.7 (CH), 128.4 
(CH), 127.1 (CH), 126.6 (CH), 125.7 (CH), 117.7 (CH), 107.3 (CH), 22.8 (Cq), 18.4 (CH2). 
19F NMR (282 MHz, CDCl3) δ = –119.48 (td, J = 10.1, 5.5 Hz). IR (ATR): 3025, 1734, 1565, 
1417, 1357, 1261, 1192, 1150, 936, 813, 739, 689 cm−1. MS (ESI) m/z (relative intensity): 
378 (90) [M+Na]+, 356 (100) [M+H]+. HR-MS (ESI) m/z calcd for C23H19N3F [M+H]
+ 
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The general procedure G was followed using  6-chloro-1-(pyrimidin-2-yl)-1H-indole 71l 
(45.7 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186la (58.8 
mg, 79%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 8.19 (d, 
J = 1.9 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.25–7.18 (m, 3H), 7.16–7.10 (m, 4H), 6.63 (s, 
2H), 6.04 (d, J = 16.0 Hz, 1H), 5.96 (d, J = 16.0 Hz, 1H), 1.50–1.45 (m, 2H), 1.26–1.21 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ = 158.2 (CH), 157.9 (Cq), 143.5 (Cq), 137.6 (Cq), 137.5 
(Cq), 136.5 (CH), 129.0 (Cq), 128.4 (CH), 127.3 (Cq), 127.2 (CH), 126.7 (CH), 125.7 (CH), 
122.3 (CH), 121.0 (CH), 117.9 (CH), 113.7 (CH), 107.2 (CH), 22.7 (Cq), 18.4 (CH2). 
IR (ATR): 3025, 2221, 1562, 1417, 1350, 1298, 958, 911, 811, 739, 688 cm−1. MS (ESI) 
m/z (relative intensity): 394 (30) (35Cl) [M+Na]+, 372 (100) (35Cl) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H19N335Cl [M+H]
+ 372.1262, found 372.1264. 
 
 
Methyl (E)-1-(pyrimidin-2-yl)-2-(1-styrylcyclopropyl)-1H-indole-6-carboxylate (186na) 
The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole-6-carboxylate 
71n (50.5 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 
mmol) for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 5:1) yielded 186na 
(62.5 mg, 79%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 
8.78 (s, 1H), 7.96 (dd, J = 8.3, 1.5 Hz, 1H), 7.65 (dd, J = 8.3, 0.6 Hz, 1H), 7.24–7.17 (m, 
2H), 7.16–7.10 (m, 4H), 6.70 (s, 1H), 6.04 (d, J = 16.2 Hz, 1H), 5.95 (d, J = 16.2 Hz, 1H), 
3.96 (s, 3H), 1.52–1.46 (m, 2H), 1.27–1.22 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 168.2 
(Cq), 158.4 (CH), 157.8 (Cq), 146.0 (Cq), 137.5 (Cq), 136.6 (Cq), 135.9 (CH), 132.5 (Cq), 
128.4 (CH), 127.4 (CH), 126.7 (CH), 125.7 (CH), 124.7 (Cq), 122.8 (CH), 119.9 (CH), 118.2 
(CH), 115.3 (CH), 107.0 (CH), 52.0 (CH3), 22.6 (Cq), 18.3 (CH2). IR (ATR): 3023, 2949, 
1708, 1563, 1418, 1360, 1279, 1221, 1127, 1093, 956, 910, 811, 735, 688 cm−1. MS (ESI) 
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m/z (relative intensity): 418 (100) [M+Na]+, 396 (100) [M+H]+. HR-MS (ESI) m/z calcd for 
C25H22N3O3 [M+H]




The general procedure G was followed using  7-methyl-1-(pyrimidin-2-yl)-1H-indole 71o 
(41.6 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186oa (52.7 
mg, 75%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ = 8.78 (d, J = 4.9 Hz, 2H), 7.54 (d, 
J = 7.4 Hz, 1H), 7.28–7.20 (m, 2H), 7.20–7.12 (m, 5H), 7.04 (d, J = 7.2 Hz, 1H), 6.63 (s, 
1H), 6.01 (d, J = 16.0 Hz, 1H), 5.83 (d, J = 16.0 Hz, 1H), 2.00 (s, 3H), 1.45–1.39 (m, 2H), 
1.08–1.01 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 159.5 (Cq), 157.9 (CH), 143.2 (Cq), 
137.4 (Cq), 136.9 (Cq), 134.9 (CH), 128.9 (Cq), 128.3 (CH), 127.7 (CH), 126.6 (CH), 125.8 
(CH), 125.4 (CH), 121.7 (Cq), 121.2 (CH), 119.4 (CH), 118.4 (CH), 105.3 (CH), 21.5 (Cq), 
19.7 (CH3), 16.8 (CH2). IR (ATR): 3029, 1644, 1593, 1560, 1415, 1355, 1229, 955, 807, 
739, 689 cm−1. MS (ESI) m/z (relative intensity): 374 (95) [M+Na]+, 352 (100) [M+H]+. HR-
MS (ESI) m/z calcd for C24H22N3 [M+H]
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The general procedure G was followed using 1-(Pyrimidin–2-yl)-1,5,6,7-tetrahydro-4H-
indol-4-one 71p (42.5 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 
mg, 0.32 mmol) for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 2:1) 
yielded 186pa (54.0 mg, 76%) as a white solid. M.p. = 157–159 °C. 1H NMR (400 MHz, 
CDCl3) δ = 8.75 (d, J = 4.8 Hz, 2H), 7.22–7.17 (m, 3H), 7.14–7.08 (m, 3H), 6.58 (s, 1H), 
5.95 (d, J = 15.9 Hz, 1H), 5.75 (d, J = 15.9 Hz, 1H), 2.92 (t, J = 6.2 Hz, 2H), 2.55 (dd, J = 
7.2, 5.6 Hz, 2H), 2.19–2.13 (m, 2H), 1.32 (dd, J = 3.5, 4.5 Hz, 2H), 1.03 (dd, J = 3.5, 4.5 
Hz, 2H). 13C NMR (101 MHz, CDCl3) δ = 194.9 (Cq), 158.4 (CH), 157.3 (Cq), 145.5 (Cq), 
137.8 (Cq), 137.5 (Cq), 135.7 (CH), 128.4 (CH), 127.4 (CH), 126.7 (CH), 125.7 (CH), 121.0 
(Cq), 119.5 (CH), 106.9 (CH), 38.0 (CH2), 23.9 (CH2), 23.8 (CH2), 21.2 (Cq), 17.5 (CH2). IR 
(ATR): 2942, 1649, 1566, 1415, 1303, 1226, 974, 940, 805, 750, 692 cm−1. MS (ESI) m/z 
(relative intensity): 733 (100), 378 (60) [M+Na]+, 356 (60) [M+H]+. HR-MS (ESI) m/z calcd 




The general procedure G was followed using 2-(4-methoxylphenyl)pyridine 71s (36.8 mg, 
0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a (46.1 mg, 0.32 mmol) for 5.0 h. 
Isolation by column chromatography (n-hexane/EtOAc 10:1) yielded 186sa (26.8 mg, 41%) 
as a colorless solid. M.p. = 103–106 °C. 1H NMR (300 MHz, CDCl3) δ = 8.71 (dd, J = 5.0, 
1.9 Hz, 1H), 7.64 (td, J = 7.7, 1.9 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 
7.29–7.17 (m, 6H), 7.14 (dd, J = 7.8, 1.0 Hz, 1H), 6.96 (dd, J = 8.3, 1.0 Hz, 1H), 5.95 (d, J 
= 15.9 Hz, 1H), 5.86 (d, J = 15.9 Hz, 1H), 3.77 (s, 3H), 1.02–0.97 (m, 2H), 0.76–0.70 (m, 
2H). 13C NMR (75 MHz, CDCl3) δ = 157.3 (Cq), 156.8 (Cq), 148.7 (CH), 142.0 (Cq), 139.2 
(CH), 137.7 (Cq), 135.5 (CH), 131.8 (Cq), 129.1 (CH), 128.4 (CH), 127.5 (CH), 126.6 (CH), 
125.7 (CH), 125.6 (CH), 124.4 (CH), 121.7 (CH), 109.8 (CH), 55.9 (CH3), 27.7 (Cq), 16.3 
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(CH2). IR (ATR): 3004, 2937, 2837, 1640, 1574, 1459, 1426, 1352, 1254, 1056, 961, 784, 
736, 694 cm−1. MS (ESI) m/z (relative intensity): 350 (30) [M+Na]+, 328 (100) [M+H]+.   
HR-MS (ESI) m/z calcd for C23H22NO [M+H]





The general procedure G was followed using N-(2-(1-(pyrimidin-2-yl)-1H-indol-3-
yl)ethyl)acetamide 71t (55.9 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a 
(46.1 mg, 0.32 mmol) for 5.0 h. Isolation by column chromatography (CH2Cl2/EtOAc 20:1) 
yielded 186ta (15.2 mg, 18%) as a yellow oil and 186ta’ (28.9 mg, 34%) as a yellow solid. 
186ta: 1H NMR (300 MHz, CDCl3) δ = 8.82 (d, J = 4.8 Hz, 2H), 8.09 (d, J = 8.0 Hz, 1H), 
7.68 (d, J = 6.9 Hz, 1H), 7.35–7.25 (m, 6H), 7.19 (t, J = 4.9 Hz, 2H), 6.45 (d, J = 15.9 Hz, 
1H), 6.33 (d, J = 15.9 Hz, 1H), 5.62 (t, J = 6.6 Hz, 1H), 3.68 (dt, J = 6.6, 6.9 Hz, 2H), 3.15 
(t, J = 6.9 Hz, 2H), 1.74 (s, 3H), 1.22–1.09 (m, 2H), 1.04–1.09 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ = 170.3 (Cq), 158.3 (CH), 158.0 (Cq), 138.4 (Cq), 137.7 (Cq), 137.0 (CH), 136.1 
(Cq), 129.1 (Cq), 128.7 (CH), 127.7 (CH), 127.0 (CH), 126.0 (CH), 123.6 (CH), 121.8 (CH), 
118.9 (CH), 117.7 (CH), 117.0 (Cq), 113.2 (CH), 39.5 (CH2), 25.1 (CH2), 23.3 (CH3), 21.0 
(Cq), 18.0 (CH2). IR (ATR): 3293, 3051, 2923, 1648, 1562, 1455, 1424, 1356, 1296, 1204, 
963, 744, 696 cm−1. MS (ESI) m/z (relative intensity): 445 (50) [M+Na]+, 423 (100) [M+H]+. 
HR-MS (ESI) m/z calcd for C27H27N4O [M+H]
+ 423.2185, found 423.2179. 
 





acetamide (186ta’)  
The general procedure G was followed using N-(2-(1-(pyrimidin-2-yl)-1H-indol-3-
yl)ethyl)acetamide 71t (55.9 mg, 0.20 mmol) and (2-cyclopropylideneethyl)benzene 185a 
(46.1 mg, 0.32 mmol) for 5.0 h. Isolation by column chromatography (CH2Cl2/EtOAc 20:1) 
yielded 186ta (15.2 mg, 18%) as a yellow oil and 186ta’ (28.9 mg, 34%) as a yellow solid. 
186ta’: M.p. = 74–75 °C. 1H NMR (300 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 7.79–
7.73 (m, 1H), 7.61 (dd, J = 6.3, 2.8 Hz, 1H), 7.24–7.17 (m, 3H), 7.12–7.05 (m, 3H), 7.01–
6.96 (m, 2H), 5.46 (brs, 1H), 4.88 (d, J = 8.5 Hz, 2H), 4.57 (t, J = 7.7 Hz, 1H), 3.53–3.27 
(m, 4H), 3.03–2.84 (m, 2H), 1.93 (s, 3H), 1.70 (s, 3H). 13C NMR (101 MHz, CDCl3) δ = 
169.9 (Cq), 158.1 (CH), 158.0 (Cq), 145.8 (Cq), 140.5 (Cq), 137.0 (Cq), 136.5 (Cq), 129.4 
(Cq), 128.7 (CH), 128.0 (CH), 125.9 (CH), 123.0 (CH), 121.3 (CH), 118.4 (CH), 117.8 (CH), 
114.9 (Cq), 112.5 (CH), 110.7 (CH2), 44.6 (CH), 39.5 (CH2), 38.7 (CH2), 24.4 (CH2), 23.4 
(CH3), 23.1 (CH3). IR (ATR): 3294, 3055, 2927, 1647, 1561, 1454, 1420, 1365, 1263, 1020, 
803, 741, 698 cm−1. MS (ESI) m/z (relative intensity): 447 (100) [M+Na]+, 425 (65) [M+H]+. 
HR-MS (ESI) m/z calcd for C27H29N4O [M+H]
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The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole (71a) (41.6 mg, 
0.20 mmol) and 1-(2-cyclopropylideneethyl)-2-fluorobenzene 185b (51.9 mg, 0.32 mmol) 
for 3.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ab (57.6 
mg, 81%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ = 8.77 (d, J = 4.8 Hz, 2H), 8.15 (dd, 
J = 8.3, 1.0 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H), 7.33–7.15 (m, 3H), 7.13–7.05 (m, 2H), 7.01–
6.89 (m, 2H), 6.67 (s, 1H), 6.16 (s, 2H), 1.49–1.43 (m, 2H), 1.27–1.22 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ = 159.84 (d, 1JC–F = 249 Hz, Cq), 158.3 (Cq), 158.1 (CH), 142.6 (Cq), 
139.7 (d, 4JC–F = 5.5 Hz, CH), 137.2 (Cq), 128.1 (Cq), 127.7 (d, 4JC–F = 8.0 Hz, CH), 127.4 
(d, 4JC–F = 4.2 Hz, CH), 125.6 (d, 3JC–F = 12 Hz, Cq), 123.9 (d, 4JC–F = 3.5 Hz, CH), 123.2 
(CH), 121.8 (CH), 120.3 (CH), 119.8 (d, 4JC–F = 2.8 Hz), 117.6 (CH), 115.6 (d, 2JC–F = 22 
Hz, CH), 113.5 (CH), 107.6 (CH), 23.1 (Cq), 18.5 (CH2). 19F NMR (377 MHz, CDCl3) δ = (-
117.8) – (-117.9) (m). IR (ATR): 3044, 1644, 1563, 1418, 1352, 1222, 1192, 958, 803, 743, 
676, 629 cm−1. MS (ESI) m/z (relative intensity): 378 (90) [M+Na]+, 356 (100) [M+H]+.   
HR-MS (ESI) m/z calcd for C23H19N3F [M+H]




The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (41.6 mg, 
0.20 mmol) and 1-(2-cyclopropylideneethyl)-4-iodobenzene 185c (84.4 mg, 0.32 mmol) for 
4.0 h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded a mixture of 
186ac and 186aa (51.8 mg, 45% yield for 186ac, 15% yield for 186aa) as a yellow oil. 
1H NMR (400 MHz, CDCl3) δ = 8.75 (d, J = 4.7 Hz, 2H), 8.13 (d, J = 8.0 Hz, 1H), 7.62 (dd, 
J = 8.0, 1.1 Hz, 1H), 7.51 (d, J = 8.4 Hz, 2H), 7.24 (td, J = 7.5, 1.1 Hz, 1H), 7.10 (t, J = 4.8 
Hz, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.66 (s, 0.25H, 186aa), 6.65 (s, 0.75H, 186ac), 5.95 (s, 
2H), 1.49–1.43 (m, 2H), 1.27–1.22 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.3 (Cq), 
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158.1 (CH), 142.3 (Cq), 137.9 (CH), 137.41 (CH), 128.8 (Cq), 128.4 (Cq), 127.6 (CH), 126.1 
(Cq), 125.8 (CH), 123.2 (CH), 121.8 (CH), 120.4 (CH), 117.6 (CH), 113.5 (CH), 107.6, 91.4 
(Cq), 22.8 (Cq), 18.5 (CH2). IR (ATR): 3044, 2924, 1710, 1564, 1453, 1424, 1354, 1301, 
1218, 1004, 959, 804, 745, 697 cm−1. MS (ESI) m/z (relative intensity): 486 (45) [M+Na]+, 
464 (60) [M+H]+. HR-MS (ESI) m/z calcd for C23H19N3I [M+H]




The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (41.6 mg, 
0.20 mmol) and (3-cyclopropylidenepropyl)benzene 185d (50.6 mg, 0.32 mmol) for 3.5 h. 
Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ad (52.0 mg, 74%) 
as a colorless solid. M.p. = 81–82 °C. 1H NMR (300 MHz, CDCl3) δ = 8.69 (d, J = 4.8 Hz, 
2H), 8.04 (dd, J = 8.1, 1.2 Hz, 1H), 7.57 (d, J = 6.6 Hz, 1H), 7.26–7.13 (m, 5H), 7.05 (t, J 
= 4.8 Hz, 1H), 6.91 (d, J = 6.4 Hz, 2H), 6.58 (s, 1H), 5.31 (d, J = 15.5 Hz, 1H), 5.22 (dt, J 
= 15.5, 5.9 Hz, 1H), 3.11 (d, J = 5.9 Hz, 2H), 1.39–1.35 (m, 2H), 1.10–1.06 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ = 158.3 (Cq), 157.9 (CH), 143.2 (Cq), 140.9 (Cq), 137.3 (Cq), 
137.2 (CH), 128.7 (Cq), 128.5 (CH), 128.3 (CH), 126.5 (CH), 125.8 (CH), 123.0 (CH), 121.6 
(CH), 120.2 (CH), 117.5 (CH), 113.2 (CH), 106.8 (CH), 38.8 (Cq), 22.0 (CH2), 17.7 (CH2). 
IR (ATR): 3026, 1728, 1562, 1418, 1352, 1302, 1198, 1024, 964, 802, 740, 693, 630 cm−1. 
MS (ESI) m/z (relative intensity): 374 (100) [M+Na]+, 352 (75) [M+H]+. HR-MS (ESI) m/z 
calcd for C24H22N3 [M+H]
+ 352.1814, found 352.1817. 
 





The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (41.6 mg, 
0.20 mmol) and (2-cyclopropylideneethyl)cyclohexane 185e (48.1 mg, 0.32 mmol) for 3.0 
h. Isolation by column chromatography (n-hexane/EtOAc 15:1) yielded 186ae (52.9 mg, 
77%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.04 (d, J 
= 8.1 Hz, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.27 (ddd, J = 8.4, 7.1, 1.5 Hz, 1H), 7.23–7.19 (m, 
1H), 7.16 (t, J = 4.8 Hz, 1H), 6.56 (s, 1H), 5.07 (d, J = 15.6 Hz, 1H), 4.95 (dd, J = 15.6, 7.0 
Hz, 1H), 1.67–1.54 (m, 4H), 1.44–1.39 (m, 2H), 1.35–1.29 (m, 2H), 1.18–1.00 (m, 5H), 
0.73 (ddd, J = 12.2, 12.2, 3.3 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.4 (Cq), 158.1 
(CH), 143.5 (Cq), 137.4 (Cq), 134.1 (CH), 133.0 (CH), 128.7 (Cq), 122.9 (CH), 121.5 (CH), 
120.2 (CH), 117.5 (CH), 112.9 (CH), 106.2 (CH), 40.7 (CH), 33.2 (CH2), 26.2 (CH2), 26.1 
(CH2), 21.7 (Cq), 17.7 (CH2). IR (ATR): 2925, 1561, 1421, 1351, 1324, 1206, 815, 747 cm−1. 
MS (ESI) m/z (relative intensity): 366 (100) [M+Na]+, 344 (40) [M+H]+. HR-MS (ESI) m/z 
calcd for C23H26N3 [M+H]




The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (41.6 mg, 
0.20 mmol) and heptylidenecyclopropane 185f (44.2 mg, 0.32 mmol) for 4.0 h. Isolation by 
column chromatography (n-hexane/DCM 8:1) yielded 186ag (41.8 mg, 63%) as a colorless 
oil. 1H NMR (300 MHz, CDCl3) δ = 8.80 (d, J = 4.8 Hz, 2H), 8.04 (d, J = 8.1 Hz, 1H), 7.58 
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(d, J = 7.4 Hz, 1H), 7.26–7.14 (m, 3H), 6.56 (s, 1H), 5.14 (d, J = 15.5 Hz, 1H), 5.02 (dt, J = 
15.5, 6.5 Hz, 1H), 1.72 (dt, J = 6.5, 6.5 Hz, 2H), 1.39–1.34 (m, 2H), 1.23–1.16 (m, 2H), 
1.10–0.95 (m, 6H), 0.83 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 158.3 (Cq), 
158.0, 143.4 (Cq), 137.2 (Cq), 135.3, 128.7 (Cq), 128.2 (CH), 122.8 (CH), 121.5 (CH), 120.1 
(CH), 117.4 (CH), 112.9 (CH), 106.4 (CH), 32.3 (CH2), 31.2 (CH2), 29.3 (CH2), 22.5 (CH2), 
21.7 (Cq), 17.4 (CH2), 14.0 (CH3). IR (ATR): 2923, 2853, 1564, 1454, 1424, 1354, 1301, 
1200, 967, 802, 743, 679 cm−1. MS (ESI) m/z (relative intensity): 354 (90) [M+Na]+, 332 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C24H26N3 [M+H]




The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole (71a) (41.6 mg, 
0.20 mmol) and dec–9-en-1-ylidenecyclopropane 185g (57.1 mg, 0.32 mmol) for 4.0 h. 
Isolation by column chromatography (n-hexane/DCM 8:1) yielded 186ag (58.7 mg, 79%) 
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.80 (d, J = 4.7 Hz, 2H), 8.06 (d, J = 8.2 
Hz, 1H), 7.59 (dd, J = 7.7, 1.3 Hz, 1H), 7.30–7.25 (m, 1H), 7.20 (td, J = 7.4, 1.1 Hz, 1H), 
7.15 (t, J = 4.8 Hz, 1H), 6.57 (s, 1H), 5.83 (ddt, J = 17.0, 10.3, 6.7 Hz, 1H), 5.15 (d, J = 
15.5 Hz, 1H), 5.09–4.94 (m, 3H), 2.03 (dt, J = 7.2, 7.2 Hz, 1H), 1.74 (dt, J = 7.2, 7.2 Hz, 
1H), 1.39–1.29 (m, 4H), 1.20 (tt, J = 9.9, 6.6 Hz, 2H), 1.13–0.99 (m, 6H). 13C NMR (101 
MHz, CDCl3) δ = 158.4 (Cq), 158.1 (CH), 143.5 (Cq), 139.3 (CH), 137.3 (Cq), 135.4 (CH), 
128.8 (Cq), 128.2 (CH), 122.9 (CH), 121.6 (CH), 120.2 (CH), 117.5 (CH), 114.3 (Cq), 113.1 
(CH), 106.5 (CH), 33.9 (CH2), 32.4 (CH2), 29.7 (CH2), 29.0 (CH2), 28.9 (CH2), 28.9 (CH2), 
21.8 (Cq), 17.6 (CH2). IR (ATR): 2923, 2851, 1564, 1453, 1421, 1353, 1198, 965, 908, 802, 
742, 679 cm−1. MS (ESI) m/z (relative intensity): 394 (18) [M+Na]+, 372 (100) [M+H]+.   
HR-MS (ESI) m/z calcd for C25H30N3 [M+H]
+ 372.2434, found 372.2433. 






The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (41.6 mg, 
0.20 mmol) and (cyclopropylidenemethyl)cyclopentane 185h (39.1 mg, 0.32 mmol) for 5.0 
h. Isolation by column chromatography (n-hexane/DCM 8:1) yielded 186ah (29.0 mg, 46%) 
as a white solid. M.p. = 113–115 °C. 1H NMR (300 MHz, CDCl3) δ = 8.84 (d, J = 4.8 Hz, 
2H), 7.99 (d, J = 7.2 Hz, 1H), 7.54 (dd, J = 7.1, 1.8 Hz, 1H), 7.25–7.14 (m, 3H), 6.49 (s, 
1H), 5.18 (d, J = 2.5 Hz, 1H), 2.04–1.93 (m, 4H), 1.55–1.45 (m, 2H), 1.45–1.37 (m, 2H), 
1.33–1.27 (m, 2H), 1.00–0.93 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 158.5 (Cq), 158.2 
(CH), 146.7 (Cq), 145.4 (Cq), 137.0 (Cq), 128.9 (Cq), 124.1 (CH), 122.6 (CH), 121.5 (CH), 
120.0 (CH), 117.5 (CH), 112.9 (CH), 105.0 (CH), 34.4 (CH2), 28.6 (CH2), 26.8 (CH2), 26.0 
(CH2), 19.9 (Cq), 17.9 (CH2). IR (ATR): 2921, 2855, 1563, 1455, 1422, 1349, 1318, 1283, 
1195, 1022, 803, 744, 680 cm−1. MS (ESI) m/z (relative intensity): 338 (30) [M+Na]+, 316 
(100) [M+H]+. HR-MS (ESI) m/z calcd for C21H22N3 [M+H]




The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (41.6 mg, 
0.20 mmol) and (cyclopropylidenemethyl)cyclohexane 185i (43.6 mg, 0.32 mmol) for 5.0 
h. Isolation by column chromatography (n-hexane/CH2Cl2 8:1) yielded 186ai (34.3 mg, 
52%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ = 8.85 (d, J = 4.8 Hz, 2H), 7.98 (d, J 
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= 7.6 Hz, 1H), 7.59–7.49 (m, 1H), 7.25–7.13 (m, 3H), 6.49 (d, J = 0.8 Hz, 1H), 5.08 (s, 1H), 
2.23–2.10 (m, 2H), 1.83–1.72 (m, 2H), 1.37–1.25 (m, 8H), 1.02–0.92 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ = 158.6 (Cq), 158.2 (CH), 146.5 (Cq), 144.1 (Cq), 137.0 (Cq), 129.0 
(Cq), 125.5 (CH), 122.6 (CH), 121.5 (CH), 120.0 (CH), 117.5 (CH), 112.7 (CH), 104.0 (CH), 
36.8 (CH2), 29.4 (CH2), 28.6 (CH2), 27.0 (CH2), 26.6 (Cq), 18.2 (CH2). IR (ATR): 2921, 2849, 
1559, 1454, 1420, 1352, 1262, 1196, 1024, 967, 801, 737, 681 cm−1. MS (ESI) m/z (relative 
intensity): 354 (100) [M+Na]+, 330 (25) [M+H]+. HR-MS (ESI) m/z calcd for C22H24N3 [M+H]
+ 





The general procedure G was followed using 1-(pyrimidin-2-yl)-1H-indole 71a (41.6 mg, 
0.20 mmol) and (S)-(3,7-dimethyloct-6-en-1-ylidene)cyclopropane 185j (57.1 mg, 0.32 
mmol) for 7.0 h. Isolation by column chromatography (n-hexane/DCM 8:1) yielded 186aj 
(45.3 mg, 61%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ = 8.78 (d, J = 4.8 Hz, 2H), 
8.05 (d, J = 8.2 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.27–7.13 (m, 3H), 6.56 (s, 1H), 5.08 (d, 
J = 15.5 Hz, 1H), 4.97 (t, J = 7.1 Hz, 1H), 4.87 (dd, J = 15.5, 8.1 Hz, 1H), 1.87–1.78 (m, 
2H), 1.72–1.67 (m, 1H), 1.67 (s, 3H), 1.54 (s, 3H), 1.38–1.34 (m, 2H), 1.08–0.94 (m, 4H), 
0.66 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 158.4 (Cq), 158.1 (CH), 143.6 
(Cq), 137.4 (Cq), 134.1 (CH), 133.8 (CH), 131.1 (Cq), 128.8 (Cq), 125.0 (CH), 122.9 (CH), 
121.6 (CH), 120.2 (CH), 117.5 (CH), 113.1 (CH), 106.5 (CH), 37.1 (CH2), 36.2 (CH), 25.8  
(CH2), 21.8 (Cq), 21.0 (CH3), 18.0 (CH3), 17.8 (CH3), 17.5 (CH2). IR (ATR): 2915, 2855, 
1564, 1453, 1423, 1353, 1199, 965, 803, 743, 679 cm−1. MS (ESI) m/z (relative intensity): 
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394 (80) [M+Na]+, 372 (100) [M+H]+. HR-MS (ESI) m/z calcd for C25H30N3 [M+H]
+ 372.2440, 
found 372.2434. 




To a 25 mL schlenk tube was added 184aa (135 mg, 0.40 mmol), diethyl 
acetylenedicarboxylate 207 (204 mg, 1.2 mmol, 3.0 equiv), hydroquinone (8.8 mg, 0.080 
mmol, 20 mol %) and 1,4-dioxane 2.0 mL. Then stirred at 100 ºC for 24 h. Removed the 
solvent under vacuum and the residue was purified by column chromatography on silica 
gel (n-hexane/EtOAc 5:1) affording 208 (140 mg, 72%) as a yellow solid. M.p. = 149–
150 °C. 1H NMR (300 MHz, CDCl3) δ = 8.83 (d, J = 4.8 Hz, 2H), 8.29 (dd, J = 8.3, 1.0 Hz, 
1H), 7.44 (d, J = 7.7 Hz, 1H), 7.28–7.22 (m, 1H), 7.21–7.12 (m, 5H), 7.06 (dd, J = 7.8, 1.8 
Hz, 2H), 6.20 (s, 1H), 6.00 (dd, J = 4.7, 2.7 Hz, 1H), 4.61 (t, J = 5.9 Hz, 1H), 4.27 (q, J = 
7.1 Hz, 2H), 4.01 (dddd, J = 17.9, 10.8, 7.1, 3.7 Hz, 2H), 3.44 (ddd, J = 23.4, 6.5, 2.8 Hz, 
1H), 3.23 (dt, J = 23.5, 5.0 Hz, 1H), 1.34 (t, J = 7.1 Hz, 3H), 1.02 (t, J = 7.1 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ = 167.8 (Cq), 167.5 (Cq), 158.4, 158.1 (Cq), 140.2 (Cq), 139.1 (Cq), 
138.3 (Cq), 137.1 (Cq), 133.6 (Cq), 129.8 (Cq), 129.2 (Cq), 128.8 (CH), 128.4 (CH), 127.2 
(CH), 123.5 (CH), 122.8 (CH), 122.1 (CH), 120.5 (CH), 117.3 (CH), 113.9 (CH), 109.3 (CH), 
61.4 (CH2), 60.9 (CH2), 48.2 (CH), 28.8 (CH2), 14.2 (CH3), 13.9 (CH3). IR (ATR): 2983, 
1715, 1567, 1423, 1344, 1248, 1147, 1068, 810, 744, 705 cm−1. MS (ESI) m/z (relative 
intensity): 516 (100) [M+Na]+, 494 (90) [M+H]+. HR-MS (ESI) m/z calcd for C30H28N3O4 
[M+H]+ 494.2074, found 494.2072. 




Diethyl 6-[1-(pyrimidin-2-yl)-1H-indol–2-yl]-[1,1'-biphenyl]–2,3-dicarboxylate (209) 
The electrochemical dehydrogenative annulation of 3 was carried out in a divided cell (P4 
glass filter as separator) with a GF anode (10 mm × 15 mm × 6 mm) and a Pt cathode (10 
mm × 15 mm × 0.25 mm). The anodic cell was charged with 208 (0.1 mmol, 49.3 mg), 2,3-
dichloro–5,6-dicyano-1,4-benzoquinone (DDQ) (0.02 mmol, 20 mol %, 5.5 mg), n-Bu4NBF4 
(1.0 mmol, 32.9 mg), CH2Cl2 (4.0 mL) and MeOH (1.0 mL). The cathodic cell was charged 
with nBuN4BF4 (1.0 mmol, 32.9 mg), CH2Cl2 (4.0 mL) and MeOH (1.0 mL). Electrolysis was 
performed at 25 °C with a constant current of 5.0 mA maintained for 5.0 h. The anodic 
solution was transferred to a separating funnel charged with H2O (50 mL) and CH2Cl2 (50 
mL) and the GF anode was rinsed with CH2Cl2 (4 × 10 mL). The organic phase was 
collected and dried over anhydrous sodium sulfate. The evaporation of the solvent and 
subsequent column chromatography on silica gel (n-hexane/EtOAc 5:1) afforded 209 (32.1 
mg, 65%) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ = 8.50 (d, J = 4.8 Hz, 2H), 8.17 
(d, J = 8.1 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.1 Hz, 1H), 7.58 (d, J = 7.5 Hz, 
1H), 7.26–7.18 (m, 2H), 7.10 (d, J = 7.5 Hz, 1H), 7.06–6.98 (m, 3H), 6.81 (d, J = 7.5 Hz, 
2H), 6.60 (s, 1H), 4.40 (q, J = 7.2 Hz, 2H), 3.98 (q, J = 7.2 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H), 
0.90 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ = 168.7 (Cq), 165.9 (Cq), 157.9 (CH), 
157.2 (Cq), 139.5 (Cq), 138.5 (Cq), 137.8 (Cq), 137.2 (Cq), 137.0 (Cq), 136.3 (Cq), 130.7 
(CH), 129.2 (CH), 129.1 (CH), 129.0 (Cq), 127.5 (CH), 127.5 (CH), 127.3 (Cq), 124.0 (CH), 
122.2 (CH), 120.7 (CH), 117.1 (CH), 114.0 (CH), 111.3 (CH), 61.7 (CH2), 61.3 (CH2), 14.3 
(CH3), 13.7 (CH3). IR (ATR): 2982, 2259, 1719, 1565, 1422, 1263, 1183, 1147, 1067, 1019, 
911, 803, 733, 700 cm−1. MS (ESI) m/z (relative intensity): 514 (100) [M+Na]+, 492 (35) 
[M+H]+, 446 (35). HR-MS (ESI) m/z calcd for C30H26N3O4 [M+H]
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